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ABSTRACT
PURIFICATION AND CHARACTERISATION OF MYELOID BLAST CELLS
FROM HUMAN FETAL LIVER AND STUDIES OF CHANGES IN INOSITOL
METABOLISM DURING THEIR DIFFERENTIATION TOWARDS
MONOCYTES.
A homogeneous population of myeloid blast cells was purified by negative selection
from human fetal liver by enzyme digestion of liver tissue, ficoll fractionation,
indirect erythrocyte rosette sedimentation of unwanted cells, after coating these cells
with monoclonal antibodies directed against erythroblasts and macrophages, and
finally by cell elutriation. Characterisation of these cells confirmed their
undifferentiated status and in culture these cells generated only neutrophils and
macrophages. Treatment of these cells with lOnM phorbol myristate acetate (PMA)
induced rapid terminal monocyte differentiation of 62% of this population and also
completely inhibited the neutrophil differentiation of the remaining cells. The
undifferentiated blast cells were maintained in culture in a serum-free medium
containing 100 U/ml interleukin-3 and lmg/1 inositol which permitted the
equilibrium labelling of cells with [^H] myo-inositol and the subsequent analysis of
concentrations of inositol metabolites within these cells. High concentrations of
various inositol metabolites, similar to those found in HL60 cells, were observed in
normal myeloid blast cells and following PMA-induced monocyte differentiation of
these cells significant changes occurred - namely a decrease in inositol
tetrakisphosphate (InsPq) and inositol pentakisphosphate (InsP5) and an increase in
glycerophospho-inositol (GPI). These changes in response to PMA, with the
exception of the rise in GPI, are similar to those reported in HL60 cells undergoing
monocyte differentiation and suggest that abundant inositol polyphosphates may play
an important role in myeloid differentiation.
A second section of this thesis describes a case of primary myelofibrosis associated
with defective erythropoiesis in which cytogenetic analysis suggested the possible
involvement of a new putative human oncogene regulating erythropoiesis.
Subsequent analysis using a cDNA probe to this putative oncogene (pSEA, the
human homolcx^of the viral oncogene SEA of the S13 avian erythroblastosis virus)
indicated that this locus was not disrupted by the chromosomal translocation
observed in this patient.
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INTRODUCTION CHAPTER 1.
HAEMOPOIESIS AS A MODEL SYSTEM IN DEVELOPMENTAL BIOLOGY
The human haemopoietic system generates and maintains throughout adult life
at least eight different terminally differentiated and functional cell types which
are derived from a finite number of pluripotential stem cells (Figure 1). This
capacity to generate and maintain populations of widely diverse functional cell
types from a limited number of ancestral cells is an important property of
successful embryonic and evolutionary development which is common to all
higher organisms. The sequence of events, whereby stem cells give rise to
diverse functional end cells involves the cellular processes of self-renewal,
lineage commitment, proliferation and differentiation which are extremely
complex, and difficult to study. However, an understanding of these events at
the molecular level is obviously important in developmental biology and in
resolving the perturbations in these processes which occur in disease states
such as lineage dysplasias and neoplasias. The haemopoietic system is
particularly well suited to studies of development as it is possible to access
sources of pluripotential human haemopoietic stem cells and primitive
progenitor cells from tissues such as adult bone marrow, fetal liver and
neonatal cord blood. The availability of these cells has permitted the
development of in vitro model systems to study important events which
regulate haemopoiesis.
The human haemopoietic system is subject to perturbation of the cellular
processes which control lineage commitment, proliferation and differentiation
resulting in disease states such as lineage aplasias, lineage dysplasias and
lineage neoplasias. Cells isolated from patients with these disorders can also
be subjected to in vitro study and knowledge of the biochemical and
molecular events associated with these disease states may lead to new ways of
treating and preventing these conditions and to a new understanding of the
events which govern normal developmental processes. Therefore, study of the
developmental processes of both normal and malignant haemopoietic cell
populations has the potential to identify the biochemical and molecular events
which regulate normal cell development and the mechanism by which they




















































STRUCTURE AND REGULATION OF THE HAEMOPOIETIC SYSTEM
Over the past 25 years considerable advances have been made in our
knowledge of the structure and regulation of the haemopoietic system.
Evidence supports the existence of, as yet unpurified, pluripotential
haemopoietic stem cells (PHSCs) which are capable of generating and
maintaining throughout adult life eight different terminally differentiated
and functional cell types (Figure 1). Stem cells exhibit properties of self-
renewal and pluripotency. PHSCs give rise to intermediate precursor
cells, called progenitors or colony forming cells (CFCs), which were first
recognised by their ability to generate colonies of differentiated progeny
in response to appropriate colony-stimulating factors (CSFs). These
progenitor cells are transit amplifying populations which exhibit
properties of limited self-renewal capacity, commitment to a restricted
range of lineages and both proliferation and differentiation in response to
appropriate CSFs. Progenitor cells eventually become restricted to a
single lineage and ultimately generate functional mature cells that are
terminally differentiated and which have no further potential for self-
renewal (Figure 2). Such terminally differentiated cells have a finite life
span and normal numbers of peripheral blood cells are maintained by a
balanced continual production of new cells. The mechanisms whereby
normal haemopoiesis is regulated are outlined in more detail below.
2.1 Pluripotential haemopoietic stem cells
2.1.1. Evidence for the existence of PHSCs
The first experimental evidence for the existence of pluripotential
haemopoietic stem cells (PHSCs) came from reconstitution experiments
in mice, where bone marrow cells harvested from normal mice were
used to reconstitute the lymphohaemopoietic system of mice that had
received lethal doses of irradiation (Ford et al, 1956; Micklem et al,
1966). When low numbers of marrow cells were injected, colonies
containing megakaryocytes, granulocytes and erythroid cells but not
lymphoid cells could be identified in the spleens of irradiated mice (Till
and McCulloch, 1961). These colonies were found to have been
3
Figure 2: Two dimensional model of the haemopoietic system illustrating how the
transient amplifying populations of committed progenitor cells and immature cells
can generate large numbers of end stage mature cells from a small number of
pluripotent stem cells.
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derived from single marrow cells using irradiation-induced chromosomal
markers and the cells which gave rise to these colonies became known
as colony forming units-spleen (CFU-S). The CFU-S was originally
considered to be an assay for murine PFISC but it has since been shown,
by the use of cell elutriation to separate PFISC from CFU-S and other
progenitors, that long term repopulation of haemopoiesis in irradiated
recipients can be obtained without any CFU-S (Jones et al, 1990). In
fact CFU-S are a heterogeneous group of multipotential haemopoietic
progenitor cells with late day-12 (the time taken to develop colonies)
CFU-S representing more primitive progenitors and early day-8 CFU-S
representing later more committed progenitors.
However, despite the lack of assays for PHSCs, it was subsequently
shown in elegant experiments using chromosomal markers induced
either by irradiation (Wu et al, 1968; Abramson et al, 1977) or by
retroviral integration (Dick et al, 1985; Keller et al, 1985; Lemischka et
al, 1986) that the cells of both the murine myeloid and lymphoid
lineages can be derived from a single cell with a high capacity for self-
renewal. The ability to reconstitute the lymphohaemopoietic system in
irradiated recipients following the infusion of bone marrow cells from
either syngeneic or allogeneic donors is now a well-established
therapeutic procedure in clinical medicine, recently recognised by the
award of a Nobel Prize ^ (Thomas et al, 1975; Santos 1987). Other
indirect evidence supporting the existence of PHSCs comes from the
demonstration of clonal markers in human blood cell neoplasms
(Fialkow, 1980). For example in chronic granulocytic leukaemia (CGL)
the marker Philadelphia (Ph) chromosome and glucose-6-phosphate
dehydrogenase (G-6-PD) isoenzyme restrictions have been found in cells
of the megakaryocyte, erythroid, granulocyte, monocyte and B
lymphocyte lineages but not in fibroblasts or other tissues (Richman et
al, 1985). Furthermore cases of T lymphoid blast crises have been
reported in CGL indicating that the target cell for transformation in this
condition probably is a PHSC (Hernandez et al, 1982; Griffin et al,
1983; Chan et al, 1986). In sideroblastic anaemia G-6-PD isoenzyme
restriction has been found in haemopoietic cells as well as in both T and
1E Donnall Thomas MD, Nobel Laureate 1990 (Hamblin, 1991).
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B lymphoid cells (Prchal et al, 1978) and other disorders where there is
evidence to support a clonal defect in pluripotent HSCs include
paroxysmal nocturnal haemoglobinuria (Rosse, 1989) and aplastic
anaemia (Marsh and Geary, 1991).
2.1.2 Characterisation of Pluripotent haemopoietic stem cells.
The further characterisation of human PHSCs has proved problematic as
there is no suitable in vitro assay for PHSCs and because it has been
difficult to purify and separate this very low frequency cell population
from other cell types. Even extensive experimentation in the murine
system, where reconstitution experiments can be more easily
undertaken, has only achieved limited enrichment for murine PHSCs
(Visser et al, 1984; Spangrude et al, 1991). But despite these
limitations considerable information on the nature of putative human
PHSCs and how they differ from committed progenitor cells has
accumulated from reconstitution data in primate and human bone
marrow transplantation (Kaizer et al, 1985; Berenson et al, 1988) and
from various in vitro studies (Table 1). These in vitro studies have used
combinations of different protocols for cell fractionation to separate
mature cells and committed progenitor cells from cell populations
containing putative HSCs. These cell fractionation methods have
included density separation, counter flow centrifugal elutriation, positive
and negative immunoselection, positive selection by flow cytometry and
the treatment of cells by S phase specific chemotherapeutic agents such
as 4-hydroperoxycyclophosphamide (4-HC), 5-fluorouracil (5-FU) and
hydroxyurea (HU). Using these methods, in vitro assays have been
described for cells giving rise to blast colonies (CFU-Blast; Leary and
Ogawa, 1987; Rowley et al, 1987; Brandt et al, 1988) and for cells
giving rise to colonies of high proliferative potential (HPP-CFC; McNiece
et al, 1990). These CFCs exhibit properties different to those of
committed progenitor cells and may closely resemble PHSCs. Other
assay systems have exploited the use of long term bone marrow
cultures (LTBMC) describing stroma-dependent blast colony-forming
cells (Gordon et al, 1987a) and the initiation of haematopoiesis by the
subsequent assay of committed progenitor cells (Winton and Colenda,
1987; Sutherland et al, 1989). Furthermore, novel in vivo assay
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systems for human PHSCs have been developed which are able to
sustain human haemopoietic engraftment and these include the use of
SCID-hu mice (Peault et al, 1991) and the in utero transplantation of
sheep with sources of human PHSCs (Srour et al, 1992).
Table 1. Properties discriminating committed progenitor cells





Flow cytometric low forward higher forward
light scattering low orthagonal low orthagonal
characteristics
Surface antigen CD34 + CD34 +
expression HLA DR - HLA DR +
Lin - Lin +
Sensitivity to S-phase - +
chemotherapeutic agents
Dependence upon CSFs - +
^for more detailed explanation see text.
These and other studies listed below have indicated that putative human
PHSCs a) exhibit low forward and vertical light scatter properties
following flow cytometry (Andrews et al, 1989; Verfaillie et al, 1990);
b) are positive for the CD34 cell surface antigen but negative for the
HLA-DR antigen and other lineage (lin-) specific markers (Keating et al,
1984; Gordon et al, 1985a;) and c) are more resistant to therapy with
chemotherapeutic agents such as 4-HC, 5-FU and HU than committed
progenitor cells (Siena et al, 1985; Gordon et al, 1985b) indicating that
these cells are in Gq or the resting phase of the cell cycle. Data also
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suggest that cells such as the CFU-blast may survive, but not proliferate
in the absence of CSFs indicating that PHSCs may not be dependent on
CSFs for their survival (Leary and Ogawa, 1987).
In contrast the committed progeny of stem cells (progenitor cells), a)
exhibit higher forward light scatter following flow cytometry indicating
larger size (Sutherland et al, 1989) (this may reflect exit from Gq); b)
are positive for the CD34 and HLA-DR antigens (Civin et al, 1984; Civin
et al, 1987; Lu et al, 1987), express activation antigens such as the
transferrin receptor, CD71 (Peschel et al, 1989) and CD38 (Terstappen
et al, 1991) and begin to express lineage specific markers (Lin + ) such
as CD33 and CD11b in the case of myeloid progenitors (Andrews et al,
1989; Peschel et al, 1989); c) are sensitive to therapy with agents such
as 4-HC and 5-FU and d) require colony stimulating factors and/or
interleukins for both their survival and proliferation (Suda et al, 1985). A
more detailed description of these cytokines follows on later.
2.1.3. Regulation of PHSCs
The mechanisms whereby PHSCs are regulated to divide and undergo
self-renewal or lineage commitment remain poorly understood. However
there is evidence, obtained from the study of murine CFU-S, to support
the possible negative feedback regulation of PHSCs by a specific stem
cell inhibitor (SCI) produced by mature cells. Medium conditioned by
either murine or human bone marrow cells has been shown to
selectively inhibit the proliferation of primitive murine multipotential
haemopoietic cells (CFU-S) but not the proliferation of more
developmentally restricted progenitor cells (Lord et al, 1976; Wright et
al, 1980). Recently this 'stem cell inhibitor' has been shown to be
produced by human macrophages and to be identical to a known
cytokine, macrophage inflammatory protein 1-a (MIP-1a), indicating that
the mechanisms involved in the regulation of both murine and human
HSCs may be identical (Graham et al, 1990). In the case of CFU-S
regulation there is evidence to support the existence of a stimulator that
switches these cells into the cell cycle (Lord et al, 1977; Toksoz et al,
1980) indicating that the proliferative status for CFU-S or PHSCs may
be modulated by the relative levels of an inhibitor and stimulator.
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The mechanisms whereby PHSCs undergo either self-renewal or
commitment to generate progenitor cells remain unknown. It was
originally proposed that the stem cells either underwent self-renewal or
became committed to a particular lineage according to a defined
probability. This process was believed to occur at random during
subsequent cell divisions and to be independent of the previous history
of cell divisions. The random nature of this process (labelled
"stochastic") was described as being analogous to radioactive decay,
whereby following analysis of a large number of events, a regular
pattern of haemopoiesis would be achieved (Till et al, 1964). The
mechanisms whereby the probabilities of either self-renewal or lineage
commitment might be determined were not proposed. Following the
observation of a range of multipotent and oligopotent progenitor cells it
was then proposed that lineage commitment occurred with a
progressive loss of differentiation potentials but still in a stochastic
manner (Ogawa et al, 1983).
However, other theories have argued that lineage determination in
haemopoiesis is not a random process. One viewpoint proposes that
environmental influences such as the bone marrow microenvironment
(Curry and Trentin, 1966) or the presence of humoral factors (Heyworth
et al, 1988) determine the outcome of lineage determination (Figure 3b).
Alternatively it has been proposed that lineage determination is
genetically pre-determined and occurs in a sequential manner. An early
model proposed the sequential losses of differentiation options (Nicola
and Johnson, 1982) but a more recent model proposes that lineage
potentials in haemopoiesis are expressed individually and in a genetically
predetermined sequence as progenitor cells mature (Figure 3c) (Brown et
al, 1989). The latter model cites evidence to support the fact that
differentiation is genetically programmed within cells and is able to
explain how environmental influences interact with expressed lineage
potentials to permit differentiation along one pathway of maturation.
Another feature of this model, quite distinct from others, is the close
developmental relationship between certain lineages such as
megakaryocytes and erythrocytes, granulocytes and monocytes and
monocytes and B cells (Brown et al, 1990).
9
Figure 3 Lineage determination in haemopoiesis.
Figure 3a illustrates a conventional representation of decision points
during the diversification of haemopoietic progenitor cells.
Differentiation pathway options are designated p1, p2, etc. GEMM-
CFC and GM-CFC are colony forming cells restricted to
granulocyte/erythrocyte/macrophage/megakaryocyte differentiation
and granulocyte/macrophage differentiation respectively. Figure 3b
illustrates a multipotent haemopoietic stem cell where differentiation
options p1-p5 (possibly induced by environmental influences such as
the local presence of haemopoietic growth factors) are
simultaneously and equally available. Figure 3c illustrates an ordered
(genetically predetermined) process of progenitor cell development.
Differentiation options p1-p6 are expressed individually and in a
preferred order. Cells gradually acquire one differentiation potential
followed by loss of this capacity as the next differentiation option is
expressed (Adapted from Brown et al, 1990).
The direct evidence to support these theories of lineage commitment
in haemopoiesis will require experiments to be performed on single
PFISCs to enumerate the number of lineage options available within a
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2.2 Haemopoietic Progenitor Cells
Haemopoietic progenitor cells were first recognised when colonies of
mature granulocytes and macrophages were grown from individual
haemopoietic cells which had been placed in semi-solid medium
containing appropriate colony-stimulating activity (Bradley and Metcalf,
1966; Pluznik and Sachs, 1966). This demonstration of in vitro factor
dependent colony growth of haemopoietic progenitor cells (or colony
forming cells (CFCs)) stimulated intense research activity which resulted
in the discovery of haemopoietic progenitor cells for other lineages and
the identification of the soluble factors which stimulated the growth of
colonies from these colony forming cells. The use of karyotypic
markers, G-6-PD isoenzyme studies and the growth of colonies from
single manipulated cells confirmed the clonal nature of haemopoietic
colonies (Singer et al, 1979; Metcalf et al, 1980) and the progenitor
basis of human haemopoiesis is now well established (Figure 4); Nathan,
1990; Pike and Robinson, 1970; Tepperman et al, 1974; Iscove et al,
1974; Clarke and Housman, 1977; Fauser and Messner 1979; Ash et al,
1 981; Messner et al, 1 982.
Haemopoietic progenitor cells, which are the descendants of PHSCs, act
as transit amplifying populations by exhibiting properties of a limited
self-renewal capacity, commitment to a restricted range of lineages and
both proliferation and differentiation in response to appropriate CSFs.
Progenitor cells eventually become restricted to a single lineage and
ultimately generate mature cells which are terminally differentiated and
which have no further potential for self-renewal. The ability of
progenitor cells to proliferate and differentiate in response to a range of
lineage restricted or specific CSFs offers a mechanism whereby
haemopoietic lineages can be amplified in response to the increased CSF
concentrations which occur in pathological conditions such as tissue
hypoxia, infection or chemo-radiation induced cytopenia (Cannistra and
Griffin, 1988). Furthermore, the recent cloning of CSFs and other
cytokines involved in the regulation of haemopoiesis has permitted the
opportunity to use these agents clinically in the treatment of patients
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Figure 4. The progenitor basis of haemopoiesis.
The figure demonstrates a differentiation map of myeloid progenitor cells
beginning with the pluripotent haemopoietic stem cell. Although the
existence of these progenitor cells is well established, their exact
positions in the differentiation map in relation to each other and to the
PHSC remains unresolved. In contrast, the lymphoid progenitors remain
poorly defined but they have been included for completeness. CFU-
GEMM = colony forming unit - granulocyte, erythrocyte,
megakaryocyte, monocyte; CFU-Meg = colony forming unit-
megakaryocyte; BFU-E = blast forming unit - erythroid; CFU-E= CFU-
erythroid; CFU-Eo = CFU-eosinophil; CFU-Bas = CFU-basophil; CFU-GM
= CFU-granulocyte, monocyte; CFU-G = CFU-granulocyte; CFU-M =
CFU-monocyte. The factors that stimulate the growth and
differentiation of particular progenitors are shown to the right of the
lines connecting the progenitors to their more mature progeny. The
asterisks next to stem cell factor (SCF) indicate provisional stimulatory
activities based on early experimental data. There appears to be a
hierarchy of development with SCF, IL-6 and IL-3 acting on early
multipotent myeloid progenitors, GM-CSF acting to a weaker extent on
early multi-lineage progenitors but more strongly on a broad range of
later progenitors and Epo, G-CSF, M-CSF and IL-5 acting on later
progenitors. The effects of IL-3 and GM-CSF on lineage specific
progenitors are seen primarily in synergy with late acting factors such as
Epo, G-CSF, M-CSF and IL-5: (For further explanation see Figure 5 and
text). The principal tissue sources of these positive regulatory cytokines
are shown at the bottom of the figure. Negative regulators of
haemopoiesis are not shown because their actions are complex and their
physiological significance remains to be determined.
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2.3 Cytokines involved in haemopoietic progenitor cell regulation.
The factors or cytokines that regulate haemopoiesis were originally
identified as constituents of supernatants derived from heterogeneous
cell populations or cell lines and their effects were detected in bio-
assays on target populations. Many of these factors have now been
purified and their genes cloned and it has become evident that they have
many actions, including the induction of secondary cytokines, which
overlap with the actions of other cytokines. Individual cytokines had
previously been allocated more than one name when they had displayed
different actions on different target cell populations but an international
nomenclature has now been adopted. The adopted system includes the
colony-stimulating factors (CSFs), the interleukins and a group of
miscellaneous cytokines, many of which are negative regulators. These
are described in more detail below. The CSFs promote the growth,
differentiation and survival of haemopoietic progenitor cells, particularly
those in the myeloid lineages and in addition enhance a variety of
functional properties of mature haemopoietic cells. The interleukins are
another group of cytokines that were originally believed to be produced
by lymphocytes and macrophages and which were thought to act
primarily on B or T lymphoid cells. However it is now known that
interleukins are produced by a broad spectrum of cell types and that
these cytokines can in many circumstances, act on cells other than
those in the lymphoid lineage. The cytokines that stimulate the growth
and differentiation of particular haemopoietic progenitors are shown in
Figure 4 and Tables 2 and 3 list key biochemical and physical properties
of well-characterised human cytokines.
2.3.1. Interleukin 3
Interleukin 3 (IL-3) is produced from activated T cells and was originally
known as multi-CSF on account of its ability to support the survival,
self-renewal, proliferation and differentiation of a wide range of early
haemopoietic progenitors including the mixed myeloid progenitor CFU-
GEMM, the megakaryocyte-CFC, the granulocyte macrophage- CFC and
the early erythroid progenitor, BFU-E. In the presence of IL-3 these






















































































































































































































































early erythrocytes, neutrophils, eosinophils, basophils, macrophages and
megakaryocytes (Clark and Kamen, 1987). IL-3 has been shown to
support the proliferation of the earliest identifiable multi-lineage
progenitors in both mouse and man and to display synergy with IL-6 in
this property (Leary et al, 1988). Furthermore IL-3 has been shown to
exhibit synergism with G-CSF and possibly with GM-CSF to enhance the
proliferation of committed myeloid progenitors (Paquette et al, 1987,
Sieff et al, 1987). Both mature neutrophils and macrophages and their
precursors express IL-3 receptors and enhanced survival and function of
mature cells in the presence of IL-3 has been documented in vitro
(Whetton and Dexter, 1989). The observations of the effects of GM-
CSF, G-CSF, M-CSF, IL-5 and erythropoietin (vide infra) suggest a
hierarchical role for the CSFs with IL-3 acting predominantly on early
multi-lineage progenitors, GM-CSF acting to a weaker extent on early
multi-lineage progenitors and more strongly on a broad range of later
progenitors and G-CSF, M-CSF, IL-5 and erythropoietin (Epo) acting later
still to support the growth of late progenitors that are already committed
to their particular lineages (Figure 4, Figure 5).
The gene for IL-3 is located on the long arm of chromosome 5 along
with the genes coding for GM-CSF, IL-5, IL-4 and the M-CSF receptor.
Early studies on the in vivo administration of recombinant human (rh) IL-
3 in humans have shown great promise by producing a multi-lineage
response with an increase in leucocytes (eosinophils, neutrophils and
lymphocytes), platelets and reticulocytes. The subsequent
administration of GM-CSF following IL-3 has produced a further
synergistic leucocyte response (Hoelzer et al, 1991). IL-3 probably
plays an important role in the maintenance of steady state haemopoiesis
but a more limited role in the haemopoietic response to stress in
contrast to the more lineage restricted CSFs - GM-CSF, G-CSF, M-CSF
and Epo (Figure 6; Cannistra and Griffin, 1988).
2.3.2. Granulocyte-monocyte colony-stimulating factor
In vitro, granulocyte-monocyte colony stimulating factor (GM-CSF)
primarily supports the proliferation and differentiation of macrophage,
neutrophil and eosinophil colonies and colonies containing both
18
erythrocyte
Figure 5: Illustration of the developmental hierarchy of responsiveness of
haemopoietic progenitor cells to different growth factors. The erythroid lineage is
shown as an example. The ability of factors to exert their maximal effects at different
stages of maturation permits a synergistic response with factor combinations. For
example the in vitro combination of IL-3 and Epo is able to generate much larger
numbers of normoblasts and erythrocytes from a single BFU-E progenitor than
when either factor is used alone.
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neutrophils and macrophages. These effects are mediated by direct
actions on the colony forming cells (CFC) - GM-CFC, M-CFC, G-CFC and
Eo-CFC (Metcalf, 1986). In addition GM-CSF can also in vitro promote
the formation of a) mixed myeloid colonies indicating CSF activity
towards the mixed myeloid progenitor, CFU-GEMM (Sieff et al, 1985)
and b) erythroid colonies in the presence of erythropoietin indicating
activity towards the early erythroid progenitor, BFU-E (Sieff et al, 1985,
Donahue et al, 1985). Flowever the CSF activity directed towards
mixed myeloid and early erythroid progenitors is less than that observed
for IL-3 (Sieff et al, 1987). Studies of the addition of GM-CSF to
cultures grown in the presence of IL-3 have produced conflicting results.
One study showed no increase in the number of either BFU-E or CFU-
GM colonies produced suggesting that most if not all GM-CSF
responsive progenitors also respond to IL-3 (Sieff et al, 1987). However
another study demonstrated enhanced G-M colony formation when both
factors were present suggesting synergy between IL-3 and GM-CSF for
the growth of committed myeloid progenitors (Paquette et al, 1987).
The in vivo response to rhGM-CSF supports the factor's net dominant
actions on the later progenitors by producing dose dependent increases
in neutrophils, monocytes and eosinophils but not in reticulocytes or
platelets (Moore, 1991a). However the sequential in vivo administration
of rhGM-CSF has resulted in marked synergistic leucocyte responses
that are encouraging (Hoelzer et al, 1991). The administration of rh
GM-CSF in vivo, in contrast to rh G-CSF, generates significant dose
dependent side effects and these may be related to GM-CSF's known
capacity to generate the secondary production of cytokines and other
inflammatory mediators such as IL-1, TNF and prostaglandins from
activated monocytes.
CSFs also typically enhance the functional activity of mature cells and
the actions of GM-CSF on mature eosinophils, neutrophils and
monocytes are well described (Moore, 1991a). GM-CSF is produced by
endothelial cells, fibroblasts, and also monocytes and T cells largely in
response to inflammatory mediators such as IL-1 and TNF. The
combination of its local effect on mature cells and systemic effect on
myelopoiesis offers a mechanism whereby an appropriate response to






Figure 6: Simple schematic illustration of the haemopoietic cytokine response to infection.
The combination of llie local and systemic production of the myeloid haemopoietic cytokines
IL-6, IL-3, IL-5, GM-CSF, G-CSF and M-CSF not only permits the increased production
of granulocytes and monocytes from bone marrow but also enhances the maturation, survival
and functional properties of mature cells. IL-2 release activates T and B cell mediated
immune responses.
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2.3.3. Granulocyte colony-stimulating factor
Granulocyte colony-stimulating factor (G-CSF) is a lineage specific CSF
which promotes the growth and differentiation of committed
neutrophilic granulocyte progenitors (CFU-G) and which also enhances
the survival and function of mature neutrophils. The gene for G-CSF is
located on chromosome 7 (7q 11.2-2.1) and G-CSF is produced from
endothelial cells and fibroblasts in response to IL-1 and TNF production
from monocytes activated following an inflammatory stimulus. G-CSF
can also be produced from activated monocytes themselves (Moore,
1991a). The in vivo administration of recombinant human (rh) G-CSF
results in neutrophil leucocytosis and has been highly successful in the
treatment of chemotherapy induced neutropenia, congenital, chronic
idiopathic and cyclical neutropenia syndromes (Moore, 1991a) and also
drug induced agranulocytosis (Patton et al, 1992). G-CSF influences the
functions of mature neutrophils by enhancing their ability to
phagocytose particles, to produce superoxide anions in response to the
bacterial peptide f-Met-Leu-Phe and to kill tumour targets through
antibody-dependent cellular cytotoxicity (Clark and Kamen, 1987). The
observation in the murine system that G-CSF can act on early
progenitors by synergising with IL-3 to increase megakaryocyte colony
formation has not been demonstrated in humans (McNiece et al, 1 988)
although G-CSF has been shown to synergise with IL-3 in the production
of total colonies produced from committed myeloid progenitors (Sieff et
al, 1987: Paquette et al, 1987).
2.3.4. Macrophage colony-stimulating factor
Macrophage colony-stimulating factor (M-CSF) is a lineage specific CSF
which promotes the growth and differentiation of committed
macrophage progenitors (CFU-M) but this proliferative property of
human M-CSF is much weaker than that observed for human M-CSF
acting on murine macrophage progenitors. This indicates that the main
function of human M-CSF may be as a survival and activating factor for
mature monocytes and macrophages rather than as a proliferation and
differentiation factor for their precursors (Clark and Kamen, 1987). In
response to M-CSF macrophages have demonstrated enhanced survival,
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increased phagocytosis and intracellular killing of micro-organisms,
enhanced tumour cell killing and the production of cytokines such as
GM-CSF, prostaglandin-E and a-interferon (Whetton and Dexter, 1989).
M-CSF is produced from endothelial cells and fibroblasts in response to
IL-1 and TNF production from monocytes activated following an
inflammatory stimulus. Flowever M-CSF can also be produced from
monocytes themselves in response to inducers such as GM-CSF and a-
INF indicating that an autocrine mechanism may act to control
monocyte/macrophage function during the inflammatory response. M-
CSF binds to a high affinity cell surface receptor that is expressed on
committed precursor cells but to a much higher degree on macrophages.
The M-CSF receptor (M-CSFR) is encoded by the c-fms proto-oncogene
which is located at 5q33.3, and is a transmembrane glycoprotein with
an intracellular tyrosine kinase domain.
Recombinant human M-CSF (rhM-CSF) is currently being administered in
a phase 1 study to patients with metastatic melanoma. Dose dependent
increases in circulating monocytes, which are morphologically large and
extensively vacuolated, have been observed along with modest
decreases in platelet counts. Enhanced functional activity of monocytes
has also been demonstrated along with clinical anti tumour effects and
the treatments have been tolerated well. Other potential indications
advocated for rhM-CSF therapy include therapy for invasive fungal
infections and differentiation therapy for acute myeloid leukaemias and
myelodysplastic syndromes. Recombinant human M-CSF has also been
shown to shorten the period of chemotherapy induced neutropenia but
this effect is probably mediated by the release of secondary cytokines
from activated monocytes such as G-CSF and GM-CSF (Bajorin et al,
1991).
2.3.5. Interleukin 5
Interleukin 5 (IL-5) is produced from T cells and is a lineage specific CSF
for committed eosinophil progenitors which also enhances the functional
activity of mature cells. The human gene for IL-5 is located at 5q31.
Both IL-3 and GM-CSF can also stimulate eosinophil colonies in vitro as
they are multi-lineage in their effects but the regulation of eosinophilia in
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pathological circumstances remains poorly understood. In addition to its
effects on eosinophils, murine IL-5 is also a B cell growth factor but
these properties have not been demonstrated for human IL-5 (Sanderson
et al, 1 988).
2.3.6. Erythropoietin
Erythropoietin (Epo) is a major growth factor responsible for the
regulation of erythropoiesis. It is a true hormone whose existence has
been postulated for many years (Carnot and Deflandre, 1906). It is
secreted into the blood from proximal peritubular cells in the kidney in
response to anaemia and/or tissue hypoxia and acts on erythroid
precursors in the marrow via a recently identified high affinity receptor
(Hambley and Mufti, 1990; D'Andrea and Jones, 1991). Its main site of
action is on the late erythroid progenitor, CFU-E, which is only
responsive to Epo and not to other growth factors. Epo enhances the
proliferation, differentiation and maturation of CFU-E and its progeny to
generate small colonies of erythrocytes (» 120 cells) and offers the
mechanism whereby increased demands for erythropoiesis can be met.
The early erythroid progenitor, BFU-E, is stimulated by IL-3 or GM-CSF
and to a much lesser extent by high concentrations of Epo to divide and
generate CFU-E that can then become responsive to Epo. Therefore Epo
in combination with IL-3 or GM-CSF ultimately generates very large
colonies of differentiated erythroblasts (>2000 cells) which are in fact a
collection of multiple smaller CFU-E colonies (Nathan, 1990; Sieff et al,
1987). The human gene for Epo resides on chromosome 7 and
recombinant human (rh) Epo was the first haemopoietic growth factor
licensed for clinical use. It has proved strikingly effective for the
treatment of anaemia associated with end stage renal failure and is
currently being evaluated in other areas such as the anaemia of
prematurity, autologous blood transfusion, the anaemia of chronic
disease, human immunodeficiency virus associated anaemia and
anaemias associated with primary haematological disorders such as
myeloma and the myelodysplastic syndromes (MDS) (Erslev, 1991;
Davis & Morstyn, 1992). The demonstration in the mouse of
megakaryocyte maturational properties due to Epo has not been shown
in the human haemopoietic system ( Ishibashi et al, 1987).
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2.3.7. Stem Cell Factor (SCF) or c-kit ligand
Stem cell factor is a recently identified haemopoietic growth factor of
great importance whose role in human haemopoiesis remains to be fully
defined. SCF is a stromal derived factor required for murine PHSCs that
is the product of the Steel (SI) locus and the ligand for the tyrosine-
kinase receptor c-kit that is the product of the murine W locus. Mice
with homozygous defects at either the W or SI loci exhibit defective
haemopoiesis, granulopoiesis and melanogenesis indicating that the c-kit
ligand/receptor interaction is of fundamental importance to the
development of these organ systems (Zsebo et al, 1990; Bernstein et al,
1991). The bone marrow of mutant SI mice can reconstitute the
lymphohaemopoietic system of unirradiated W mutant mice, and SCF
has been shown to exhibit potent multi-lineage activity on early murine
myeloid and lymphoid progenitors (McNiece et al, 1991a; Williams et al,
1992). In the human system recombinant human SCF does not promote
haemopoietic colony formation when used alone, but in combination
with other CSFs such as IL-3 or GM-CSF or Epo, SCF stimulates the
growth of greater numbers of colonies that are of increased size than
those seen when the CSFs are used alone (McNiece et al, 1991b). This
synergistic activity of SCF with other CSFs is present on CD34 +
lineage negative cells - the earliest identifiable haemopoietic precursors
(Bernstein ID et al, 1991; Brandt et al, 1992). However whether this
activity is present on cells within this group which are true PHSCs
remains to be determined. Early in vivo studies in primates have shown
that rhSCF stimulates multi-lineage haematopoiesis by increasing the
numbers of peripheral blood erythrocytes, lymphocytes, monocytes,
neutrophils, eosinophils and basophils. Increases in marrow
megakaryocytes were consistently observed but the observed increases
in platelet counts were inconsistent (Andrews et al, 1991). These
preliminary data indicate that SCF is a powerful proliferative st't mulus
for multipotent haemopoietic progenitor cells and possibly for PHSCs.
Its interactions with other haemopoietic cytokine regulators and its
ultimate role in human haemopoiesis remain to be defined but SCF
would appear to be an agent with great therapeutic potential.
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2.3.8. Interleukin 6
Interleukin 6 (IL-6) is a recently characterised multi-functional cytokine
that plays a pivotal role in the co-ordinated host response to injury (Van
Snick, 1990). Both IL-1 and TNF, the initial triggers of the host response
to injury are potent inducers of IL-6 that can be released from many cell
types including fibroblasts, endothelial cells, macrophages and
keratinocytes. Other IL-6 inducers include primary factors such as viral
infection and bacterial lipopolysaccharide. IL-1 and IL-6 share some
properties and synergy, for example in the production of IL-2 from
activated T cells, and it is probable that many of the functions originally
attributed to IL-1 are due to IL-6 (Ikebuchi et al, 1988). Following IL-6
release, acute phase protein synthesis is initiated in the liver, ACTH is
released from the pituitary gland, T cells and haemopoietic precursors
become responsive to their growth and differentiation factors and
antibody production is stimulated in activated B cells. Other properties
include keratinocyte, mesangial cell and B cell proliferation and the
abnormal production of IL-6 is implicated in the pathogenesis of many
diseases including plasma cell neoplasms, mesangial proliferative
glomerulonephritis, psoriasis, rheumatoid arthritis, and AIDS.
The IL-6 gene is located on chromosome 7 and both cis and trans
regulating factors are involved in the regulation of IL-6 gene expression
(Flirano et al, 1990). The IL-6 receptor (IL-6R) is an 80 Kd glycoprotein
that is widely expressed on many cell types in accordance with its
multiple functional properties. It possesses structural similarities to the
IL-1R with an extra cellular region bearing homology with a domain of
the immunoglobulin superfamily and an intracellular portion that does
not possess a tyrosine kinase domain. Signal transduction is believed to
be mediated by an associated non covalently linked 130Kd glycoprotein
(Hirano et al, 1990; D'Andrea and Jones, 1991).
However of special interest are the effects of IL-6 on haemopoietic cells.
IL-6 has been shown to act in synergy with IL-3 in promoting the
proliferation of human multipotential blast cell colonies (Ikebuchi et al,
1987; Leary et al, 1988) and this may be due to IL-6 recruitment of
primitive progenitors into cell cycle. IL-6 also has potent thrombopoietic
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maturational properties in mice in vitro (Ishibashi et al, 1989a;
Quesenberry et al, 1991) and IL-6 induces an increase in platelet number
in vivo in both mice and monkeys (Ishibashi et al, 1989b; Asano et al,
1990). The importance of IL-6 in human megakaryopoiesis has recently
been confirmed by the demonstration of in vitro synergy with IL-3 in the
stimulation of megakaryocyte colonies (Imai et al, 1991) and by the
finding of elevated serum IL-6 levels in patients with reactive
thrombocytosis (Hollen et al, 1991). The clinical application of IL-6 or
inducers of IL-6 such as IL-1 possibly in combination with IL-3 or GM-
CSF for the treatment of hypoproliferative thrombocytopenia can be
expected in the near future.
2.3.9. Interleukin 1
Interleukin 1 (IL-1) release along with TNF is an essential trigger for the
subsequent co-ordinated host response to injury (Bagby, 1989; Starnes,
1991). IL-1 is principally released by activated macrophages in
response to invasive stimuli but it can be produced by many cell types
including endothelial cells, fibroblasts, epidermal cells and smooth
muscle cells. Factors such as cell to cell contact, possibly mediated by
cell adhesion molecules, and other cytokines can also induce IL-1
production (di Giovine and Duff, 1990). IL-1 induction from stimulated
cells can be significantly inhibited by pre-treatment of cells with
glucocorticoids and IL-4.
IL-1 is able to affect haemopoiesis and orchestrate the host response to
injury via the production of secondary cytokines. It acts on fibroblasts
and endothelial cells to induce IL-6, GM-CSF, IL-3, G-CSF, M-CSF, PDGF
and also the autocrine production of further IL-1. IL-1 has been claimed
to act in synergy with IL-3 on multi-lineage haemopoietic progenitor cells
but it has proved difficult to confirm whether these effects are due to
the direct actions of IL-1 on progenitor cells or to the indirect actions
mediated by the release of secondary cytokines (Leary et al, 1988;
Ikebuchi et al, 1988; Kobayashi et al, 1991). IL-1 also acts on
endothelial cells to produce plasminogen activator inhibitor and von
Willebrand factor and is a potent stimulator of bone resorption
(Haworth, 1 989).
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IL-1 activity is due to two molecules IL-1a and IL-1B that have identical
properties and act through a common 70Kd high affinity receptor that is
expressed on most somatic cells. IL-1 a and IL-1 IS share 26% amino
acid homology and are the products of separate genes located on
chromosome 2. It has been proposed that IL-IS evolved by reverse
transcription of IL-1 a during evolution. Of interest is the observation
that IL-1 protects mice from the irradiation-induced lethal haemopoietic
syndrome when the IL-1 a is given before irradiation but the mechanism
of this radioprotective effect remains poorly understood (Neta, 1990).
2.3.10. Interleukin 2.
Interleukin 2 (IL-2), originally described as T cell growth factor, is the
main stimulator of the T cell mediated immune response. IL-2 is
produced by helper T cells that become activated in response to antigen
binding in association with antigen presenting cells (APC) (Pierce, 1989).
The activation process, although dependent on IL-1 and IL-6 production
from APC, is extremely complex and is the result of poorly understood
multiple surface receptor/ligand interactions. Following antigen
activation, helper T cells produce IL-2, start to express its receptor and
are induced to proliferate. Further actions include the production of
other cytokines such as interferons and IL-5, increased activity of non-
MHC restricted cytotoxic effector cells such as natural killer (NK) cells
and lymphokine-activated killer (LAK) cells and the proliferation and
differentiation of antigen-stimulated B cells. The IL-2 receptor is now
well characterised. The high affinity receptor is composed of two non
covalently linked peptide subunits (p55Kd a and p70Kd B) which can
independently bind IL-2 with lower affinity (Hamblin, 1988). A single
copy of the human IL-2 gene exists on chromosome 4 and the gene has
been successfully cloned. Recombinant human IL-2 has been widely
used in vitro in the study of the T cell immune response and in vivo as
immunotherapy for cancer patients (Rees, 1990).
2.3.11. Interleukin 4
Interleukin 4 (IL-4) is a product of activated T cells that was originally
described as a potent cofactor for the stimulation and differentation of B
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cells. Particular properties included the stimulation of IgG and IgE
isotype switching within activated B cells. IL-4 has been subsequently
shown to co-stimulate T cell proliferation in conjunction with phorbol
esters, to enhance the antigen presenting ability of some macrophages
and to synergise with IL-3 in the production of murine mast cells. These
properties of IL-4 of the stimulation of IgE and mast cell production have
suggested a crucial role for IL-4 in the regulation of the allergic response
(Paul, 1991). Other murine studies have indicated that IL-4 is
synergistic with lineage specific CSF, for the in vitro proliferation of
myeloid, erythroid, megakaryocyte and multi-lineage progenitors
(Peschel et al, 1987) but these properties may not be of physiological
significance as the observed effects were sub optimal to those of IL-3.
The role of IL-4 in human haemopoiesis remains unknown.
2.3.12. Interleukin 7.
Interleukin 7 (IL-7) was first described in the mouse as a stromal cell
derived factor, called lymphopoietin-1, which was required for the
growth of pre-B cells. Both the murine and human genes have been
cloned and IL-7 has been shown to stimulate the growth but not
differentiation of both pre-B cells and T cell precursors. Myeloid
precursor cells and mature B cells are unresponsive to IL-7 but mature T
cells will respond to IL-7 in the presence of a secondary stimulus such
as antigen or mitogen (Pierce, 1989; Henney, 1989; Namen et al,
1990). Additional early data from murine reconstitution experiments
also suggests a possible role for IL-7 in platelet production (Namen et al,
1990).
2.3.14 Interleukin 9
Interleukin 9 (IL-9) is a cytokine originally purified from a murine T-cell
line and the cDNA encoding the human homologue has been isolated
from a human leukaemic cell line (Yang et al, 1989; Mock et al, 1990;
Renauld et al, 1990). IL-9 has been mapped to human chromosome 5
and early in vitro studies have shown that IL-9, in combination with Epo,
is able to support the growth of early IL-3 responsive BFU-E (Donahue et
al, 1990). Further characterisation of this cytokine is awaited.
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2.3.14 Interleukin 11.
Interleukin 11 (IL-11) is a cytokine recently cloned from an immortalised
primate bone marrow stromal cell line, the cDNA of which shows 97%
identity with a cDNA sequence isolated from a human fetal fibroblast
cell line (Paul et al, 1990). Recombinant human IL-11, in combination
with IL-3, enhances human megakaryocytopoiesis in vitro (Bruno et al,
1991; Teramura et al, 1992) and rhlL-11, when used alone, is able to
increase megakaryocyte ploidy, indicating that IL-11 has thrombopoietin
activity. In vivo, in rats, rhlL-11 shows a dose dependent increase in
platelet numbers which appears to be mediated by the promotion of
megakaryocyte maturation (Yonemura et al, 1993). Further
characterisation of this potentially important cytokine is awaited.
2.3.15. Leukaemia inhibitory factor (LIF)
Leukaemia inhibitory factor is a multi-functional cytokine which shares
some properties with IL-6. It was originally described in the mouse
following the induction of differentiation and the suppression of growth
of the M1 mouse myeloid leukaemia cell line (Hilton et al, 1988). The
human homologue has been cloned (Gough et al, 1988) and rhLIF has
been given to nonhuman primates where it has been shown to raise the
platelet count and to induce the synthesis of acute phase proteins
(Mayer et al, 1993). Further characterisation of LIF is awaited.
2.3.16. Negative haemopoietic regulators
Spectacular progress in the knowledge of stimulatory growth factors for
haemopoietic cells has been made in recent years; the development of
knowledge of inhibiting factors that affect haemopoietic cell proliferation
has been much slower. Inhibiting factors are likely to be of physiological
importance in maintaining stem and early progenitor cells in quiescent
state and in opposing the actions of stimulatory factors on progenitor
cells. The balance between stimulatory and inhibiting influences offers a
mechanism whereby haemopoiesis can be regulated (Axelrad, 1990;
Moore, 1991b; Wright & Pragnell, 1992). The properties of some
known negative regulators are summarised in Table 4 and described in
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more detail below. The stem cell inhibitor, MIP-1a, has been described
previously (p 8).
Transforming growth factor - beta (TGF-R)
TGF-fc is a potent inhibitor of progenitor cell proliferation which has been
shown to inhibit the colony formation of CFU-GEMM, CFU-Mega, BFU-E,
CFU-E and CFU-GM (Sing et al, 1988; Hino et al, 1988; Cashman et al,
1 990) but its role as a physiological regulator in haemopoiesis remains
unknown. It also inhibits IL2 dependent T cell activation and is induced
in activated T-cells where it may act in a physiological down regulatory
response (Kehrl et al, 1986). In contrast, TGF-(3 which is contained in
platelet a-granules stimulates fibroblast proliferation and wound healing
following platelet activation (Haworth, 1989).
Tumour necrosis factor (TNF-a) and lymphotoxin
These two cytokines are closely linked inside the HLA complex on
chromosome 6 and act with identical functions through the same
receptor. TNF-a is principally released from activated macrophages in
response to invasive stimuli and along with IL-1 is an essential trigger
and mediator of the host inflammatory response. TNFa has many
functions (Brenner, 1988) including actions on endothelial cells and
fibroblasts to induce the production of GM-CSF, M-CSF, G-CSF and IL-6.
However in contrast to IL-1, TNFa is inhibitory to the growth of
haemopoietic progenitor cells in vitro especially in combination with
gamma-interferon (Broxmeyer et al, 1986),
Leukaemia associated inhibitor (LAI)
This was first described as a factor secreted by myeloid leukaemia cells
which reversibly inhibits normal CFU-GM growth but not that of
leukaemia cells. This could provide a selective growth advantage for
leukaemia cells and may explain the characteristic granulocytopenia
observed in acute myeloid leukaemia (Olofsson and Olsson 1980;
Axelrad, 1990). It has since been demonstrated to be produced by
normal cells but its physiological significance remains unknown.
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Inhibin
Inhibin is a glycoprotein hormone produced by the Sertoli cells of the
testis and the granulosa cells of the ovary that acts as a negative feed
back regulator to inhibit excessive secretion of follicle stimulating
hormone (FSH) from the anterior pituitary gland. Inhibin has also been
found in vitro to suppress erythroid colony formation of BFU-E and CFU-
E of human bone marrow but only when these progenitors have been
stimulated to grow by the FSH releasing protein activin. The CSF
activity of activin is mediated through accessory cells which are
probably T cells or macrophages. Inhibin has no effects on IL-3, GM-
CSF or Epo stimulated colony formation (Axelrad, 1990). The
physiological significance of this regulatory system of erythroid
progenitor growth is unknown.
Negative regulatory protein (NRP)
NRP is a physiological negative regulator of murine erythropoiesis. It
reversibly inhibits the stimulatory action of IL-3 on murine BFU-E
(Axelrad, 1990). Its relevance to human haemopoiesis remains
unknown.
Ac-SDKP tetrapeptide
Ac-SDKP is a tetrapeptide that is believed to be part of a larger molecule
that is active in vivo. This molecule prevents the entry of murine CFU-S
into cell cycle after sublethal irradiation or cytotoxic treatment and has
been shown to protect mice from the lethal haematological side effects
of the S-phase specific cytotoxic reagent cytosine arabinoside (Ara-C).
The agent did not affect the response of the murine tumour to Ara-C.
The discovery of a factor in humans which could reversibly protect
human PHSCs would have significant therapeutic potential (Axelrad,




























































































































2.4 The Bone Marrow Microenvironment
The bone marrow is the only site in normal adult mammals where
haemopoiesis takes place and following the injection of haemopoietic
stem cells in experimental or clinical bone marrow transplantation
procedures, long term haemopoiesis still establishes itself only in the
bone marrow. These local tissue influences, critical for haemopoiesis,
have collectively been named the bone marrow or haemopoietic micro
environment. Immunologists, who showed that the thymus and the
Bursa of Fabricius (in birds) were essential for T and B cell development
respectively, highlighted first the importance of the micro environment in
blood cell development but early data on the importance of stromal
elements in the regulation of haemopoiesis came from the study of mice
with mutational defects of the stromal cell environment. Such SI
mutant mice (SI/SI^) exhibited defective erythropoiesis that could not be
rescued by normal marrow stem cells and, when irradiated, such mice
could not support the growth of transplanted normal CFU-S (McCulloch
et al, 1965). However when bone marrow from normal mice was joined
to Sl/S|d spleen, the implanted normal marrow stroma was able to
support active erythropoiesis while adjoining SI/SI^ stroma remained
quiescent (Wolf, 1979). The SI mutation has now been characterised as
a defect in the stromal production of stem cell factor (p 25).
Our further knowledge of the bone marrow microenvironment has been
greatly increased following the development of techniques which have
successfully reproduced in vitro the stromal cell dependent maintenance
of sustained haemopoiesis. Early systems described culture conditions
which were optimal for myelopoiesis (Dexter et al, 1977; Moore et al,
1979; Gartner and Kaplan 1980) but these were further developed to
permit long term in vitro lymphopoiesis (Whitlock and Witte, 1982). In
such long term bone marrow cultures (LTBMC) a heterogeneous, multi-
layered adherent layer of stromal cells develops after 2-3 weeks of
culture and in these cultures both putative PHSCs and haemopoietic
progenitor cells can be maintained for up to several months. However,
if the adherent layer fails to form or if it is disrupted, sustained
haemopoiesis will not occur. This supportive bone marrow stroma
contains an extra-cellular matrix (ECM) and a variety of cell types
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including fibroblasts, endothelial cells, adipocytes and macrophages.
Accessory cells such as T cells or monocytes/macrophages which may
secrete multiple cytokines combine with the bone marrow stroma to
complete the bone marrow microenvironment.
Haemopoietic precursor cells interact with the bone marrow
microenvironment via the release of soluble cytokines and via a complex
pattern of cell-cell and cell-matrix interactions (Torok-Storb, 1988;
Gordon et al, 1988; Clark et al, 1992) to ultimately generate more
mature cells that are then released from the adherent stromal layer.
(Figure 7). For example, haemopoietic progenitor cells have been shown
to be preferentially located in the adherent layer of LTBMC (Coulombel
et al, 1983) and the colony-forming ability of the CFU-blast (believed to
be a very primitive multipotent cell) described by Gordon et al, 1987 is
stroma dependent. Developing granulocytes in LTBMC are usually found
in association with adipocyte rich areas of stroma and maturing
normoblasts and reticulocytes both in vivo and in vitro are commonly
seen in close juxta-position to central macrophages (Dexter, 1982).
The cell-matrix interactions have been further characterised. The extra
cellular matrix consists of fibronectin, laminin, multiple types of collagen
and proteoglycans molecules (Gordon, 1988). Proteoglycans molecules
consist of a protein core to which glycosaminoglycans molecules (GAG)
such as chondroitin sulphate and heparin sulphate are attached. Studies
have demonstrated that GAG can bind CSFs such as IL-3 and GM-CSF
and present them to haemopoietic progenitor cells (Gordon et al,
1 987b; Roberts et al, 1 988) and have also shown that fibroblast derived
fibronectin preferentially binds to early erythroid progenitors (Tsai et al,
1987). In addition to these cell-cell and cell-matrix interactions it is
becoming increasingly recognised that many of the regulatory cytokines




Figure 7: Schematic diagram showing the cellular and cell/matrix interactions
operative within the bone marrow microenvironment. A complex network of
interactions is generated by the 1) heterogeneity of the stromal cell and
haematopoietic cell types; 2) production of several different growth factors and
inhibitors; 3) heterogeneity of extra cellular matrix molecules and 4) differing




INTRACELLULAR EVENTS ASSOCIATED WITH THE REGULATION
OF NORMAL HAEMOPOIESIS.
Knowledge at the biochemical and molecular level of the intracellular
events associated with the regulation of normal haemopoiesis is
fundamentally important to our understanding of the mechanisms
involved in disordered haemopoiesis. Previous studies have indicated
that malignant haemopoietic cells exhibit cell surface characteristics
similar to normal cells and that the mechanisms involved in their
malignant potential relate to disordered internal events at the molecular
level. Haemopoietic malignancies and dysplasias reflect an imbalance
between the processes which integrate normal cell growth, lineage
commitment and differentiation, illustrating how closely linked these
processes are in both normal and abnormal cells. However, in contrast
to our knowledge of the external factors that regulate haemopoiesis
(See Chapter 2) our understanding of the internal molecular events
associated with the processes of lineage commitment, cell growth and
differentiation is extremely limited.
However a great stimulus to research in this area has been the
identification of oncogenes and the recent cloning of haemopoietic
growth factors and their receptors. Cellular proto-oncogenes (c-oncs)
code for proteins which control cell growth and differentiation in normal
cells. These products were first recognised in RNA tumour viruses as
being the constituents (viral oncogenes) responsible for their ability to
transform cells to a malignant phenotype. Study of the structure and
sequence of viral oncogenes (v-oncs) has shown them to be closely
homologous with cellular proto-oncogenes and it is believed therefore,
that the viral genes evolved through retrovirus capture and subsequent
mutation of cellular proto-oncogenes. It has since been shown that
these cellular proto-oncogenes encode for products such as growth
factors, growth factor receptors and mediators of intracellular
transduction pathways. Abnormal cellular proto-oncogene expression is
involved in human malignancies, including those of the haemopoietic
system. The intracellular events that are involved in these processes are
described in more detail below. To date the activities of known
37
transforming oncogenes and haemopoietic growth factors, are best
understood in the context of mitogenesis and cell proliferation. In
contrast, the intracellular events governing processes such as lineage
commitment and cellular differentiation are poorly understood and the
purpose of the experimental work described in this thesis is to develop
our knowledge in these important areas.
3.1 Haemopoietic regulatory cytokines
The importance of haemopoietic growth factors to the survival,
proliferation, differentiation and activation of haemopoietic cells at
various stages of development has been described previously (Chapter
2). Of enormous additional significance to the biology of neoplasia was
the discovery that the viral oncogene (v-sis) product was closely
homologous with a human growth factor, the R>-chain of platelet derived
growth factor (PDGF) (Waterfield et al, 1983). However the factors
governing the gene expression of haemopoietic growth factors and the
role of abnormal expression of CSFs in haemopoietic malignancy remain
poorly understood. Although evidence has suggested that such
cytokines as GM-CSF and IL-6 may play a role by either autocrine or
paracrine mechanisms in the pathogenesis of acute myeloid leukaemia
and myeloma respectively the intracellular mechanisms involved remain
unknown (Lang and Burgess, 1990). What is clear, however, is that the
genes that encode for certain haemopoietic growth factor receptors do
have oncogenic potential (see below).
3.2 Haemopoietic regulatory cytokine receptors
The very recent cloning of haemopoietic growth factors and their
receptors has facilitated further study of the intracellular biochemical
events associated with CSF-induced cell proliferation and differentiation.
It was the establishment of growth factor dependent cell lines which
express high numbers of individual cytokine receptors that enabled a
large number of cytokine receptors to be isolated, cloned and
sequenced. This knowledge of the structure of cytokine receptors has
generated increased understanding of the processes of receptor-ligand
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interaction and subsequent intracellular signal transduction (Kaczmarski
and Mufti, 1991; Vairo and Hamilton, 1991; Kan et al, 1992).
All cytokine receptors are transmembrane glycoproteins made up of an
extracellular amino-terminal portion, responsible for binding the
appropriate ligand, a short hydrophobic transmembrane region and a
carboxy-terminal intracellular portion. The intracellular portion of the
molecule is responsible for the transduction of signals that are the
consequence of ligand binding. Many receptors share structural
similarities and these have been grouped together in the cytokine
receptor superfamily (Figure 8). This structural homology is also shared
between haemopoietic and non-haemopoietic growth factor receptors
(e.g. for growth hormone and prolactin) and may in part explain the
overlapping actions of different cytokines and further supports the
concept that the cytokine network has developed from a common
evolutionary ancestor. The basis of this structural homology is a 210
amino acid stretch of the ligand binding domain which contains four
conserved cysteine residues and a repeated tryptophan-serine motif
separated by a random amino acid residue (Trp-Ser-X-Trp-Ser) which in
most receptors is placed just proximal to the transmembrane domain
(Figure 9). However, not all cytokine receptors share this particular
structure. Other receptors, such as the M-CSF receptor, the IL-1
receptor and the PDGF receptor have immunoglobulin domains in their
extracellular portions and form part of the immunoglobulin like
superfamily. These receptors do not share the homologous regions of
the cytokine receptor superfamily. There is however some overlap
between the cytokine receptor and immunoglobulin superfamilies as
illustrated by the receptors for IL-6 and G-CSF, both of which have
immunoglobulin like domains and also structural homology with the
cytokine receptor superfamily (Figure 8). The G-CSF receptor differs
further by containing three fibronectin Type III domains between the
region containing the conserved cysteines and the transmembrane
domain (Figure 8). As fibronectin has been implicated in cell/cell
interactions and heparin binding it is possible that this region is involved
in the association of myeloid progenitor cells with marrow stromal
elements and heparin sulphate-bound growth factors. There is little
amino acid sequence homology in the intra-cytoplasmic portions of the
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Homologous ligand binding domain of cytokine receptor superfamily
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Figure 8: The overlap in structure between the immunoglobulin-like superfamily of
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Figure 9: The generic structure of the cytokine receptor superfamily
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cytokine receptor superfamily, but these intracytoplasmic portions are
rich in proline and serine residues. The mechanisms involved in signal
transduction at these receptors remain unknown. However, the
receptors for M-CSF and PDGF (part of the immunoglobulin superfamily)
and also the receptor for SCF, which is encoded by the c-kit oncogene,
are known to effect signal transduction by intrinsic tyrosine kinase
activity. The importance of protein phosphorylation in intracellular
signalling is described below (p 44).
The importance of altered growth factor receptor expression in human
malignancy has become increasingly recognised. The M-CSF receptor
and the SCF receptor are encoded by the cellular proto-oncogenes c-fms
and c-kit respectively. Point mutations within c-fms at codons 301 or
967, analogous to those found in v-fms have been found in vivo and
may result in a constitutively active or upregulated receptor with
resultant cell transformation (Tobal et al, 1990). Similarly mutations
within the stem cell growth factor receptor gene (c-kit result in
autonomous cell growth [Yarden, 1988; Catlett et al, 1990]) and the
recent demonstration of a point mutation in the murine Epo receptor,
which results in autonomous cell growth, suggests that the human EpoR
is a potential cellular proto-oncogene (Yoshimura et al, 1990). The
genetic mechanisms involved in the regulation of the expression of the
high affinity alpha subunit component of the IL-2 receptor (IL-2a R) have
been studied in detail and have provided insights into the pathogenesis
of the HTLV-1 associated adult T-cell leukaemia/lymphoma syndrome
(Kaczmarski and Mufti, 1991). HTLV-1 encodes a 40 kD trans-
activating regulatory protein, Tax, that upregulates viral replication
through binding to a DNA-binding site within the viral long term repeat
(LTR) sequences. The viral DNA-binding site is homologous to the
promoter regions for human IL-2aR and IL-2. The binding of Tax
proteins to these sites sets up an autocrine loop enabling IL-2 secretion
as well as IL2aR expression with resulting T-cell proliferation.
3.3 Intracellular signal transduction
The activation of a membrane receptor by the binding of a ligand such




















































message that is transmitted to the nucleus to effect gene transcription
and subsequent events such as DNA synthesis or cellular differentiation.
Further study has shown that these biochemical messages involve
changes in the intracellular metabolism of inositol and changes in the
phosphorylation status of intracellular proteins. In some instances it has
been shown that these phosphorylation events induce the expression of
nuclear transcription factors that directly result in DNA synthesis.
These intracellular signal transduction mechanisms are outlined in more
detail below.
3.3.1. Intracellular protein phosphorylation
The discovery of cyclic adenosine monophosphate (c-AMP) dependent
protein kinase some 20 years ago indicated how important reversible
phosphorylation is in the regulation of protein function in eukaryotic cells
(Cohen, 1982). Four groups of protein kinases which are involved in
growth regulation have been described.
The c-AMP dependent protein kinase (PKA)
Certain ligand-receptor interactions particularly those involving hormones
result in the activation of membrane bound adenylate cyclase to yield c-
AMP as a second messenger. The interaction between the receptor and
the second messenger system is mediated by regulatory guanine
nucleotide binding (G) proteins that can either be stimulatory (Gs) or
inhibiting (Gi) (Figure 10). The activation of PKA by c-AMP results in
the phosphorylation of certain target proteins but the potential
significance of these events in the control of cellular proliferation and
differentiation remains unknown.
Phospho-inositol 4,5 bisphosphate hydrolysis and Protein kinase C
Receptor ligand interactions may result in the activation of
phospholipase C mediated hydrolysis of the lipid phospho-inositol 4,5
bisphosphate (PIP2) to release inositol 1,4,5 tris-phosphate (Ins
(1,4,5)P3> and 1,2 - diacyl glycerol(DAG) (Figure 10). Once generated
in this way Ins (1,4,5) P3 mediates the release of calcium from internal
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stores which may activate calcium/calmodulin dependent protein kinases
(see below) and may be further phosphorylated to produce inositol
1,3,4,5 tetrakisphosphate (Ins (1,3,4,5)P4) which stimulates the
transport of calcium from the extracellular environment into the cell.
The second product of PIP2 hydrolysis, DAG, remains within the
membrane and activates the calcium and phospholipid dependent serine
and threonine-specific protein kinase C (Nishizuka, 1988; Berridge and
Irvine, 1989). Protein kinase C appears to have a central role in the
regulation of cell activity. In particular PKC mediated phosphorylation
events are believed to be important in receptor down regulation and
both cellular proliferation and differentiation. Key regulatory molecules
that are phosphorylated by PKC include the receptors for transferrin,
insulin, T cell antigens and epidermal growth factor (EGF) and in the
case of EGF receptor, phosphorylation results in inhibition of the
receptor's own intrinsic protein kinase activity (Rayter et al, 1989).
This finding reveals the intricate interactions of various protein kinases
in the cell whereby apparently simple protein modifications can bring
about marked changes in the physiology of cells. The tumour-promoting
phorbol ester, phorbol myristate acetate (PMA) has been shown to
directly activate PKC and PMA-treated cells have been shown to exhibit
increased expression of the mitogenic proto-oncogene transcription
factors c-jun, c-fos and c-myc.
These observations indicate that PKC activity may be an important
regulatory pathway for the control of both normal and abnormal cellular
proliferation. However PKC activation may also have an important role
in growth arrest and cellular differentiation as PMA treatment of the
human promyeloid cell line HL60 has been shown to promote terminal
monocyte differentiation in these cells.
Calcium/calmodulin dependent protein kinases
Calmodulin is an intracellular protein that undergoes conformational
change following binding with calcium which potentiates its capacity to
activate various protein kinases. One such kinase, protein kinase III,
phosphorylates elongation factor-2 (EF-2) which results in the
dissociation of EF-2 from the ribosomes, thereby inactivating protein
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synthesis. It has been proposed that rapid phosphorylation/
dephosphorylation of EF-2 in response to exogenous growth signals may
allow newly synthesised RNAs produced shortly after mitogen binding
rapid access to the translation machinery (Rayter et al, 1989).
Protein tyrosine kinases
The observations that the membrane bound receptors for the growth
factors SCF, M-CSF, EGF and PDGF (the first three of which are
encoded by the cellular proto-oncogenes c-kit, c-fms and erb-B
respectively) all have intrinsic tyrosine kinase activity in their
cytoplasmic domains strongly support the concept that intracellular
phosphorylation events are involved in their signal transduction
pathways. Other cellular proto-oncogene products e.g. c-abl, c-src
encode for cytoplasmic tyrosine kinases and the c-raf and c-mos proto-
oncogene products encode for cytoplasmic serine/threonine protein
kinases (Marshall, 1989). The substrates for these protein kinases
remain unknown but oncogenic alterations in these products appear to
result in elevated enzyme activity. For example the v-abl protein and the
bcr-c-abl fusion protein, which is produced in most cases of chronic
granulocytic leukaemia, have much greater tyrosine kinase activity than
the native c-abl proto-oncogene product.
3.3.2. Nuclear transcription factors
The localisation of several cellular proto-oncogene products such as
those for c-jun, c-fos, c-myc, p53 and erb-A, to the cell nucleus
completed the link in the signal transduction pathway from the cell
membrane to the nucleus. These proto-oncogene products are involved
in the regulation of gene transcription and DNA replication. The c-jun
proto-oncogene product encodes for the transcription regulator AP-1
which activates the transcription of several genes, including those for c-
fos and c-myc, which are involved in cellular proliferation. The
expression of genes which appear to be regulated by AP-1 can also be
induced by the pre-treatment of cells with the phorbol ester, PMA,
which is an activator of PKC. Therefore, this mechanism illustrates that
a membrane initiated intracellular phosphorylation event can be
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a) Synthesis ofmyo-inositol from glucose
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glycerol - 3 - phosphate
O = P
O =C C= 0
Fatty acid side chains
3 - phosphatidyl inositol (3 - ptd Ins)
Figure 11: Basic structure and synthesis ofmyo-inositol
and phosphatidyl-inositol (Ptd Ins).
For more detailed explanation see text.
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intimately linked with DNA transcription (Rayter et al, 1989). The
proto-oncogene c-erb A is the receptor for the hormone tri-iodothyronine
(T3). This is one of a superfamily of intracellular hormone receptors
which are capable of binding to DNA and regulating gene transcription.
3.3.3. Inositol metabolism
Inositol is a cyclic six carbon sugar alcohol synthesised from glucose
which exists in the biologically active stereoisomer form of myo-inositol
(Figure 11a). The inositol ring forms an integral part of membrane
bound phospholipids and also exists in water soluble intracellular inositol
metabolites including glycerophospho-inositol (GPI), inositol and inositol
phosphorylated at one or more positions of the inositol ring giving rise to
inositol mono, bis, tris, tetra, penta and hexaphosphates. Evidence is
mounting that several of the metabolites of inositol play important roles
in the regulation of eukaryotic cells.
Inositol containing phospholipids
Inositol containing phospholipids, which are a ubiquitous component of
all eukaryotic cell membranes, are based on the structure of
phosphatidyl inositol (Ptd Ins, Figure 11b). Ptd Ins is based on a
backbone of glycerol-3-phosphate which is produced by the glycolytic
pathway. The hydroxyl (OH) groups of carbon atoms 1 and 2 of
glycerol-3-phosphate are esterified by fatty acid side chains (R1, R2)
which reside within the membrane lipid bilayer. The OH group of carbon
number 3 is esterified with a phosphate group which is then attached to
the 1 carbon position of myo-inositol. The OH groups of the different
carbon atoms of the myo-inositol ring can be phosphorylated to yield
various Ptd Ins phosphates. Ptd Ins (4) phosphate and Ptd Ins (4,5)
bisphosphate are synthesised sequentially by the action of Ptd Ins 4-
kinase and Ptd Ins (4)P-5 kinase respectively. Ptd Ins (4,5)
bisphosphate (Ptd Ins (4,5) P2) is the membrane bound precursor for the
secondary messengers Ins (1,4,5) P3 and Ins (1,3,4,5) P4 described
previously (p 44).
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Another major role for inositol containing phospholipids is as a
membrane anchor for surface proteins. Many proteins which do not
contain hydrophobic membrane spanning sequences are covalently
attached to phospholipids contained within the cell membrane. In these
circumstances the carboxy terminus of the protein is linked via an
ethanolamine/glucosyl linkage to the C6 position of phosphatidyl
inositol. Because of the glycosyl-phosphatidyl-inositol linkage these
proteins are known as GPI-linked proteins (Ferguson and Williams,
1988). Of additional interest in this area has been the recent discovery
that the underlying defect in paroxysmal nocturnal haemoglobinuria
(PNH) may be due to the defective linkage of GPI linked proteins in
affected cells. PNH is associated with protean clinical manifestations
which are caused by the absence of important regulatory molecules
from the surface of haemopoietic cells. These molecules include
complement control proteins such as decay accelerating factor,
membrane inhibitor of reactive lysis (MIRL, CD59) and C8 binding
protein which, when reduced on PNH erythrocytes, increase the
susceptibility of these cells to complement mediated lysis. Other
missing surface proteins include lymphocyte function antigen 3 (LFA-3,
CD 58) and the major receptor on neutrophils for the Fc portion of IgG
(FCRIII, CD16). Absent LFA-3 may contribute to the defective control
of haemopoiesis observed in PNH and the absence of FCRIII from
neutrophils may contribute to the increased susceptibility to infection
seen in this condition. The common feature of these and the other
surface proteins missing in PNH is that they are all attached to the cell
membrane by GPI anchors (Rosse, 1990).
Intracellular inositol phosphates
In addition to lipid containing inositol phosphates, eukaryotic cells also
contain phosphorylated forms of myo-inositol. These compounds, being
highly polar, are water soluble and are predominantly located within the
cytoplasm. Detailed information concerning the metabolism and
functions of intracellular inositol metabolites, particularly, the highly
phosphorylated forms, is lacking but recent evidence suggests that they
may have a role in myeloid differentiation (Michell et al, 1990). Cells
from the human promyeloid cell line HL60 contain high concentrations
49
of the highly phosphorylated inositol compounds, inositol
pentakisphosphate (Ins P5) and inositol hexakisphosphate Ins Pq)
(French et al, 1991). During dimethylsulphoxide (DMSO) induced
neutrophil differentiation of HL60 cells, there is a 3-fold increase in the
intracellular concentration of Ins P5 and, in contrast, following PMA-
induced monocyte differentiation the intracellular concentration of Ins P5
in HL60 cells falls by 90% (French et al, 1991). In addition to a fall in
Ins P5 PMA-induced monocyte differentiation was also associated with
a fall in the intracellular concentrations of inositol tetrakisphosphate (Ins
P4) and Ins Pq. These changes, which may suggest an important role
for the abundant inositol polyphosphates in myeloid differentiation, were
investigated further in this thesis. It was important to determine
whether the high levels of the highly phosphorylated inositol compounds
seen in HL60 cells are a feature of either leukaemic potential or
immature myeloid cells and also whether the observed changes in levels
seen in HL60 cells also occur in normal myeloid cells as they undergo
differentiation. To study these questions a homogeneous population of
undifferentiated myeloid blast cells was purified from human fetal liver
and subjected to analysis of the intracellular concentrations of inositol
phosphates as they underwent PMA-induced monocyte differentiation.
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CHAPTER 4.
MODEL SYSTEMS FOR THE STUDY OF INTERNAL BIOCHEMICAL
EVENTS IN HUMAN HAEMOPOIETIC CELLS.
The opportunity to study internal biochemical and molecular events
within haemopoietic cells, which are related to lineage commitment,
proliferation and differentiation is dependent upon the availability of
suitable experimental model systems. Although considerable progress
has been made from the study of murine experimental systems, these
may not be relevant to human haemopoiesis, particularly where
disordered events result in lineage aplasias, dysplasias and neoplasias.
The relative advantages and disadvantages to be gained from studying
differing models of human haemopoiesis are presented below. It is
proposed that an integrated approach, gaining knowledge from all
available model systems, be followed in order to resolve these issues.
4.1. Haemopoietic cell lines
Haemopoietic cell lines offer considerable advantages through their
ability to produce large numbers of cells which are relatively
homogeneous and routinely available. The numbers of cells available are
sufficient for biochemical and molecular studies (Lubbert and Koeffler,
1988). Some examples of haemopoietic cell lines which have been
particularly useful as models for the study of haemopoietic cell
proliferation and differentiation are listed in Table 5. Other haemopoietic
cell lines have also made significant contributions. Because many cell
lines are dependent on growth factors for either their survival or
proliferation potential, such cell lines have been used 1) in bioassays for
cytokines (e.g. for IL-2 or for IL-6), 2) for the isolation and purification of
high affinity cytokine receptors and 3) for the study of the mechanisms
of cytokine signal transduction and subsequent cytokine actions.
However significant differences exist between normal cells and cell
lines. Normal haemopoietic cells are factor dependent and have normal
karyotypes. Tumour cells are also generally factor dependent and have
subtle genetic differences which may or may not be detectable at the
karyotypic level. Haemopoietic cell lines have been generated from
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tumour cells and these cell lines generally lose their factor dependence
and also become increasingly genetically altered with continued passage
in tissue culture. Therefore cell lines have significant limitations
because they neither represent normal cells nor de novo leukaemia cells
which are the cell populations of greatest interest.
Therefore disadvantages of cell lines as model systems include the
limited choice of suitable cell lines available for study and problems
concerning the interpretation of the results obtained. For example it
may be difficult to determine whether the effects observed relate to
events occurring 1) as part of normal cellular processes, or 2) whether
the events are related to the cells abnormal transformed status or 3)
relate to long term passage in vitro. Furthermore the limited range of
haemopoietic cell lines available already show evidence of lineage
commitment and are therefore not amenable for the study of events
relating to the lineage commitment, proliferation and differentiation of
the most primitive haemopoietic precursors.
An interesting model system not yet available for the study of human
haemopoiesis has been the isolation of a series of murine multi-potential
haemopoietic cell lines known as FDCP-Mix which grow continuously in
the presence of IL-3 (Factor-Dependent Continuous cell lines, Paterson
Laboratories, Spooncer et al, 1986). These cells are non-leukaemic and
have a normal karyotype and in the absence of IL-3 they die. However
when cultured in association with marrow stromal cells in the absence
of IL-3 or in low concentrations of IL-3 in combination with other
myeloid growth factors, these cells show evidence of differentiation
along different myeloid lineages (Heyworth et al, 1990). It would be a
great advantage to isolate from humans similar normal multi-potential
growth factor dependent haemopoietic continuous cell lines.
4.2. Normal human haemopoietic cell populations
To overcome the problems of interpretation of results obtained from the
study of transformed cell lines one would prefer to study normal cell
populations. However, for the study of biochemical and molecular





















































































population but it has proved difficult to isolate haemopoietic precursor
cells in sufficient numbers for such studies. Haemopoietic precursor
cells only exist at very low frequencies in haemopoietic tissues such as
adult bone marrow, fetal liver and neonatal cord blood. However, the
increasing sophistication of haemopoietic precursor cell fractionation
procedures and the ability to maintain undifferentiated cells in serum-
free media in the presence of cocktails of the recently cloned
haemopoietic growth factors have permitted a great opportunity to
generate homogeneous populations of normal haemopoietic precursors
in sufficient numbers for appropriate biochemical studies. The cell
fractionation techniques employed have included density gradient
separation, separation of cells following lectin or plastic adherence,
positive or negative selection using monoclonal antibodies directed
against cell surface antigens, cell sorting following flow cytometry, cell
separation using centrifugal counter flow elutriation and the treatment of
cells by S phase specific chemotherapeutic agents. The studies
described in this thesis include the development of a homogeneous
population of undifferentiated myeloid cells from human fetal liver which
was used for subsequent biochemical analysis.
However the availability of model systems for biochemical and molecular
analysis is of limited value unless one knows what events to study.
This is a problem when the events are unknown, such as those internal
events which regulate lineage commitment, proliferation and
differentiation within haemopoietic cells. Under these circumstances
one either has to adopt a shotgun approach and study many avenues
blindly in the hope that one will prove fruitful or alternatively select
individual avenues for study based on previous observations made from
other model systems. One major area where clues have arisen as to the
mechanisms governing normal and abnormal cell development has come
from the study of individual cases of haemopoietic lineage neoplasias
and dysplasias.
4.3. Individual cases of haemopoietic neoplasias and dysplasias
Individual cases of leukaemias and lineage dysplasias result from
perturbations of the normal cellular processes which control lineage
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commitment, proliferation and differentiation. Many of these cases have
been associated with structural chromosomal abnormalities such as
chromosomal translocations, inversions, deletions and amplifications
(Rabbitts and Rabbitts, 1989; Berger, 1992). Further study of these
chromosomal abnormalities has indicated that genes which code for key
regulators of lineage commitment, proliferation and differentiation are
located at or near the sites of the chromosomal aberrations. In cases of
chromosomal deletions, these abnormalities may be a guide to the
location of tumour suppression genes and such abnormalities have been
shown to be involved in the pathogenesis of retinoblastomas and Wilm's
tumours (Rabbitts and Rabbitts, 1989). Examples where the increased
expression or activation of known cellular proto-oncogenes occurs in
human haemopoietic malignancies as a result of major chromosomal
abnormalities are shown below in Table 6.
Of special relevance to the pathogenesis of the B lineage malignancies
documented in Table 6 is the involvement of immunoglobulin (Ig) gene
loci in the chromosomal aberrations. For example the Ig heavy gene
locus is located at 14q32, the Ig kappa light chain gene locus is located
at 2p12 and the Ig lambda chain gene locus is located at 22q11. Of
parallel interest is the observation that many human T cell leukaemias
are associated with abnormalities of chromosome 14 principally
involving band 14q 11, the location of the gene for the alpha-chain of
the T cell receptor (TCR-a). The juxta position of oncogenes next to
those for either the Ig or TOR genes may result in the aberrant
expression of these oncogenes resulting in either B or T cell neoplasias
(Rabbits and Rabbitts, 1989; Berger, 1992).
Acute promyelocytic leukaemia is another haemopoietic malignancy
associated with a specific chromosomal abnormality [t(1 5;1 7)(q22;q21)]
where a re-arranged gene has been implicated in the pathogenesis of the
disease. In this case the gene for the alpha receptor for retinoic acid
(RAR-a) is translocated to join a chromosome 15 transcription unit,
originally named MYL but now called PML, and transcribed as part of a
fusion mRNA which is believed to encode for an abnormal RAR-a
protein. The normal RAR-a gene codes for a nuclear receptor protein



































































































myeloid differentiation (Biondi et al, 1991). It has recently been shown
that these patients respond to differentiation therapy with all-trans
retinoic acid (trans RA) and it is believed the arranged RAR-a gene may
confer therapeutic sensitivity of the disease to trans RA (Warrell et al,
1991; Borrow & Solomon, 1992)).
However there are many well defined structural chromosomal
abnormalities which occur in association with human haemopoietic
malignancies which have not been resolved at the molecular level
(Berger, 1 992). Some examples are listed below in Table 7. It is likely
that key genes involved in haemopoietic cell regulation will be found to
be located at the site involved in these chromosomal aberrations.
Table 7 Human haemopoietic malignancies associated with well
described chromosomal abnormalities which have not been
defined at the molecular level.
Malignancy Chromosomal abnormality
AML (M2) t (8; 21 )(q22;q22)
AML (M4Eo) inv(1 6) (p13;q22) or del(16)(q22)
AML (M5) t(9; 1 1 )(p21 ;q23)
ALL t (4; 1 1 )(q21 ;q23)
ALL t( 1; 1 9)(q23;p13)
AML Acute myeloblasts leukaemia
ALL Acute lymphoblastic leukaemia.
In addition to cytogenetic and molecular DNA analysis, cells from cases
of haematological dysplasias and neoplasias can be used in culture
studies. Indeed, this is how haemopoietic cell lines have been produced
but only a very small minority of such cultures ultimately generate
transformed phenotypes which can be maintained in culture indefinitely.
The recent cloning of many haemopoietic growth factors and cytokines,
on which both many normal and malignant haemopoietic cells are
dependent for survival, has offered the opportunity to maintain such
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cells in culture for prolonged periods in order that biochemical and
molecular studies can be performed. Indeed, the option of studying
both normal cells and their transformed counterparts enables
comparative analyses to be undertaken which may indicate the
molecular phenomena associated with neoplasia.
As the purification of adequate numbers of homogeneous normal
haemopoietic precursors for studies of lineage commitment and
differentiation has proved difficult, it is useful to consider the potential
of abnormal stem cells for similar studies. In this regard cases of
primary myelofibrosis (PMF) are of considerable interest as PMF is
generally associated with greatly increased levels of circulating
haemopoietic progenitors including multi-lineage progenitors (CFU-
GEMM), megakaryocyte progenitors (CFU-Meg), erythroid progenitors
(BFU-E) and granulocyte-macrophage progenitors (CFU-GM)( Partenen et
al, 1 982; Douer et al, 1 983; Hibbin et al, 1 984; Carlo-Stella et al, 1 987;
Craig et al, 1991). Indeed many cases of PMF have even shown
erythropoietin independent erythroid colony formation (Hibbin et al,
1984; Carlo-Stella et al, 1987). Therefore, as part of this thesis a single
patient with PMF was selected for investigation to assess the feasibility
of using such patients as a source of haemopoietic stem cells suitable
for further study. The results obtained were of considerable interest
and they generated different avenues of further study which are outlined




The principal objectives of this study were:
1) to purify an undifferentiated normal myeloid blast population from
human fetal liver that would be suitable for the study of intracellular
biochemical events which occur during normal myeloid differentiation;
2) to study changes in the intracellular concentrations of inositol
phosphates as these undifferentiated normal myeloid blast cells
underwent phorbol myristate acetate-induced monocyte differentiation;
3) to compare the results obtained for values of intracellular
concentrations of inositol phosphates within undifferentiated normal
myeloid cells with those previously obtained from the study of HL60
cells and to compare the changes observed after PMA-induced
monocyte differentiation of both cell types.
As a contributory part of this thesis an individual case of primary
myelofibrosis was selected for further study for two reasons:
1) to determine the potential of such patients as a source of
haemopoietic cells to develop model systems which can be used to
characterise biochemical and molecular events associated with lineage
commitment, proliferation and differentiation in the human haemopoietic
system;
2) to confirm clinical and morphological features in the patient
suggesting an intrinsic defect in erythropoiesis and by further karyotypic
and molecular study to determine the possible chromosomal location of
genes which encode key regulators of erythroid lineage development.
The clinical, haematological and morphological features of the case are
described in the material and methods section (p 61).
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SECTION 2. MATERIALS AND METHODS
CHAPTER 6. CELLS
6.1 Normal Cells
Normal peripheral blood cells were used as control cells for
histochemical and immunostaining procedures performed on fractionated
fetal liver cells. They were also used as positive control cells for
titrations of monoclonal antibodies used in this study.
6.1.1. Peripheral blood mononuclear cells
Mononuclear cells, consisting of lymphocytes and monocytes were
prepared from the peripheral blood of healthy donors by ficoll
fractionation (Boyum, 1968). Heparinised blood (8 mis) was layered
onto 3 ml ficoll hypaque (Pharmacia, UK) and centrifuged at 400g for 40
minutes at 20°C. The interface cells were carefully harvested with a
Pasteur pipette and washed in RPMI 1640 medium (Gibco, UK)
containing 2% V/V fetal calf serum (FCS, Gibco, UK), first at 500g for
10 minutes, then twice at 250g for 10 minutes at 20°C.
6.1.2.Dextran sedimented peripheral blood leucocytes
Neutrophil rich suspensions were prepared by erythrocyte sedimentation
of peripheral blood using a solution of 6% hydroxyethyl starch in 0.9%
saline (Hespan, Du Pont, UK). Heparinised blood was mixed with
hespan in a ratio of 7:1 and the mixture was incubated at 37°C for 60
minutes. The upper layer containing leucocytes was carefully removed
and washed three times in RPMI 1640 medium containing 2% V/V FCS
(250g for 10 minutes at 20°C).
6.1.3 Bone marrow cells
Bone marrow cells from haematologically normal donors were obtained,
with informed consent and local hospital ethical committee approval,
either from the sternum of patients undergoing cardiac surgery or from
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donors for allogeneic bone marrow transplantation. Fresh bone marrow
was collected into Iscove's Modified Dulbecco's Medium (IMDM, Gibco,
UK) containing 2.5 iu/ml preservative free heparin (monoparin, CP
Pharmaceuticals, UK). Mononuclear cells used for assays of colony
forming cells were fractionated on ficoll hypaque as described above and
washed three times in IMDM containing 2% V/V FCS. For the
establishment of long term bone marrow culture stromal layers, dextran
sedimented cells were prepared as described above and washed three
times in IMDM containing 2% V/V FCS.
6.1.4. Tonsillar B lymphocytes
Tonsillar lymphocytes in the Gq phase of cell cycle were used in
comparative cell cycle studies. These were prepared by Dr J Gordon,
Department of Immunology, from tonsillectomy specimens provided by
the Ear, Nose and Throat Hospital, Birmingham. A single cell suspension
was prepared by using fresh tonsils free of red cells and by teasing small
pieces of lymphoid tissue in buffered balanced salt solution (BBSS).
Lymphocytes were obtained by fractionation using ficoll hypaque, as
described above. B cells were purified by negative selection after
rosetting T cells with sheep erythrocytes and B cells in the Gq phase of
the cell cycle were further purified by using a 62.5% Percoll (Pharmacia,
UK) gradient. Cells banding below 62.5% Percoll constituted the Gq
population of tonsil cells.
6.2. Cells from a patient with primary myelofibrosis
6.2.1. Patient's details
A 71 year old man presented with anaemic symptoms, 8cm
hepatomegaly and 12cm splenomegaly. His Hb was 4.3g/dl, WBC 2.8 x
10^/1 with neutrophils 2.2 x 10^/1 including hypersegmented forms,
lymphocytes 0.3 x 10^/1, monocytes 0.2 x 10^/1 ,myelocytes <0.1 x
109/l , blasts 0.1 x 10^/1, normoblasts 1 per 100 WBC and platelet
count 95 x 10^/1 . His blood film showed tear drop poikilocytes but
infrequent normoblasts which were rarely seen on subsequent blood
films. His reticulocyte count was 33 x 10^/1 and both the serum and red
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cell folate were reduced. Bone marrow aspiration was unsuccessful and
a trephine biopsy was hypercellular showing marked granulocytic
hyperplasia, absent normoblasts, megakaryocytes of increased size with
irregular nuclei and increased reticulin fibrosis, consistent with features
in cases reported by Barosi et al, 1983. He was initially supported with
folic acid, allopurinol and blood transfusion and was subsequently
treated with hydroxyurea and oxymethalone. He remained transfusion
dependent but after 7 months developed an increasing leucocyte count
with an increasing proportion of blast cells which were refractory to
therapy with hydroxyurea. He died 9 months after presentation having
followed a course similar to patients reported by Bentley et al, 1977.
6.2.2. Peripheral blood cells
Venous blood taken into dipotassium ethylenediaminetetra-acetic acid
(l<2 EDTA) was used for full blood count and blood film analysis. These
investigations were carried out by the Haematology department of the
Queen Elizabeth Hospital (QEH), Birmingham. For cytogenetic analysis,
assays of colony forming cells and cell culture studies, mononuclear
cells separated from peripheral blood collected into preservative free
heparin were used. These cells were fractionated on ficoll hypaque as
described above and washed three times in IMDM.
6.2.3 Bone marrow trephine biopsy
A bone marrow trephine biopsy was taken from the patient's right
posterior iliac crest under local anaesthesia and processed by standard
techniques in the QEH Department of Pathology. In brief, the tissue was
fixed and decalcified for 72 hours in 10% neutral buffered formalin
solution containing at first 5% and then 10% glacial acetic acid. The
tissue was then dehydrated in serial alcohol solutions, cleared through
serial chloroform solutions and finally embedded in paraffin wax.
Sections of 3p thickness were cut, mounted onto glass slides and then
stained with haematoxylin and eosin and also for reticulin fibres.
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6.2.4 Skin Biopsy
A 2 cm elliptical skin biopsy was removed from the patient's forearm
under local anaesthesia and placed in sterile RPMI 1640 medium. This
tissue was used to generate primary fibroblast cultures which were used
to assess the constitutive karyotype and to provide a source of
constitutive DNA.
6.3. Cell Lines
The cell lines listed in Table 8 were used as positive control cells for
antibody reagents used in the fractionation of cells from human fetal
liver. The relevant membrane surface antigen and reactive antibody are
listed under the cell type. The human promyeloid cell line HL60
(Gallagher et al, 1979) was used in comparative biochemical studies
with myeloid blast cells fractionated from human fetal liver.
Table 8. Human haemopoietic cell lines used in the quality control of
antibody reagents
CELL LINE CELL TYPE REFERENCE
K562 Early erythroid
Glycophorin C positive




Common leucocyte antigen positive
Reactive with McAb BK19.45.
Sundstrom and Nilsson,
1976
KG1 a CD34 antigen positive
Reactive with McAb ICH3.
Koeffler et al, 1 980
The cell lines were grown in suspension in RPMI 1640 medium
containing 10% V/V FCS and 100 U/ml penicillin and 100 pg/ml
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streptomycin (P/S; Gibco, UK). The cultures were maintained in the
exponential phase of growth by seeding in 80 cm^ tissue culture flasks
(Nunc, UK) at a density of 2-3 x 10^/ml, feeding with fresh medium on
days two or three and subculturing when the cells had reached a density
of 1-2 x 106/ml. All cultures were maintained in a LEEC incubator at
37°C in a humidified atmosphere containing 5% CC>2- Cell lines were
cryopreserved as follows. Cells from a healthy culture were pelleted and
resuspended at 1 x 10^ cells/ml in cold FCS containing 5%
dimethylsulphoxide (DMSO, Fisons Scientific,UK). The cell suspension
was aliquotted into a 1 ml sterile freezing ampoule, placed in an
expanded polystyrene container and incubated for 30 minutes at - 20°C,
6 hours at -70°C and then transferred into liquid nitrogen. This method
was also used to cryopreserve peripheral blood mononuclear cells and
skin fibroblasts obtained from the patient with primary myelofibrosis. To
recover viable cells after storage in liquid nitrogen the following thawing
procedure was adopted. Ampoules containing cells were thawed quickly
at 37°C and the cells transferred to a universal container on ice.
Twenty mis of cold RPMI 1640 containing 10% FCS were added
dropwise to cells which were then subsequently washed twice,




FRACTIONATION OF FETAL LIVER CELLS
7.1 Tissue
Whole fetal livers were obtained from abortuses from prostaglandin
induced terminations of mid trimester pregnancies which had been
carried out at two local hospitals, the Robert Nursing Home and the
Calthorpe Nursing Home. All handling of fetal tissue was performed in
agreement with a code of practice recommended by a Government
Committee, the Polkinghorne report (Command Paper CM762 HMSO,
1989), and was supervised by a central co-ordinator, Professor P H
Gallimore of the Department of Cancer Studies, University of
Birmingham. Under these guidelines maternal consent for the use of
fetal material for research purposes had been obtained by a neutral third
party and the identity of patients and source of fetal material was
unknown to the investigators. The research utilising fetal tissue was
carried out under special licence from the Department of Health and
Social Security and in addition was approved by the local hospital ethical
committee.
Freshly delivered fetuses ranging from 16-20 weeks gestation were
placed in refrigerated containers and were available for collection, 2-18
hours following delivery. Tissue viability was shown to be variable but
was not obviously related to the interval following delivery of the fetus.
However, storage of delivered fetuses at refrigerated temperatures was
important and efforts were made to achieve this aim as much as
possible. Individual fetuses were placed in sterile dissecting trays and
washed externally with alcohol. Using sterile instruments, the fetal liver
was removed intact and placed in sterile RPMI 1640 medium containing
100 U/ml penicillin and 100pg/ml streptomycin (P/S).
7.2 Preparation of mononuclear cells
During the course of the project mononuclear suspensions of fetal liver
cells were obtained using two different methods. The first method had
been developed previously in our laboratory (Toksoz and Brown, 1984).
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This method was later superceded by a method incorporating enzyme
digestion of liver tissue. Both methods incorporated ficoll hypaque
fractionation of cell suspensions to harvest cells of buoyant density
<1.077. Haemopoietic stem cells and progenitor cells are known to be
present within this fraction of cells.
7.2.1 Preparation of mononuclear cells following mechanical disruption
of tissue
Whole livers were washed three times in RPMI 1640 medium and placed
in a sterile plastic Petri dish (Sterilin, UK) in 10 mis of medium.
Connective tissue around the liver and the gall bladder were removed,
and the liver gently teased with forceps and scissors. Fragments were
initially disrupted by aspirating through a 10 ml syringe and then through
a 19 gauge needle. The cell suspension was made up to 40 mis with
RPMI 1640, transferred to two sterile universal containers and then
filtered through sterile cotton wool three times. The cotton wool had
been previously washed in de-ionised water and the cotton wool
columns were prepared by loosely packing, under water, 1 ml cotton
wool into the barrel of a 5 ml syringe. The syringe barrels were then
drained and autoclaved in small sealed storage packets. The resulting
filtered single cell suspension was then fractionated by centrifugation
over ficoll hypaque as previously described. The interface cells were
carefully harvested with a sterile Pasteur pipette and washed three
times, as described previously, in RPMI containing 100 U/ml penicillin,
100 pg/ml streptomycin and 5% V/V FCS. Viable nucleated cells, as
assessed by phase contrast microsocopy, were enumerated in a
haemocytometer chamber. At least 200 cells were counted.
7.2.2. Preparation of mononuclear cells following enzyme digestion of
tissue
This method is illustrated schematically in Figure 12. Following
washing in medium and the removal of surrounding connective tissue as
described above, the liver was gripped by forceps at the junction of the
right and left main bile ducts as they emerged from the liver. Using a
pair of scissors haemopoietic tissue was gently teased by blunt
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dissection away from the connective tissue of the biliary tree which was
then discarded. Larger tissue fragments were initially disrupted by
aspiration through a 10 ml syringe and then by passage through a 19
gauge needle. The cell suspension was made up to 25 mis with RPMI
1 640 medium and transferred to a 25 cm2 tissue culture flask to which
was added 5 mis of a freshly prepared enzyme solution containing 3
mg/ml hyaluronidase (Sigma, UK), 3 mg/ml collagenase (Sigma, UK) and
6 mg/ml dispase (Sigma, UK). The enzymes had been dissolved in
serum free RPMI 1640 medium and the solution sterilised by passage
through a 0.2 pm disposable filter (Gilman Sciences, UK). The cell
suspension was then incubated with the enzymes at 37°C for 45
minutes with gentle agitation at 1 5 minute intervals. This resulted in the
dissolution of small tissue fragments into a unicellular suspension. After
45 minutes incubation the enzyme digest mixture was made up to 60
mis with RPMI 1640 medium containing 10% V/V FCS to inhibit further
enzyme activity. After further passage through a 1 9 gauge needle an
aliquot of 100 pi was removed for cell counting and cytocentrifuged
preparations and the remainder dispersed in 5 x 12 ml volumes for
fractionation on 5 x 6 ml cushions of ficoll hypaque in universal
containers (400g for 40 minutes at 20°C). Ten mis of supernatant
medium were removed before harvesting the total interface using a
sterile Pasteur pipette. The cells were washed three times in RPMI
1640 containing 2% V/V FCS as previously described and were then
resuspended in 24 mis RPMI 1640 medium containing 2% V/V FCS. An
aliquot of 100 pi was removed for counting and cytocentrifuged
preparations and the cells were fractionated a second time on ficoll
hypaque in two 12 ml aliquots as described above. The interface cell
population was harvested and washed as described above and an aliquot
removed for cell counting and cytocentrifuged preparations. On some
occasions, due to the availability of fetal tissue in the late evenings, cells
were incubated overnight following enzyme digestion and prior to ficoll
fractionation which was performed the following day. In these
circumstances, following enzyme digestion, the cells were pelleted at
400 g for 10 minutes, washed once in RPMI 1640 containing 10% V/V
FCS and resuspended in 60 mis RPMI 1640 medium containing 20%
V/V FCS for overnight incubation at 37°C in a humidified atmosphere
containing 5% C02-
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1 ml aliquots 8 x 106 cells/ml.
o—10#
I J«
rosetted monocyte and erylhroblast
o
cell
1) Tissue fragmentation of
16-20 wk fetal liver.
2) Enzyme digestion to
unicellular suspension
60 mis.
3) Ficoll fractionation 1.
5 x 12 ml harvest interface
cells.
4) Ficoll fractionation 2.
2 x 12 ml harvest interface
cells.
5) Erythrocyte rosette
depletion of unwanted cells.
a) Incubate cells with Mc Abs to
glycophorin C, monocyte Ag.
b) Wash off primary antibodies.
c) Incubate with sheep rbc's coated
with antibody to mouse
immunoglobin.
antigen
negative d) Remove rosetted (antibody
positive) cells by centrifugation
over ficoll hypaque.
e) Harvest interface (Antigen
negative) cells.
Figure 12: Schematic representation of fractionation of undifferentiated
myeloid blast cells from human fetal liver following enzyme digestion of
liver tissue and indirect erythrocyte rosette depletion of unwanted cells.
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7.3 Erythrocyte rosette depletion of unwanted cells
The isolation of undifferentiated myeloid blast cells from human fetal
liver was undertaken by the process of removing unwanted cells using
the technique of indirect erythrocyte rosette sedimentation. This
method is illustrated schematically in figure 12. For example, to remove
erythroblasts, which express the glycophorin C antigen on their cell
surface, cells were incubated with a mouse monoclonal antibody to
glycophorin C (Ret40F). After washing away the primary antibody, the
cells were then incubated with sheep erythrocytes coated with antibody
to mouse immunoglobulin. The resulting rosetted cells were removed by
centrifugation over ficoll hypaque. Antigen negative cells remaining at
the interface were harvested for subsequent use.
7.3.1. Reagents used in erythrocyte depletion experiments
a) Sheep erythrocytes
Sheep erythrocytes were supplied weekly as fresh 50% whole blood in
Alsever's anticoagulant (The Binding Site, UK) and were stored at 4°C
prior to use.
b) Antibody to mouse immunoglobulin
The antibody to mouse immunoglobulin, used to coat sheep
erythrocytes, was a DEAE chromatography purified immunoglobulin
fraction of polyclonal sheep antibody to mouse IgG (PC 271, The
Binding Site, UK). Purified mouse IgG had been used as the immunising
agent and the antiserum had been adsorbed with human tissue. Prior to
use the antibody was dialysed thoroughly against 0.9% saline to remove
phosphate anions which interfere with the chromium chloride coupling of
immunoglobulin to erythrocytes. The antiserum was centrifuged at
13,000 rpm (MSE Micro Centaur centrifuge; Fisons, UK) for 30 minutes
to remove high molecular weight complexes and assayed for protein
content by using a commercially available assay procedure (Bradford,
1976, Biorad, UK).
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c) Chromic chloride solution
Chromic chloride was used to couple immunoglobulin irreversibly to
sheep erythrocytes. A stock solution of 1 mg/ml in 0.9% saline was
prepared (BDH, UK) and the solution was left to age for 2 months.
After this time period, the pH was adjusted to 5.0 by the dropwise
addition of 1M NaOH. The working solution was a 1/10 dilution of the
stock solution in 0.9% saline.
d) Coating of sheep erythrocytes with antibody to mouse
immunoglobulin
Antibody to mouse immunoglobulin was coupled to sheep erythrocytes
by using a modification of a previously reported method (Ling and
Richardson,1 981). Sheep erythrocytes were washed five times in sterile
0.9% saline by centrifugation at 1000g for 10 minutes. A 10%
suspension of erythrocytes in sterile saline was prepared and 1 ml
transferred to a sterile tube. The erythrocytes were sedimented by
centrifugation at 400g for 10 minutes and the supernatant was
discarded. To the red cell pellet was added that volume of the antibody
to mouse immunoglobulin known to contain 0.3 mg protein. Using a
vortex mixer 0.8 ml of the working chromium chloride solution (at 0.1
mg/ml in 0.9% saline) was added slowly to the
erythrocyte/immunoglobulin mixture and the sides of the tube were then
carefully washed down by the addition of further sterile 0.9% saline.
The tube was then left overnight at 4°C. The following day the
supernatant was carefully removed and discarded and the
immunoglobulin coated erythrocytes were washed twice in RPMI 1640
by centrifugation at 400g for 10 minutes. The erythrocytes were finally
resuspended in 4 ml of RPMI 1640 containing 100 U/ml pencillin -
100pg/ml streptomycin and 2% V/V FCS. The coated cells were stored
at 4°C and were used for up to 2 months without loss of activity.
Before use each batch of antibody coated erythrocytes was subjected to
quality control as follows. The binding capacity of various batches of
antibody coated erythrocytes against antibody coated cells was
assessed using blood mononuclear cells and U937 cells which had been
coated with 2 fold dilutions of a constant batch of the monoclonal
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antibody BK19.45. This antibody recognises the CD45 antigen (Brown
et al, 1981) which is well expressed on blood mononuclear cells and
expressed to a lesser extent on U937 cells.
e) Primary antibody reagents used in rosette depletion
experiments
Two mouse monoclonal antibodies were used as primary antibody
reagents in the rosette depletion experiments described in this thesis.
These were 1) Ret40F, a tissue culture supernatant antibody to
glycophorin C which is an antigen expressed on cells of the erythroid
lineage (Gatter et al, 1988). This reagent was kindly supplied by Dr D Y
Mason, Oxford; and 2) 61 D3, an antibody directed against an antigen
expressed on monocytes and macrophages (Nunez et al, 1982). This
was available as either an ascitic fluid or tissue culture supernatant from
our own laboratory. All reagents contained saturating amounts of
antibody as revealed by titration experiments using both the indirect
rosette and indirect immunofluorescence techniques. The antibody to
glycophorin C (Ret40F) was titrated against the early erythroid cell line
K562 and 61 D3 was titrated against peripheral blood mononuclear cells.
Additional experiments adding in other primary antibodies to the
depletion cocktail were undertaken but these are not described in this
thesis.
f) Acridine orange solution
A saturated solution of acridine orange (Sigma, UK) was prepared by
dissolving 0.1g in phosphate buffered saline, pH 7.1 and stored in the
dark at 4°C. Seventy five pi of the stock solution were added to 20 mis
of phosphate buffered saline, pH 7.1 to provide the working solution.
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7.3.2 Erythrocyte rosette depletion technique
Following ficoll hypaque fractionation, fetal liver mononuclear cells were
resuspended in RPMI 1640 containing 2% V/V FCS and saturating
amounts of a mixture of selected monoclonal antibodies reactive against
unwanted cell populations. Initial experiments were carried out in 500
pi aliquots at a cell density of 4 x 10®/ml and the cells were incubated
with antibodies for 15 minutes at room temperature. In later
experiments the volume was increased to 1ml of cells at 8 x 10®/ml and
the incubation period was extended to 30 minutes. Following two
washes in RPMI 1640 containing 2% V/V FCS, the cells were
resuspended in 250pl of sheep erythrocytes coated with antibody to
mouse immunoglobulin and centrifuged at 300g for 3 minutes. After a
further 5 minutes incubation at 4°C, the cells were resuspended and
pooled. An aliquot of 50pl was mixed with 50pl of acridine orange
solution and rosette positive cells were enumerated by fluorescence
microscopy using a Zeiss microscope equipped with an HB50 mercury
burner for incident illumination (Ling and Richardson, 1 981). Viable cells
forming rosettes with >3 erythrocytes were classified as positive cells.
The remaining cells, in 6 ml aliquots, were fractionated over 3 mis ficoll
hypaque to remove rosetted cells and excess sheep erythrocytes. The
remaining interface cells were harvested, washed three times in RPMI
1640 containing 2% FCS and enumerated prior to further use.
7.4 Elutriation of fetal liver mononuclear cells
Elutriation of fetal liver mononuclear cells was performed by using the
JE-6B elutriation system and the standard chamber (Beckman
Instruments, UK). Details describing the assembly, operation and
sterilisation of the system are contained in the manufacturer's manual
and the system is illustrated in figure 13. Counter current elutriation
uses liquid flow versus centrifugal force to separate a suspension of
single cells or particles of different size and density. A cell suspension is
loaded at a constant flow rate onto the base of a chamber in a
centrifuge rotor. When centrifugal and counterflow forces are balanced
particles of a specific size remain at the base of the rotor chamber.
Larger particles also remain in the rotor but smaller, lower density
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particles and liquid are washed out through the top of the chamber. If
the rotor speed is kept constant, increasing the flow rate of fluid loaded
into the base of the rotor chamber will wash out increasingly larger,
more dense particles. This can also be achieved by maintaining a
constant flow rate and reducing the rotor speed. Cells remaining in the
rotor can be collected washing out the remaining cells, the rotor off
fraction. The relationship between flow rate (F), particle diameter (D)




Where X = a constant which takes into account the cross sectional area
of the chamber at the elutriation boundary, the radius at the elutriation
boundary, the viscosity of the suspending medium, the density
difference between the particles and the suspending medium and which
assumes that particles are of an equal density.
Cells suspended in RPMI 1640 containing 2% V/V FCS were loaded
onto the elutriator in a volume of 4-5 ml at an initial flow rate of 4.7
ml/minute and constant rotor speed of 1950 rpm. Sterile phosphate
buffered saline, pH 7.1 (Sigma, UK) containing 2% V/V FCS was used
as the elutriation buffer. The flow rate was increased in increments of
approximately 4.3 ml/minute up to 34.5 ml/minute and 100 ml fractions
were collected at each flow rate. The rotor off fraction was also
collected in some experiments. Elutriation fractions were centrifuged at
250g for 10 minutes and resuspended in RPMI 1640 containing 2% V/V
FCS. Initial assessments included enumeration, cytochemical staining of
cytocentrifuged preparations and marker analysis. For subsequent
culture studies individual or pooled fractions were recentrifuged and













































































































CHARACTERISATION OF CELL POPULATIONS
8.1 Cytocentrifuge preparation of cells
Washed cells were resuspended in RPMI 1640 containing 2% V/V FCS
at concentrations of 3-8 x 10^/ml. Fifty pi aliquots of the cell
suspension were cytocentrifuged for 3 minutes at 500 rpm onto clean
washed slides (Cytospin II Cytocentrifuge, Shandon, UK). The slides
were dried immediately and used for subsequent histochemical and
immunostaining procedures. On occasions when immunostaining
procedures were performed later slides were air dried for 48 hours and
stored unfixed wrapped in aluminium foil at -20°C. Before use frozen
slides were equilibrated with room temperature for 2 hours prior to
removal of the aluminium foil.
8.2 Histochemical staining techniques
8.2.1 May-Grunwald-Giemsa
Romanowsky staining was performed by the May-Grunwald-Giemsa
method (Dacie and Lewis, 1984) using an automated staining instrument
(Hemastainer, Geometric Data, USA). Differential cell counts were
performed on a minimum of 400 cells. In the case of the histochemical
stains described below a minimum of 200 cells were also enumerated.
8.2.2. Sudan Black B
Sudan Black B staining was used to identify cells showing evidence of
granulocytic or monocytic maturation. Air dried films or cytocentrifuged
preparations were fixed in phosphate buffered acetone - formaldehyde
for 90 seconds and stained as previously described (Dacie and Lewis,
1984). Films were then counterstained using Mayer's haemalum for 5
minutes, washed under running tap water for 5 minutes, air dried and
mounted under an aqueous mountant. All histochemical staining
procedures included slides containing positive control cells.
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8.2.3 Chloroacetate esterase
Chloroacetate esterase staining was used to identify cells showing
evidence of granulocytic maturation. Films were fixed in phosphate
buffered acetone - formaldehyde as described above and washed for 10
minutes in running tap water. Three mg naphthol AS-D chloroacetate
substrate (Sigma, UK) was dissolved in 1ml dimethyl formamide (Sigma,
UK) in a glass container. Fifty pi of fresh 4% sodium nitrite (BDH, UK)
was mixed with 50 pi of new fuchsin (Gurr, UK) and after 60 seconds
19 ml of 0.066M phosphate buffer, pH 7.6 was added to the dye
mixture. The substrate and dye solutions were then mixed and the films
incubated in the reaction mixture for 15 minutes at room temperature.
Films were then washed under running water for 10 minutes and
counterstained using Mayer's haemalum. Positive cells showed a red
reaction product.
8.2.4. Monocyte specific esterase
Staining for monocyte specific esterase was carried out by two methods
using either alpha naphthyl acetate or alpha naphthyl butyrate as the
substrate. The diffuse positive dark red reaction pattern typical of
monocytes was used to identify cells showing evidence of monocytic
maturation. In contrast, a dot like reaction pattern is seen in
subpopulations of T lymphocytes. The method using alpha naphthyl
acetate as the substrate was performed as previously described (Yam et
al, 1971). The method using alpha naphthyl butyrate is described
below. Films were fixed in phosphate buffered acetone-formaldehyde as
described above. Ten mg of alpha naphthyl butyrate (Sigma, UK) were
dissolved in 0.5 ml 2-methoxyethanol (BDH, UK) in a glass container and
added to 9.8 ml 0.067M phosphate buffer, pH 6.3. Twenty five pi of
hexazotised pararosanilin HCI (Taab Laboratories, UK) were mixed with
25 pi of fresh 4% sodium nitrite and after 60 seconds mixed with the
substrate solution. The slides were then incubated in the reagent
mixture for 45 minutes in a 37°C water bath. Following washing with
water, the slides were counterstained with either Mayer's haemalum or
methyl green.
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8.2.5 Periodic acid - Schiff reaction
The periodic acid - Schiff (PAS) reaction depends on the liberation of
carbohydrate radicals from glycoproteins and their oxidation to
aldehydes by the Schiff reagent. A positive reaction, which is not
lineage specific is seen in haemopoietic cells showing signs of
maturation and the strongest reactions are seen in mature neutrophilic
granulocytes. Undifferentiated cells particularly myeloblasts are either
negative or stain diffusely pale pink. Films were fixed in phosphate
buffered acetone-formaldehyde and stained without prior diastase
digestion using the method of Dacie and Lewis, 1984.
8.3 Immunophenotypic analysis of cells
A variety of immunostaining methods was used in the characterisation
of cells depending on factors such as 1) the number of cells available for
analysis; 2) antigen localisation and sensitivity to fixation and 3) the time
available for immunostaining procedures. In all immunostaining
procedures, positive, negative and substitution controls were included
and a minimum of 200 cells were enumerated. A list of the antibodies
used is shown in Table 9.
8.3.1 Indirect immunofluorescence technique
An indirect immunofluorescence technique was used on cytocentrifuge
preparations to identify cells reacting with the monoclonal antibody AGF
4.48, which recognises neutrophilic granulocytes from promyelocyte to
neutrophil stages of maturation (Fisher et al, 1982). Unfixed cytospin
preparations were incubated with AGF4.48 tissue culture supernatant
for 30 minutes at room temperature in a moist chamber. The slides
were washed using a wash bottle and by dipping briefly into three
consecutive baths of BBSS. The cells were then incubated in 50 pi of
fluorescein conjugated sheep antibody to mouse immunoglobulin (own
laboratory) diluted 1/50 in BBSS and containing 10% v/v normal sheep
serum and 5% v/v FCS. The slides were rinsed and washed in BBSS
containing 0.1% bovine serum albumin (Sigma, UK) by stirring










































































































































































































containing 25 g/l of 1,4 diazobicyclo (2.2.2) octane (Aldrich Chemical
Co., UK) buffered at pH 8.6 in order to retard quenchng of the
fluorescein labelled antibody when observed by fluorescence
microscopy. Indirect immunofluorescence was used to identify the
presence of cell surface antigens on unfixed cells in cell suspension.
Fresh cells were washed three times in BBSS containing 2% v/v FCS
and resuspended at 2 x lO^cells/ml. Fifty pi of the cell suspension were
incubated with 50 pi of the primary mouse monoclonal antibody reagent
for 30 minutes at room temperature. The cells were washed twice in
buffer and incubated with fluorescein conjugated sheep antibody to
mouse immunoglobulin (as above) for 30 minutes at 4°C. After two
washes in buffer the cells were resuspended in a small volume,
mounted, sealed under molten wax and examined by fluorescent
microscopy. For assessment of CD34 positive cells within rosette
depleted fetal liver mononuclear cells an FITC conjugated antibody to
mouse lgG2a was used to avoid staining of residual monoclonal
antibodies. The antibodies used in depletion experiments were of
isotypes other than lgG2a.
8.3.2. Indirect immunoperoxidase technique
An indirect immunoperoxidase technique on cytocentrifuged preparations
was used to stain for the presence of lactoferrin, a known constituent of
neutrophil secondary granules (Pryzwansky et al, 1979). Fixation and
blocking of endogenous peroxidase activity was achieved by incubation
for 20 minutes in methanol formalin (1:1) containing 0.6% 30% v/v
hydrogen peroxide (BDH, UK). After washing, incubation for 20 minutes
at room temperature with a mixture of 20% normal human AB serum
and 20% swine serum was used to prevent non specific binding. The
preparations were then incubated for 30 minutes at room temperature
with a 1:50 dilution of an IgG fraction of a polyclonal sheep antibody to
lactoferrin (PC062), The Binding Site, UK). After washing, the slides
were incubated for a further 30 minutes with a 1/100 dilution of a horse
radish peroxidase conjugated swine antibody to sheep immunoglobulin
(PP361, The Binding Site, UK). After washing and colour development
with 3,3 diaminobenzidine, nuclei were counterstained with Mayer's
haemalum. Slides were mounted in DPX mountant (BDPI, UK) and
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examined under light microscopy. Phosphate buffered saline, pH 7.1
containing 0.1% BSA was the dilution and washing buffer used in the
above staining procedure.
8.3.3. Immuno alkaline phosphatase technique
Immunocytochemical staining for mature T and B lymphocytes was
performed on cytocentrifuge preparations by the immunoalkaline
phosphatase technique using monoclonal antibodies to the CD3 and
CD22 antigens as previously described (Erber et al, 1984). To prevent
non specific binding, 0.1% BSA was added to the wash and dilution
buffers and dilutions of the primary and secondary antibody were
supplemented with 10% normal rabbit serum. The CD3 antibody
(M756, diluted 1 in 100), CD22 antibody (M738, diluted 1 in 200),
rabbit antibody to mouse immunoglobulin (Z259, diluted 1 in 25) and
alkaline phosphatase : anti-alkaline phosphatase (APAAP) complexes
(D651, diluted 1 in 50) were purchased from Dako, UK. To enhance the
sensitivity a 10 minute repeat incubation step with both the antibody to
mouse immunoglobulin and the APAAP complexes was performed.
8.3.4. Direct erythrocyte rosette technique
Cell surface antigens may be detected by a simple direct technique using
sheep erythrocytes coupled with a primary antibody (Ling and
Richardson, 1981). This is a routine method employed in the immuno-
diagnostic laboratory, Department of Immunology, University of
Birmingham and sheep erythrocytes coupled with primary antibodies
were kindly provided by Mr P R Richardson. These reagents were daily
checked against positive and negative control cells. The assay was
performed to determine directly the number of cells expressing a
particular antigen when cells had been previously coated with
monoclonal antibodies for cell depletion experiments. In this case
indirect assays give a potentially inaccurate measure of the number of
positive cells due to the presence of residual unseparated antibody
coated cells. Thirty pi of a 5% suspension of primary antibody coated
cells were added to 100 pi of test cells suspended in RPMI 1640
containing 2% FCS at 6 x 10^/ml. The cells were centrifuged at 250g
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for 3 minutes and incubated for a further 5 minutes at 4°C. Fifty jixl of
acridine orange solution was then added and rosette positive cells
enumerated as previously described.
8.3.5. Indirect erythrocyte rosette technique
The principle and practice of the indirect erythrocyte rosette technique is
identical to that used in the rosette depletion of unwanted cells from
human fetal liver. For small scale assays, a saturating amount of
primary antibody was added to 50 j_il of a cell suspension at 2 x 10®/ml.
The cells were incubated for 15 minutes at room temperature with
gentle agitation and washed as previously described. Thirty pi of sheep
erythrocytes coated with antibody to mouse immunoglobulin were then
added and the enumeration of rosette positive cells was carried out as
previously described.
8.4 Physiological assays
8.4.1 Analysis of the phagocytic capacity of cells
The ability of cells to phagocytose complement-coated yeast cells was
performed as previously described (Toksoz et al, 1982). Glutaraldehyde
fixed yeasts (Saccharomyces cerevisiae) were mixed in 0.2% procion
rubine in 0.2M Na.iHP04 for 2 hours at room temperature. The dyed
yeasts were then washed free of surplus dye in complement fixation test
buffer (CFT, Oxoid, UK). For complement coating 2 x 10^ organisms
were suspended in 800 pi of CFT and 200 pi of fresh normal sheep
serum was added. The mixture was incubated for 30 minutes at 37°C
and agitated at 5 minute intervals to keep the yeasts suspended. The
yeasts were then washed twice and resuspended in 20 mis CFT and
stored as 0.5 ml aliquots at -20°C. For the phagocytosis assay 5 x 10^
cells were washed in RPMI 1640 containing 10% v/v FCS and the
supernatant discarded. To the pelleted cells were added 50 pi of RPMI
1640 containing 10% v/v FCS and 10% v/v fresh human AB serum and
50 pi of the opsonised yeast suspension. The mixture was incubated at
37°C for 30 minutes and then mounted in a haemocytometer. Viable
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mononuclear cells seen to contain > 3 intracellular dyed yeasts were
enumerated as phagocytic cells.
8.4.2. Analysis of the colony forming ability of cells
The number of cells able to form colonies in semi-solid medium was
determined using a method similar to that described by Ash et al, 1981.
In the case of a colony forming unit - granulocyte macrophage (CFU-GM)
assay 2 x 10^ - 2 x 10^ mononuclear cells were seeded in duplicate in a
1.0 ml volume of IMDM containing 1.2% methyl cellulose (Sigma, UK),
20% v/v FCS, 1% de-ionised bovine serum albumin, 5 x 10"^M 2-
mercaptoethanol (Sigma, UK), 5% phyto-haemagglutinin stimulated
leucocyte conditioned medium (PHA-LCM) and 100 U/ml penicillin - 100
pg/ml streptomycin. Colonies containing >40 cells were enumerated at
day 12. For assessment of blast forming unit-erythroid (BFU-E) colonies
an identical system containing, in addition, erythropoietin (Eprex, Cilag,
UK) at 3 U/ml was used and the cells were plated at densities ranging
from 0.2 - 2 x 10^/ml. Clusters of >3 erythroid colonies or single
erythroid colonies containing >300 cells were enumerated as BFU-E.
The nature of sample colonies was confirmed by staining
cytocentrifuged preparations of single colony contents harvested by
micropipette under a dissecting microscope.
The phytohaemagglutinin stimulated leucocyte conditioned medium
(PFIA-LCM) had been prepared as follows. A fresh donation of whole
blood collected into citrate phosphate dextrose adenine from a normal
donor was fractionated by using ficoll hypaque on an IBM 2001 cell
separator to generate a mononuclear cell suspension. Ten ml aliquots of
cells suspended at 2 x 10®/ml in IMDM containing 10% v/v FCS, 2
mM/l glutamine (Gibco,UK), 100U/ml penicillin/1 OOpg/ml streptomycin
and 1 mg phytohaemagglutinin (Wellcome, UK) were cultured in 25 cm^
tissue culture flasks at 37°C in a humidified atmosphere containing 5%
CO2 for 5 days. The tissue culture supernatants were then harvested,
pooled, sterilised by microfiltration, aliquotted in small volumes and
stored at -20°C. A single unit of blood generated a batch of 50ml PHA-
LCM which was used for all the colony assays. The PHA-LCM was
titrated in CFU-GM and BFU-E assays of normal bone marrow
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mononuclear cells and used at an optimal concentration of 5%. The
bovine serum albumin, methylcellulose, fetal calf serum and 2-
mercaptoethanol had also been prepared as single large batches
sufficient for all assays and were stored at -20°C. The de-ionised BSA
was prepared as a 10% stock solution as follows. Ten g of BSA
(Sigma, UK) were dissolved in 44 ml H2O overnight at 4°C.
Deionisation was performed using an analytical grade mixed bed resin
type AG501 - X8(D) (Biorad, UK) and the resulting solution was freeze
dried overnight. The albumin was then dissolved in 94 ml IMDM
containing 100 U/ml penicillin and 100 pg/ml streptomycin, filter
sterilised, aliquotted in 1ml volumes and stored at - 20°C.
8.4.3. Analysis of the phase of the cell cycle
Mononuclear cells fractionated from human fetal liver and rosette
depleted using the Ret40F and 61 D3 antibodies were assayed for the
percentages of cells in Gq/G-i, S, and G2/M phases of the cell cycle.
The assay was based on the principle that flow cytometric analysis of
propidium iodide stained nuclei represents DNA content. Test cells were
prepared at 2 x 106/ml, processed using a commercial kit (Cycletest,
Becton Dickinson, UK) and analysed using commercial software (Cellfit,
Becton Dickinson, UK) in a flow cytometer (FACScan, Becton Dickinson,
UK). For comparison analyses were simultaneously performed on HL60
cells and Gq lymphocytes isolated from human tonsils.
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CHAPTER 9.
STUDIES USING BLAST CELLS PURIFIED FROM HUMAN FETAL LIVER.
9.1.1 .Culture of fetal liver cells in medium containing fetal calf serum.
Blast cells purified from fetal liver following mechanical disruption of
tissue and rosette depletion using Ret40F and 61D3 monoclonal
antibodies (directed against glycophorin C and a macrophage associated
antigen) were cultured in RPMI 1640 medium containing 20% v/v heat
inactivated FCS, 10pM hydrocortisone sodium succinate (Upjohn, UK) 5
pg/ml vitamin D3 (cholecalciferol, Sigma UK) and 100 U/ml penicillin -
100 pg/ml streptomycin. Cells were seeded at a density of 2.5 x
105/ml in 1ml volumes in individual wells of 24 well tissue culture
plates (Nunc, UK). This medium had been previously shown to support
the growth and differentiation in liquid suspension culture of human fetal
liver cells isolated following mechanical disruption and one step ficoll
hypaque fractionation (Toksoz and Brown, 1984).
9.1.2 Culture of fetal liver cells under serum-free conditions
Fetal liver blast cells were cultured under serum free conditions with and
without added IL-3 to a) promote the survival and proliferation of
undifferentiated blast cells; b) permit biochemical studies of inositol
metabolism in cells grown in medium containing inositol at 1 mg/l and
[^Hj-inositol and c) to eliminate the interference of differentiation factors
contained within fetal calf serum in the biochemical studies. Fetal liver
cells purified by enzyme digestion, ficoll fractionation, Ret40F and 61 D3
rosette depletion and elutriation were used for these studies. Cells were
cultured in RPMI 1640 medium containing 100 U/ml penicillin - 100
pg/ml streptomycin and with and without 100 U/ml human recombinant
interleukin 3 (IL-3, Genzyme, USA) in 1 ml volumes, at 5 x 10^/ml in
individual wells of 24 well tissue culture plates.
9.1.3 Induction of differentiation by phorbol myristate acetate
Phorbol myristate acetate (PMA) is known to induce rapid monocyte
maturation of the human promyeloid cell line, HL60 (Rovera et al, 1979).
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The effect of PMA on the differentiation of normal blast cells purified
from human fetal liver was studied. Cultures were established in 24
well tissue culture plates as described above. PMA treated wells
contained 10 nM PMA (Sigma, UK).
9.2 Assessment of fetal liver cultures
The fetal liver cultures described above were characterised using the
procedures outlined below. Individual wells were harvested at various
time points ranging from 12 hours to 7 days. During this procedure
wells were rinsed with cold tissue culture medium to ensure that all cells
had been harvested. This was particularly important in the case of PMA
treated cultures where significant numbers of adherent cells were
present. The contents from harvested wells were centrifuged and
resuspended in their initial volume prior to assessment of cell count and
viability. Cell viability was assessed by phase contrast microscopy.
9.2.1 .Assessment of cell growth
The effect of PMA treatment on the proliferation of blast cells purified
from fetal liver was determined by measuring DNA synthesis by the
incorporation of [^HJ-thymidine. These studies were undertaken on
blast cells purified following mechanical disruption of tissue and rosette
depletion using the Ret40F and 61 D3 monoclonal antibodies. Cells were
seeded at 1 x 10^ per well in 100 pi volumes of medium containing
fetal calf serum in flat bottomed wells of 96 well microtitre plates
(Nunc, UK). PMA treated wells contained 10 nM PMA. 0.5 pCi of [^H]-
thymidine (25 Ci/mM; Amersham International, UK) was added in 50 pi
of medium at 0, 1 2, 36, 60 and 84 hours and cultures were harvested 6
hours later on a Skatron automatic harvester (Flow Laboratories, UK).
[3p1]-thymidine incorporation was measured by scintillation counting and
incorporation determinations were performed in triplicate.
9.2.2. Assessment of cell differentiation
The degree of differentiation of cultures was assessed using a
combination of May-Grunwald-Giemsa morphology, histochemical
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staining methods and immunophenotypic analysis as described in
Chapter 8. In particular, granulocyte differentiation was assessed by 1)
the percentage of cells at the promyelocyte to neutrophil stage of
maturation following staining with MGG; 2) the percentage of cells
staining with the AGF4.48 antibody and 3) the percentage of cells
staining with antibody to lactoferrin. Monocyte maturation was
assessed by 1) the percentage of cells at the promonocyte to monocyte
stage of maturation following staining with MGG and 2) the percentage
of cells showing positive staining for monocyte specific esterase.
9.3. Analysis of intracellular inositol phosphates
These studies were undertaken in collaboration with Dr C Bunce and Dr
P French, Department of Biochemistry, University of Birmingham.
Previous studies by Dr C Bunce and Dr P French on FIL60 cells showed
that these cells could be labelled to equilibrium with [^HJ-inositol within
4-5 days of culture following which the concentrations of intracellular
inositol phosphates could be measured. Further more, following
equilibrium labelling with [^HJ-inositol, FIL60 cell monocyte
differentiation could be induced by PMA and the changes in intracellular
inositol phosphate concentrations observed. For studies of inositol
metabolism on blast cells purified from human fetal liver, cells were
cultured in inositol free RPMI 1640 medium (Northumbria Biologicals,
UK) supplemented with 1 mg/l inositol (Gibco, UK), 2 pCi/ml [^H] myo¬
inositol (Amersham International, UK), 2mM/l glutamine (Gibco, UK),
100 U/ml IL-3 and 100 U/ml penicillin 100 pg/ml streptomycin. The
[3|-l]-inositol was supplied in a 90% ethanol/10% water diluent. As the
diluent had a detrimental effect on cells, the label was freeze dried,
dissolved in tissue culture medium and filter sterilised prior to use. Cells
were cultured at 5 xlO^/ml in 1ml volumes in 24 well tissue culture
plates. On day 2, the cultures were fed by removing 0.5 ml of
supernatant medium and replacing this with 0.5ml fresh medium and
after 5 days, to permit labelling to equilibrium, individual wells were
harvested for analysis of intracellular phosphates. To study the effect of
PMA on intracellular inositol phosphate concentrations, PMA (10 nM)
was added after 5 days culture and the individual wells harvested after
culture for a further 24 hours.
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Intracellular [^H]-inositol phosphates were analysed following a process
of acid extraction and separation using anion exchange high performance
liquid chromatography (HPLC). A cell suspension of known volume and
cell counts was centrifuged at 200 g for 10 minutes and washed once in
inositol-free RPMI 1640. 0.5ml of 20% w/v trichloroacetic acid
(containing 250 pg/ml phytic acid and the equivalent of 4 pg
phosphate/ml of a phytic acid hydrolysate; Wreggett and Irvine, 1987)
was added to the cell pellet. Following mixing, the contents were
transferred to a polypropylene vial and the original centrifuge tube was
washed again with 0.3 ml 2% w/v trichloroacetic acid (TCA). The two
solutions were combined and centrifuged at 3000 g for 5 minutes. The
supernatant was retained and the precipitate washed with 0.2 ml of
2%w/v TCA. The two supernatants were combined and the TCA
neutralised by extracting it into methyl ether (4 washes with vigorous
mixing). The aqueous layer was retained and 100 pi of 50 mM EDTA
(pH 7.0) were added to prevent precipitation of salts of inositol
phosphates and the extract stored at -20°C. [^Hj-inositol phosphates
were separated using a LDC/Milton Roy gradient elution system on a
Partisil 10SAX strong anion exchange column. Inositol phosphates are
negatively charged and bind to the positively charged column. The
column was eluted with increasing concentrations of ammonium
phosphate which displaced increasingly higher inositol polyphosphates.
The Partisil 10SAX column (25 cm x 4.6 mm) was used with a pre-
column (Whatman 37-53 microns pre-column gel, 5 cm x 4.6 mm) and
a guard column (Whatman Pellucular Anion exchanger, 5 cm x 4.6
mm). The following gradient was employed using water in pump A and
initially 0.1M ammonium phosphate (pH = 3.8) in pump B changing over
to 1M ammonium phosphate (pH = 3.8) in pump B at 65 minutes.
























The column was re-equilibrated with water for at least 30 minutes prior
to re-use. The flow rate was 1 ml/minute and fractions were taken every
0.5 minutes. The radioactivity of each fraction was measured using a
Packard liquid scintillation counter (model No.2000CA), following the
addition of scintillant to each vial (0.6% PPO, 0.015% POPOP in xylene
mixed 1:1 with triton X 100). From knowledge of the specific activity
of [^HJ-inositol in the medium, the number of cells analysed, the total
amount of each inositol phosphate extracted and measurement of
individual cell diameters an estimation of the concentration of each
inositol polyphosphate per cell was made. A mean cell volume was
calculated following measurements of diameters of 100 cells and the
assumption that the cells were spheres. Individual cell diameters were




STUDIES USING CELLS FROM A PATIENT WITH PRIMARY
MYELOFIBROSIS.
10.1 Initiation of haematopoiesis on irradiated stroma from long term
bone marrow cultures from a normal donor.
Fresh peripheral blood mononuclear cells (PBMNC) from the patient with
primary myelofibrosis were tested for their ability to initiate
haematopoiesis on irradiated stroma from long term bone marrow
cultures (LTBMC) grown from a normal donor. A 10 ml long term bone
marrow culture containing 2 x 10^ marrow buffy coat cells from a
normal marrow donor was established and maintained as previously
described (Gartner and Kaplan, 1980). The LTBMC medium consisted of
IMDM containing 10% v/v FCS, 10% v/v horse serum (Flow
Laboratories, UK), 5 x 10~^M hydrocortisone sodium succinate (Solu-
cortef, Upjohn, UK) and 100 U/ml penicillin - 100 pg/ml streptomycin.
To establish the long term bone marrow cultures, 2 mis of fresh marrow
were collected into 5 mis heparinised IMDM. The volume was made up
to 14 mis with medium and 2 mis hespan added. Following 60 minutes
incubation at 37°C the buffy coat was harvested and washed 3 times
as described previously. A 10 ml culture containing 2x10^ cells was
established in a 25 cm^ tissue culture flask (Nunc, UK). The cultures
were fed weekly by removal of half of the supernatant medium and
replacement with fresh LTBMC medium. After 30 days non adherent
cells were removed, the adherent cells trypsinised, irradiated with 1 5 Gy
(Co 60 gamma rays, mean energy 1.25 MeV, dose rate 5.3 Gy/minute)
and 3 ml of cells at 1 x 10®/ml reseeded (at 3 x lO^/cm^) jn each of
three 35 mm diameter wells of a 6 well tissue culture plate (Nunc, UK).
After 5 days incubation, during which a healthy stroma had re¬
established, 1.5 ml of supernatant was removed from each of the 3
wells and to each of 2 wells was added 1.5 ml of LTBMC medium
containing 5.4 x 10® fresh PMF PBMNC. To the remaining well was
added 1.5 ml LTBMC medium alone to act as a negative control. To
each of two other empty 35 mm diameter wells was added 5.4 x 10®
fresh PMF PBMNC in 3 ml of LTBMC medium to act as a PMF control.
The 5 cultures were fed weekly by removing half of the supernatant and
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replacing this with fresh LTBMC medium. After 5 weeks all non
adherent cells were removed and the cells in the adherent layer
harvested by trypsinisation. Non adherent and adherent cells were
pooled, washed, counted and aliquots removed for cytospin analysis and
progenitor assays as described previously. The total number of cells
harvested from each culture was as follows - PMF PBMNC alone 11 x
1C)5 and 14 x 10^; co-cultures of PBMNC and irradiated stroma 15 x
1C)5 and 17 x 10^ and irradiated stroma alone 1.4 x 10^ cells. The
cells in the stroma alone culture were plated in duplicate at a density of
0.7 x 105/ml in an erythroid colony assay. Otherwise cells from the
other cultures were plated in triplicate in separate assays for CFU-GM
and BFU-E at densities ranging from 1.5 x 1 0^ - 2.3 x 10^/ml.
10.2. Establishment of primary fibroblast lines
Primary fibroblast cultures were generated from a skin biopsy from the
patient with primary myelofibrosis to provide a source of constitutive
DNA. The procedure was carried out with the assistance of Dr A
Sanderson, Department of Pathology. The skin biopsy was placed in a
sterile petri dish and cut into small fragments of approximately 1 mm^
using a scalpel blade. These biopsy fragments were then attached onto
roughened areas on the inner surface of 60 mm diameter petri dishes
which had been scored using a scalpel blade. The tissue was allowed to
dry for 5 minutes to permit good attachment and the fragments were
covered with Hams F10 medium containing 10% v/v FCS and 100 U/ml
penicillin - 100 pg/ml streptomycin. The cultures were incubated at
37°C in a humidified atmosphere containing 5% CO2 and fed every 3
days by careful complete replacement of the medium. When the
fibroblast layers were confluent the cells were harvested using trypsin as
follows. The cells were washed twice with serum-free tissue culture
medium and then treated with 5 mis 0.4% trypsin in RPMI 1640
containing 1mM EDTA (Gibco, UK). The cells were left for 5-10
minutes at 37°C until detachment had occurred and the trypsin action
was neutralised by adding an equal volume of culture medium containing
FCS. After washing, the cells were subcultured in 80 cm^ tissue
culture flasks and grown by repeated subculture to generate sufficient
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cells for cytogenetic analysis and DNA isolation. Cultured fibroblasts
were also cryopreserved at -70°C as described previously.
10.3 Establishment of Epstein-Barr virus (EBV) transformed B cell lines
Epstein-Barr virus transformed B cell lines were generated from the
patient with primary myelofibrosis and then subjected to karyotypic
analysis to determine whether any of the lines isolated carried the same
karyotype abnormality as the patient's cells. The cell lines were
produced in collaboration with Dr C Gregory, Department of
Immunology. Peripheral blood mononuclear cells were resuspended in
warm RPMI 1640 containing 10% v/v FCS (RPMI-10) and an optimal
dilution of concentrated cell free supernatant from the EBV producing
B95.8 marmoset cell line (Miller and Lipman, 1973). The potency of the
virus present within individual batches of B95.8 supernatant was
monitored using the fetal cord blood transformation assay (Moss and
Pope, 1972). Cells were infected at 37°C for 1-2 hours after which
time they were washed once with RPMI 10 at 37°C, resuspended in
RPMI 10 and seeded into 2 ml tissue culture wells at a concentration of
2.5 x 10® cells/ml. Regression of cultures by activated EBV specific T
cells was prevented by including 5pg/ml PHA in the culture medium.
The wells were fed every 3 days with fresh RPMI 10. EBV transformed
cell lines were established in 3 weeks at which point the cultures were
transferred to 50 cm^ tissue culture flasks, subjected to karyotypic
analysis and cryopreserved as described previously.
10.4 Karyotype analysis
Karyotypic analyses were undertaken on peripheral blood mononuclear
cells, pooled GM colonies grown from PBMNC, cultured skin fibroblasts
and EBV transformed B cell lines isolated from the patient with primary
myelofibrosis. These studies were undertaken in collaboration with Mr S
Larkins, Department of Cytogenetics, Birmingham Maternity Hospital, Dr
A Sanderson, Department of Pathology and Dr C Bunce, Department of
Immunology.
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For analysis of peripheral blood mononuclear cells unstimulated cultures
were prepared by adding 0.2 ml of peripheral blood to 5 ml of RPMI
1640 containing 10% v/v FCS and P/S. After 24 hours 0.2 jLxg/l
colcemid (Gibco, UK) was added and incubation continued for either 1
hour or 24 hours. The cells were transferred to a conical test tube,
centrifuged at 150g for 10 minutes at room temperature and
resuspended in 10 mis 0.075 M KCI. After 10 minutes at 37°C the
cells were centrifuged as above and the KCI removed. The cell pellet
was loosened and fresh fixative (3:1, methanohglacial acetic acid) was
added dropwise whilst gently mixing the cells. After 5 mis of fixative
had been added in this way the column was made up to 10 mis and the
cells centrifuged as above. The fixed cells were resuspended in fresh
fixative and centrifuged three more times and finally resuspended in
fixative to give a slightly cloudy suspension. Two drops of the cell
suspension were then dropped from a Pasteur pipette from a height of
about 0.5m onto microscope slides which had been cleaned in methanol
and wiped dry with clean tissue paper. Fresh slides were aged by either
treatment with hydrogen peroxide or baking overnight at 60°C and
banded using a trypsin-Giemsa method. Briefly slides were rinsed in
phosphate buffered saline, pH 7.1, covered with 2.8% trypsin for 10-
40 seconds, rinsed with buffer and then stained with Giemsa for 3-4
minutes. Stained slides were washed in running tap water, dried and
mounted in DPX mountant. Metaphase analysis was performed by Mr S
Larkins and Dr A Sanderson according to the international system for
human cytogenetics nomenclature.
To demonstrate any cytogenetic abnormality in CFU-GM isolated from
the patient, pooled GM colonies grown from PBMNC were harvested
into IMDM containing 20% v/v FCS and 10% v/v PHA-LCM and
incubated overnight at 37°C in 5% C02- Colcemid 0.2 pg/l was added
and after further incubation for both 1 hour and 24 hours cells were
harvested and processed as described above.
For karyotypic analysis of cultured skin fibroblasts and EBV transformed
cell lines, cells were incubated with 0.2 pg/l colcemid for 1 hour prior to
harvesting and processing as described above.
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10.5 Determination of the involvement of proto-oncogene SEA in the
t(2;1 1 )(q24/31 :q1 3) translocation observed in the patient with
primary myelofibrosis.
Karyotypic study of PBMNC from the patient with PMF revealed a
complex karyotype including the chromosomal translocation
t(2;11 )(q24/31 ;q13). Evidence from this case and a previously reported
case (Partenen et al, 1982) suggested a causal relationship between an
abnormality on the long arm of chromosome 11 and defective
erythropoiesis in PMF. The breakpoint in the case described above
(11 q 1 3) was also found to be the location of the human homolap^of the
viral oncogene SEA of the S13 avian erythroblastosis virus. Therefore
the involvement of the proto-oncogene SEA (pSEA) in this translocation
was studied at the molecular level. These studies were performed by Dr
Ruth Jarrett of the Leukaemia Research Fund Virus Centre of the
University of Glasgow by the analysis of DNA which was obtained from
patients PBMNC and skin fibroblasts. Following restriction endonuclease
OO
digestion and Southern blotting, DNA was hybridised with a P labelled
DNA probe for human pSEA. The methods are described briefly below.
High molecular weight DNA was extracted using SDS and proteinase K
as previously described (Trainor et al, 1982). Ten micrograms of DNA,
from either peripheral blood mononuclear cells or skin fibroblasts were
digested for 1 5h with the restriction endonucleases BamH1, EcoRI or
Sst1 using the conditions recommended by the manufacturer. The
digestion products were subjected to electrophoresis overnight at 32V in
0.8% agarose and transferred to Hybond-N membrane (Amersham
International, UK) by capillary transfer. Filters were subsequently
hybridised for 15h at 37° in 50% formamide/0.45M NaCI with the pSEA
probe which had been previously labelled to a specific activity of 1 x
lO^cpm/pg DNA using a modification of the method of Feinberg and
Vogelstein, 1983. After hybridisation, filters were washed extensively
with 0.5 x SSC, 0.1% SDS at 650C (1 x SSC is 0.15 M NaCI, 0.01 5M
sodium citrate, pH7). Hybridising bands were detected by auto¬
radiography at -70°C with Hyperfilm-MP (Amersham International, UK)
in a cassette using a Du Pont Quanta III screen.
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The pSEA probe was obtained from the UK DNA probe bank. This is a
4.5kb cDNA of the human homolog of the S13 avian erythroblastosis
oncogene cloned in EcoRI site of pvc13. This DNA sequence has been
mapped to chromosome 11 q 13 (Williams et al, 1 987).
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SECTION 3. RESULTS-
CHAPTER 11. PURIFICATION OF UNDIFFERENTIATED BLAST
CELLS FROM HUMAN FETAL LIVER.
11.1 Purification of undifferentiated blast cells from human fetal liver
following mechanical disruption of tissue.
In initial experiments a cell suspension was prepared from fetal liver
following mechanical disruption of tissue (see Materials and Methods).
A mononuclear cell fraction was then obtained by a single ficoll-hypaque
fractionation of cells. The total yields of cells obtained following
mechanical disruption of fetal tissue and subsequent one step ficoll
separation are shown below.
Table 1 0. Yield of mononuclear cells from fetal liver following
mechanical disruption of tissue.
Number of cells
Mean^ (95% CI) Ranqe
3.8 x 107 (3.1 - 4.6) 0.54 - 16.0 x 107
1. Number of experiments = 58.
The mean of values obtained for cell yield was 3.8 x 10^ cells per liver
and the yield was generally related to the size of the liver. Numbers of
cells obtained did not vary in relation to the time period which had
elapsed between the delivery of the fetus. As to this time period, the
fetuses were stored at 4°C prior to collection which ensured that the
livers were in a good physical condition at the time of dissection.
Assessment of the morphology of cells obtained at this stage, by
staining cytocentrifuged preparations with May-Grunwald-Giemsa
(MGG), is shown in Table 12 and illustrated in Plate 1a. The major
populations consisted of undifferentiated blast cells (48.6%) and
erythroblasts (27.4%). The remaining cells consisted of cells of the
granulocytic and monocytic lineages (12.3%), cells with morphological
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appearance of lymphocytes (8.9%) and cells which were not readily
identified and which were classed as others (2.8%).
To obtain a population of cells which was enriched with undifferentiated
blast cells, contaminating erythroblasts and monocytes/macrophages
were removed by indirect rosette sedimentation, after coating cells with
monoclonal antibodies directed against glycophorin C (Ret40F) and a
monocyte associated antigen (61 D3). To ensure that coating antibodies
were used in saturating amounts in the rosette depletion experiments,
antibody batches were titrated against both positive control cells and
fetal liver mononuclear cells by using the indirect rosette technique.
Sample titration data, obtained from tissue culture supernatants from
the Ret40F and 61D3 hybridomas are shown in Figures 14 and 15.
When used in rosette depletion procedures, the Ret40F and 61D3
antibodies were used at dilutions which were on the plateau portions of
the titration curves.
The batches of sheep erythrocytes coated with antibody to mouse IgG,
which were used to rosette fetal liver mononuclear cells coated with a
primary mouse monoclonal antibody were also subjected to quality
control procedures. A monoclonal antibody directed against the common
leucocyte antigen (BK19.45) was used as a test reagent to check
batches of sheep erythrocytes. The common leucocyte antigen (CD45)
is well expressed by peripheral blood mononuclear cells and weakly
expressed by the promonocyte line U937. A large batch of supernatant
from the BK19.45 hybridoma cell line was first titrated against
peripheral blood mononuclear cells and U937 cells, by using the indirect
immunofluorescence technique, to ensure that the batch of supernatant
contained adequate and saturating amounts of antibody. Peripheral
blood mononuclear cells were very strongly stained by BK19.45
antibody and U937 cells showed weak staining. The difference in the
level of antigen expressed by the two cell types is also reflected by
differences in the titre of BK19.45 antibody against U937 and peripheral
blood mononuclear cells (Figures 16 and 17). The batch of supernatant
was titrated at the same time against both cell types using the indirect
rosetting technique and an initial batch of coated erythrocytes. As
shown in Figures 16 and 17 and as revealed by the
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K562#cells
fetal liver mononuclear cells
FIGURE 14. TITRATION OF THE MONOCLONAL ANTIBODY
RET40F BY THE INDIRECT ROSETTE TECHNIQUE.
100 n
0 2 4 6 8
ANTIBODY DILUTION
Tissue culture supernatant was titrated against
K562 cells and fetal liver mononuclear cells.
FIGURE 15. TITRATION OF THE MONOCLONAL ANTIBODY
61D3 BY THE INDIRECT ROSETTE TECHNIQUE.
ANTIBODY DILUTION
Tissue culture supernatant was titrated against
peripheral blood mononuclear cells and fetal
liver mononuclear cells.
97
titration values obtained from the two techniques, the sensitivities of the
two assay methods are comparable with respect to the 100% values.
However, the rosette technique was more sensitive at higher dilutions of
antibody. In view of the weaker expression of common leucocyte
antigen on U937 cells, U937 cells coated with a dilution of BK19.45
antibody which was on the plateau portion of the titration curve
obtained by indirect rosetting were used to monitor the efficiency of
subsequent batches of sheep erythrocytes coated with antibody to
mouse IgG. Batches of sheep erythrocytes which gave 100% rosettes
in this test system were acceptable for use in subsequent rosette
depletion experiments.
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FIGURE 16. TITRATION OF THE MONOCLONAL ANTIBODY
BK19.45 AGAINST U937 CELLS.
ANTIBODY DILUTION
Tissue culture supernatant was titrated by using
the indirect immunofluorescence and indirect
rosette techniques.
FIGURE 17. TITRATION OF THE MONOCLONAL ANTIBODY
BK19.45 AGAINST PERIPHERAL BLOOD MONONUCLEAR
CELLS.
ANTIBODY DILUTION
Tissue culture supernatant was titrated by using
the indirect immunofluorescence and indirect
rosette techniques.
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To remove normoblasts and monocytes/macrophages from fetal liver
mononuclear cells, these cells were coated with Ret40F and 61D3
monoclonal antibodies and the rosettes formed following incubation with
antibody-coated sheep red cells were removed by centrifugation through
ficoll hypaque. Antigen negative cells which remained at the ficoll
interface were harvested for subsequent analysis. The average of the
percentage of fetal liver mononuclear cells rosetting when a combination
of the two antibodies was used was 28.2% (95% CI = 22.1-34.2; and
range = 2-58). This value for the combined percentages of normoblasts
and macrophages agreed well with the percentage of these cells as
identified by their morphology after staining cytocentrifuged preparations
with May-Grunwald-Giemsa (mean value = 29.6%; Table 12). After
rosette depletion, the combined percentage of cells rosetting after
relabelling with the monoclonal antibodies Ret40F and 61 D3 was 2.4%
(Table 11). Similarly, the combined percentages of normoblasts and
macrophages observed in MGG stained cytocentrifuged preparations of
rosette depleted populations were 0.1% (Table 12). These data show
that the rosette depletion method was highly successful in removing
normoblasts and monocytes/macrophages from fetal liver mononuclear
cells. Plate 1 illustrates samples of MGG stained cytocentrifuged cell
populations before and after rosette depletion with the Ret40F and
61 D3 monoclonal antibodies.
The average yield of cells obtained from each liver after rosette depletion
was 3.6 x 10® cells which represents 13.2% of the initial population of
fetal liver mononuclear cells (Table 11). In general the final yield of cells
related to the number of starting cells used in rosette depletion
experiments. The cells obtained following rosette depletion were
consistently viable (mean viability value = 95%; 95% CI = 94 - 96;
range = 90 - 99).
The nature of the rosette depleted population and differences from the
starting population, as observed by staining cytocentrifuged preparations
of cells with MGG, are shown in Table 12. Following the successful
removal of normoblasts and monocytes/macrophages, the percentage of
undifferentiated blast cells increased from 48.6% to 76.5%. The




























































































neutrophil stages of differentiation (8.6%), promonocytes (4.6%), cells
with the morphological appearance of lymphocytes (7.9%) and
unidentified cells (2.3%). The numbers of mature T (CD3 positive) and
B (CD22 positive) lymphocytes were enumerated by APAAP staining in
4 experiments. The numbers of combined CD3(T) and CD22(B) cells,
mean ( + SEM) were 2.0 ( + 0.4) before rosette depletion. Therefore
mature lymphocytes were present at a low frequency in the rosette
depleted population. The purified undifferentiated blast cell population
exhibited variable morphological features (Plate 1b). The nuclear
chromatin pattern was generally open with usually multiple nucleoli and
the nuclear outline varied from round to irregular convoluted forms.
Cytoplasm was either scanty or moderate in quantity, weakly to strongly
basophilic and sometimes vacuolated. Azurophilic granulation was









































































































































































Plate 1. Photomicrographs of cells purified from human fetal liver
following mechanical disruption of tissue. Plate 1a shows cells following
ficoll separation where erythoblasts and macrophages are prominent
(MGG x 500) and Plate 1b shows undifferentiated blast cells prepared
following erythroblast and macrophage depletion ( MGG x 625 ).
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11.2 Purification of undifferentiated blast cells from human fetal liver
following enzyme digestion of tissue, ficoll separation and
erythroblast and macrophage depletion.
To enhance the yield of undifferentiated blast cells obtained from each
fetal liver the purification procedure was modified. The new method
incorporated initial enzyme digestion of fetal liver tissue, subsequent
ficoll-hypaque separation of light density cells, which was performed
twice, and finally rosette depletion of fetal liver mononuclear cells using
the Ret40F and 61D3 monoclonal antibodies (see materials and
methods). The total yield of cells obtained at each stage of the
purification procedure is shown in Table 13. The average value for the
yield of cells obtained following collagenase, hyaluronidase and dispase
digestion of whole fetal liver was 2.15 x 10^ cells. The nature of the
cell population obtained following enzyme digestion of fetal liver, as
identified from the differential of MGG stained cytocentrifuged
preparations, is shown in Table 14. Following enzyme digestion the cell
population was found to consist predominantly of erythroblasts
(84.8%), which were mainly at intermediate to late stages of
development (Plate 2a). Other populations were minor and consisted of
monocytes and macrophages (5.7%), cells with the morphological
appearance of lymphocytes (2.5%), undifferentiated blast cells (5.2%),
promonocytes and cells at the promyelocyte to neutrophil stages of
maturation (0.6%) and unidentified cells (1.2%). Following the first
ficoll-hypaque fractionation step the average of values obtained for the
yield of cells was 1.07 x 10^ cells, which represented 49.8% of the cell
population obtained following enzyme digestion of whole fetal liver
(Table 13). This number of cells obtained was far greater than the yield
of cells mechanical disruption of tissue and ficoll-hypaque separation of
mononuclear cells (3.8 x 10^, Table 10). The differential of cells
obtained after the first ficoll separation did not differ significantly from
that of the cells obtained following enzyme digestion of fetal liver. After
separating the mononuclear cell population from the enzyme digest of
fetal liver, the percentage of normoblasts fell slightly from 84.8% to
80.9%. In association, there was a marginal increase in the percentages
of other minor cell populations (Table 14). The normoblasts obtained






































































































































































































































































































were similar in morphology, being predominantly at intermediate to late
stages of development (Plate 2b).
Following the second ficoll-hypaque fractionation step there was a large
fall in cell yield. The average of values obtained for the yield of cells
was 2.17 x 10*3 cells, which represented 10.1% of the initial population
obtained following enzyme digestion of fetal liver (Table 13). In
association with the fall in cell yield, there was a change in the nature of
the cell population as identified by the differential of cells seen in MGG
stained cytocentrifuged preparations. After the first ficoll-hypaque
fractionation step, the average of values obtained for the percentage of
normoblasts was 80.9%. In contrast, after fractionation of cells for a
second time over ficoll-hypaque, the average of values obtained for the
percentage of normoblasts was reduced to 52.2% (Table 14).
Furthermore, the normoblasts present after the first and second ficoll
separations were qualitatively different. After the second ficoll
separation there were higher proportions of pronormoblasts and
normoblasts at early stages of development (Plate 2c) and the
morphological discrimination between undifferentiated blast cells and
early erythroid precursors was more difficult. In association with the fall
in the normoblast population, there was an increase in other cell
populations, particularly undifferentiated blast cells (24.3%), monocytes
and macrophages (11.3%) and cells with the morphological appearance
of lymphocytes (6.2%) (Table 14). At this stage, following the second
ficoll fractionation and prior to the rosette depletion procedure, the
number of cells obtained (2.17 x 10^ cells, Table 13) remained far
greater than the yield of cells obtained following mechanical disruption
of tissue and ficoll separation of mononuclear cells (3.8 x 10? cells,
Table 10).
After fractionation of fetal liver cells over ficoll-hypaque for the second
time, the cells were depleted of normoblasts and macrophages by the
indirect rosette technique after coating cells with the monoclonal
antibodies Ret40F and 61 D3 as previously described. The data from 12
experiments in which the rosette depletion procedure was performed is
shown in Table 14. After the second ficoll fractionation, the percentage
of cells rosetting when a combination of the two depleting antibodies
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Ret 40F and 61 D3, used was 54%. This value showed good agreement
with that obtained for the combined percentages of normoblasts and
macrophages, as identified by their morphology on MGG stained
cytocentrifuged preparations which was 63.5% (Table 14). Following
rosette depletion, normoblasts and macrophages were successfully
removed as shown by the combined percentages of these cells observed
in MGG stained cytocentrifuged preparations of rosette depleted
mononuclear cells (0.8%, Table 14).
The average value for the yield of cells obtained from each liver after
rosette depletion was 7.3 x 10® cells, which represented 0.34% of the
initial population of cells obtained following enzyme digestion. These
cells were consistently viable. As in the case of the previous
purification method, the yields of cells obtained at each stage of the
purification procedure related in general to the number of starting cells.
Using the modified method incorporating enzyme digestion of liver
tissue, where the number of starting cells was higher, the average final
yield of cells obtained following rosette depletion (7.6 x 10® cells, Table
4) was greater than that obtained by using the original method of
mechanical disruption of tissue (3.6 x 10® cells, Table 1 1).
The nature of the rosette depleted population, as observed by the MGG
differential of cytocentrifuged preparations, is shown in Table 14. The
purified cell population consisted mainly of undifferentiated blast cells
(59.2%) which exhibited a morphology (Plate 2d) similar to that
described for rosette depleted cells generated using the previous method
(Plate 1b). The remaining cells consisted of promonocytes (13.9%),
cells at the promyelocyte to neutrophil stages of differentiation (8.7%),





Plate 2. Photomicrographs of cells purified from human fetal liver following
enzyme digestion of tissue. Mature erythroblasts predominate following enzyme
digestion (a) and first ficoll separation (b). Following second ficoll separation (c)
early erythroblasts and undifferentiated blasts predominate and following
erythroblast and macrophage depletion (d) undifferentiated blasts and
promonocytes are the dominant cell populations. (MGG x 500 ).
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11.3 Further purification of the undifferentiated blast cell population by
cell elutriation.
The blast cells purified following enzyme digestion of fetal liver tissue
and depletion of erythroblasts and macrophages from a mononuclear cell
fraction were themselves heterogeneous in nature. There was also a
significant contaminating population of promonocytes. To attempt to
obtain a more homogeneous blast cell population and to eliminate
contaminating promonocytes, the above cells were further purified by
cell elutriation. This procedure separates cells according to their size
and buoyant density. In two experiments, fractions were collected at
incremental flow rates of 4.7, 9.0, 13.3, 17.8, 22.0, 26.3, 30.4 and
34.5 mis/minute and the rotor off fraction was also collected.
The nature of the cell population present within each elutriation fraction,
as observed by the MGG differential of cytocentrifuged preparations, is
shown in Tables 15a and 15b and the changes in major cell populations
with respect to elutriation fraction number are charted in Figure 18. The
morphology of cells obtained from each elutriation fraction is illustrated
in Plate 3 a-i. The first two fractions obtained at flow rates of 4.7
ml/minute and 9.0 ml/minute, were dominated by cells with the
morphological appearance of lymphocytes. These cells were not present
to any large degree in subsequent fractions (< 1 3%). The third fraction,
obtained at a flow rate of 13.3 ml/minute, contained the largest
percentage of blast cells which were present at levels of 82.5% and
74.5%. The percentage of blast cells remained high in the next two
fractions which were obtained at flow rates of 17.8 ml/minute and 22.0
ml/minute. In subsequent fractions the percentage of blast cells
declined although the rate of fall was more gradual in experiment
number 2 (Figure 18). As regards monocytic cells, which were mainly
promonocytes, they were present to a small degree in the first two
fractions obtained at flow rates of 4.7 ml/minute and 9.0 ml/minute (<
3%). In subsequent fractions there was a progressive increase in the
percentage of monocytic cells and in the fraction obtained at a flow rate

















































The data are presented as a percentage of the
total cell yield and are the mean of values





























































































































































































































Pkite 3. Cells purified from human fetal liver after elutriation of
erythroblast and macrophage depleted mononuclear cells.
Illustrations are photocopies of colour photomicrographs of cells
stained with May-Grunwald-Giemsa (magnification x 500). Letters
a - h represent sequential elutriation fractions from 1 - 8 and i



























The distribution of cell numbers within each elutriation fraction was also
determined. As in the case of the differential data the results obtained
from both experiments were similar and are therefore presented as mean
values in Figure 19. Optimal separation of lymphocytes, blast cells and
monocytic cells was observed at flow rates of 13.3 ml/minute and 17.8
ml/minute. These two fractions also contained the largest numbers of
cells (fraction Nos. 3 and 4).
The first two fractions obtained at flow rates of 4.7 ml/minute and 9.0
ml/minute contained 9.6% of the total cells recovered. Almost half of
the total cells recovered (44.5%) were present within the next two
fractions obtained at flow rates of 13.3 ml/minute and 17.8 ml/minute.
Progressively smaller numbers of cells (12-6%) were present in the
fractions obtained at flow rates >22.0 ml/minute. When purified blast
cells were used in subsequent experiments the fractions obtained at
flow rates 13.3 ml/minute and 17.8 ml/minute were combined. The
yields of cells from the two experiments shown were 1.1 x 10® cells
and 0.33 x 10® cells. The data show that elutriation of cells at flow
rates of 13.3 ml/minute and 17.8 ml/minute (fraction Nos. 3 and 4)
gave rise to an optimal combination of cell yield and separation of
undifferentiated blast cells from other cell types. Cells obtained when
these two fractions were pooled were subjected to further
characterisation (Chapter 12) and were used in further studies (Chapters
14, 15).
Therefore in a further five experiments cells collected only at flow rates
of 13.3 ml/minute and 17.8 ml/minute were pooled and subjected to
further analysis. These data for the yields of cells and the percentage
differentials in the five experiments are shown in Table 16. The average
of values obtained for the yield of cells in these two fractions was 1.75
x 10® cells. This number of cells represented 0.07% of the starting
number of cells obtained following enzyme digestion of fetal liver. For
these five same experiments the average of the values obtained for the
yield of cells ( + SEM) following rosette depletion was 8.7 x 10® ( + 3.0).
Therefore 20% of the rosette depleted cells were recovered following
collection of the two elutriation fractions. The dominant cell type within
these pooled fractions was undifferentiated blast cells which accounted
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for 70% of cells. Cells with morphological appearance of lymphocytes
accounted for 15% of cells and monocytic cells (mainly promonocytes)
accounted for 11 % of cells.
Table 16 Numbers of cells obtained and the percentages of blast
cells within fractions elutriated at flow rates of 13.3 and
1 7.8ml/minute.
Experiment^.
Cells MGG differential (%)
Total No. x 10® % yield blasts promonocytes lymphocytes
1 3.27 0.08 76 14 7
2 0.88 0.07 82 14 0
3 0.53 0.03 60 11 25
4 1.04 0.05 69 10 18
5 3.04 0.12 62 8 24
Mean 1.75 0.07 69.8 11.4 14.8
(SEM) (0.58) (0.02) (4.2) (1.2) (4.9)
1. Cells were elutriated at flow rates of 13.3 ml/minute and 17.8 ml/minute and
these fractions were then pooled for analyses.
Comparison of the morphological appearances of the blast cells obtained
after cell elutriation with those obtained by merely depleting normoblasts
and macrophages from fetal liver mononuclear cells revealed that the cell
elutriated blast cells were more homogeneous in nature and present at a
higher percentage (Table 14, Table 16). The blast cells were more
uniform as regards their size, nuclear morphology and cytoplasmic
characteristics. These points are illustrated in Plates 3c-d and Plate 2d.
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CHAPTER 12 CHARACTERISATION OF UNDIFFERENTIATED
BLAST CELLS PURIFIED FROM HUMAN FETAL LIVER.
1 2.1 Characterisation of blast cells obtained following depletion of
normoblasts and macrophages from fetal liver mononuclear cells.
The blast cells obtained by depleting normoblasts and macrophages from
fetal liver mononuclear cells separated following mechanical disruption
of tissue, were characterised as to their cytochemistry, expression of
cell surface antigens, their ability to form colonies when plated in semi¬
solid medium and for the percentage of cells in each phase of the cell
cycle.
12.1. Cytochemical investigations
Cytocentrifuge preparations of blast cells were stained to reveal the
extent of their Sudan Black B and periodic acid-Schiff positivity and
whether they expressed the enzymes chloroacetate esterase
(granulocyte specific) and butyrate esterase (monocyte specific). The
results are shown in Table 17 and MGG differential data from the same
experiments are also shown for comparison.
The number of butyrate (monocyte specific) esterase positive cells was
3% and this value correlated well with the number of monocytic cells
identified following staining with MGG (4%). The number of
chloroacetate esterase (granulocytic specific) positive cells was 11 %
and this value also agreed well with the percentage of granulocytic cells
identified following staining with MGG (11%). The value for Sudan
Black B positivity, which is not lineage specific and which is present in
more mature granulocytic and monocytic cells, was 16%. This value
correlated well with the combined percentages of monocytic and
granulocytic cells identified following staining with MGG (15%). The
value for periodic acid-Schiff positivity was 12% and the staining was of
a weak, diffuse nature. This marker is seen in myeloid cells showing
evidence of maturation and is particularly strong in mature granulocytes.
This degree and nature of PAS positivity was consistent with the extent
of myeloid maturation observed in MGG stained preparations.
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Undifferentiated blast cells were clearly seen to be negative for Sudan
Black B, chloroacetate esterase, butyrate esterase and periodic acid-
Schiff reagent. Plate 4 illustrates the cytochemical staining observed.
Table 17 Cytochemical investigations on blast cells obtained
following depletion of erythroblasts and macrophages from
fetal liver mononuclear cells.
% cells positive
Cytochemical stain Mean (±SEM)
Sudan Black B 16 (3.0)
Chloroacetate esterase 11 (1.8)
Butyrate esterase 3 (1.8)
Periodic acid -Schiff 12 (4.5)
MGG differential (%)
Normoblasts 0 ( 0)
Lymphocytes 4 (2.0)
Blasts 79 (0.9)
Monocytic cells 4 (0.9)
Granulocytic cells 1 1 (2.9)
Others 2 (0.6)
No. of experiments = 3
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Plate 4. Illustration of cytochemical staining of blast cells purified
from human fetal liver following erythroblast and macrophage
depletion. Plate 4a Sudan Black B; Plate 4b Periodic acid-Schiff;
Plate 4c Chloroacetate esterase and Plate 4d Butyrate




Cells purified from human fetal liver following erythroblast and
macrophage depletion were assessed for their expression of cell surface
antigens known to be present on haemopoietic cell populations. These
studies were performed using a combination of techniques including
direct and indirect rosetting, indirect immunofluorescence and the
APAAP technique. The results are shown in Table 18. The percentage
of cells expressing common leucocyte antigen was 99% which
confirmed the haemopoietic nature of the purified cell population. The
percentage of cells expressing glycophorin C, an erythroid antigen, was
low (1%) illustrating the efficiency of the erythroblast depletion
procedure. The percentages of positive cells for the mature myeloid
antigens CD11 c, CD1 5 and CD14 were all low (<8%) and these values
were consistent with the numbers of mature myeloid cells observed
following staining with MGG (Chapter 11, Table 12). The number of
mature T cells present, as identified by CD3 staining, was also low
(1%). The antigen CD5, which identifies T cells and a subset of B cells,
was also expressed at a low level of 4%. The mean value for the
percentage of CD10 positive cells was 18% and the corresponding value
for CD19 positive cells was 14%. The CD10 antigen is expressed on B
cell progenitors and also weakly on mature granulocytes and the CD 19
antigen is a marker for early B cells and persists throughout B cell
differentiation. As the percentage of mature granulocytes in the purified
population is small, these data indicate that B cell progenitors are
present within the population purified. Very much larger percentages of
cells were positive for HLA Class II (59%), CD7 (46%) and CD34 (32%)
antigens. These antigens are known to be expressed on early
haemopoietic cells. For example Class II HLA antigen expression is a
feature of progenitor cells, B cells and macrophages. CD7 expression is
a feature of T cell and myeloid precursor cells and CD34 expression is a
feature of haemopoietic stem cells and committed progenitor cells. The
presence of large numbers of HLA class II positive, CD7 positive and
CD34 positive cells within the population purified is consistent with their
largely undifferentiated nature as revealed by cytochemical analyses.
The ability of this undifferentiated blast cell population to differentiate
and the nature of their progeny were subsequently studied.
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Table 1 8. Immunophenotypic analysis of undifferentiated blast cells
obtained following depletion of erythroblasts and
macrophages from fetal liver mononuclear cells.
% cells positive 1
Antigen Mean (±SEM)
Common leucocyte antiqen 99 (0.5)
Erythroid






CD3 (T cell) 1 (0.6)
CD5 (T cell,B cell subset) 4 (1.5)
CD10 (B cell progenitor) 18 (3.3)
CD19 (B cell) 14 (7.0)
Others
CD7 (T cell, myeloid precursors) 47 (6.3)
HLA class II (progenitors, B cells, 59 (5.5)
macrophages)
CD34 (early cells) 32 (4.2)
Negative control-^ 2 (0.8)
1 = Data from two experiments.
2 = Cells were stained using a monoclonal antibody to rotavirus
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12.1.3 Analysis of colony forming ability.
Cells, purified from human fetal liver following erythroblast and
macrophage depletion, were plated into semi-solid medium to determine
the numbers of GM-CFC and BFU-E present and to determine whether
the blast cells themselves were able to give rise to blast cell colonies.
The results are shown in Table 19. The average of values obtained for
the numbers of GM-CFC per 10^ cells of the mononuclear fraction was
152 and the corresponding value for BFU-E was 136. These values are
higher than the normal reference ranges for adult bone marrow and are
consistent with previously reported data for CFC numbers in studies of
human fetal liver cell populations (Toksoz and Brown, 1984; Rowley et
al 1978; Emerson et al 1985). Following depletion of erythroblasts and
macrophages there was some enrichment of GM-CFC and BFU-E.
Values obtained for the numbers of GM-CFC and BFU-E within the
rosette depleted population were 244 per 10^ cells and 237 per 105
cells, respectively. These numbers of colony forming cells represent
0.5% of the cell population. Therefore the large majority of the blast
cells, themselves, did not give rise to colonies under the culture
conditions used in these assays. Plate 5 illustrates examples of colony
morphology and colony identification following analysis of
cytocentrifuged preparations of individual colony contents.
Table 1 9. Assay of colony forming ability of cells purified from human
fetal liver following erythroblast and macrophage depletion.
No. of CFU per 1C)5 cells
GM-CFC1 BFU-E2
Purification stage Mean (±SEM) Mean (±SEM)
Post ficoll separation 152 (50) 136 (23)
Post rosette depletion 244 (42) 237 (43)
1.
2.
Number of experiments = 4
Number of experiments = 3
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Plate 5. Photomicrographs of colony morphology of colonies grown from
cells purified from human fetal liver . Plate 5a shows a BFU-E colony ( x
140 ) and Plate 5b shows a granulocyte-macrophage colony ( x 280 ).
Plates 5c and 5d show MGG stained cytocentrifuge preparations of the
colony contents of a granulocyte colony ( 5c ) and a macrophage colony (
5d ) respectively. Plate 5e shows the contents of a macrophage colony
stained for alpha-naphthyl acetate esterase ( x 500).
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12.1.4. Analysis of phase of cell cycle.
The percentage of the undifferentiated blast cell population at each
phase of the cell cycle is shown in Table 20. The analysis was
performed once and comparative studies were carried ovjtcoHL60 cells and
tonsillar B lymphocytes. The corresponding plots of cell number versus
DNA content are shown in Figure 20. The undifferentiated blast cell
population purified from fetal liver exhibited an S phase population
intermediate between that of tonsillar B cells and HL60 cells. It is
apparent that the vast majority (81%) of the fractionated fetal liver cells
were out of cell cycle.
Table 20. Analysis of phase of cell cycle of undifferentiated blast cell
population purified from human fetal liver following Ret40F
and 61 D3 rosette depletion.
n = 1
Phase of cell cycle
Cell Type
Fetal liver blast cells HL60 cells




gi 81 39.7 98.3
s 14.9 52.2 0.5
g2/m 4.1 8.1 1.2
12.2. Characterisation of blast cells obtained after cell elutriation.
12.2.1 Cytochemical and immunocytochemical analysis
The numbers of cells available within each elutriation fraction were small
and this therefore limited further analysis of the undifferentiated blast
cell population. However, the presence of the surface antigens CD34
and CD10 were determined, using an indirect immunofluorescence
technique, on cells within each elutriation fraction. The analysis of
CD34 positive cells was performed twice. As in the case of MGG
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Figure 20b. HL60 cells.
Figure 20c.Tonsillar B cells.
Figure 20. Cell cycle profiles of different cell populations. Test cells
were processed using a commercial kit (Cycletest, Becton Dickinson,
UK ) and analysed in a flow cytometer ( FACScan) using commercial
software (Cellfit, Becton Dickinson, UK). Cell number on the vertical
axis is plotted against fluorescence intensity ( DNA content) on the
horizontal axis. Undifferentiated myeloid blast cells exhibited an S
phase population intermediate between that of tonsillar B cells and
HL60 cells.
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differential and cell yield data, the results for both experiments were
similar and are therefore presented as the mean of values, in Figure 21.
The analysis of CD10 positive cells was performed once and the results
are also presented in Figure 21. The percentages of CD34 positive cells
were low in the first two fractions obtained at flow rates of 4.7
ml/minute (11%) and 9.0 ml/minute (8%). CD34 positive cells were
predominant in the next two fractions. In the fractions collected at flow
rates of 13.3 ml/minute and 17.8 ml/minute 36% and 38% of the cells
were CD34 positive, respectively. These fractions were also found to
contain the highest percentages of undifferentiated blast cells and the
largest cell numbers. In subsequent fractions the percentage of CD34
positive cells was lower and in the range 10-23% (Figure 21). When
the data is expressed in terms of absolute numbers of CD34 positive
cells, the yield of positive cells was also maximal in the fractions
obtained at flow rates of 133 ml/minute and n.8 ml/minute (fraction
nos. 3 and 4). The percentage of CD10 positive cells could not be
determined in the first fraction obtained at a flow rate of 4.7 ml/minute
as this fraction contained too few cells for analysis. The percentage of
positive cells was highest (40%) in the next fraction obtained at a flow
rate of 9.0 ml/minute. The value fell markedly to 12% in the next
fraction and was < 1 % in all subsequent fractions. These data,
indicating that lymphoid progenitors are contained predominantly within
early fractions, are consistent with MGG differential data which
indicated that cells with the morphological appearance of lymphocytes
were also predominantly contained within the early elutriation fractions.
They also indicate that lymphoid progenitors were not present to a
significant degree in fractions 3 and 4, which were those cells selected
for further study of changes in inositol metabolism during myeloid
differentiation.
In addition to MGG analysis, the cells obtained by pooling elutriation
fractions numbers 3 and 4 were also examined as to their degree of
granulocytic and monocytic differentiation as assessed by positive
staining with the AGF4.48 antibody and for monocyte specific esterase.
These results are shown in Table 21. The means of values obtained for
positive staining for alpha-naphthyl acetate esterase (12.2%) and with
AGF4.48 antibody (1.5%) correlate well with values obtained for
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FIGURE 21. PRESENCE OF CD 10 AND CD 34 POSITIVE
CELLS WITHIN EACH ELUTRIATION FRACTION
ELUTRIATION FRACTION NUMBER
The percentage of antigen positive cells was determined
by indirect immunofluorescence. CD 10 values are a
single data set and CD 34 data are the mean of values
from two similar experiments.
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monocytic cells (11.5%) and granulocytic cells (1.7%) as observed on
MGG stained preparations. They indicate that the degree of myeloid
differentiation was limited in this fractionated population of cells.
Table 21. Characterisation of cells obtained within pooled elutriation
fractions Nos. 3 and 4.












Promonocytes 1 1.4 (1.2)
ANAE 12.2 (2.0)
AGF 4.48 1.7 (0.6)
1. Data from 5 experiments; AGF 4.48 values from 3 experiments.
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CHAPTER 13
THE EFFECT OF TREATMENT WITH PHORBOL MYRISTATE ACETATE
(PMA) ON THE DIFFERENTIATION OF BLAST CELLS PURIFIED FROM
HUMAN FETAL LIVER.
Previous studies describing the growth and differentiation in liquid
suspension culture of mononuclear cells isolated from human fetal liver
(Toksoz and Brown, 1984) showed that these cultures generated large
numbers of mature neutrophils and macrophages for a period of up to 1
month. This observation indicated that the initial cell population
contained cells at early stages of myeloid differentiation. Therefore,
similar studies of the extent of myeloid differentiation in liquid
suspension culture were carried out on undifferentiated blast cells
purified from human fetal liver following erythroblast and macrophage
depletion. Cells purified according to the protocol incorporating
mechanical disruption of tissue were used for these studies. The effect
of phorbol myristate acetate (PMA) on the differentiation of these
normal myeloid blast cells was also studied in these experiments. PMA
is known to induce rapid monocyte differentiation of the human
promyeloid cell line HL60 (Rovera et al, 1979) but its effects on normal
progenitor cells had not been studied previously. In these cultures,
monocyte differentiation was assessed by enumerating a) cells exhibiting
monocytic (promonocytes and monocytes/macrophages) morphology
following staining with MGG and b) cells expressing a-naphthyl acetate
(monocyte specific) esterase. Granulocyte differentiation was assessed
by a) cells exhibiting granulocytic (promyelocyte, myelocyte,
metamyelocyte and mature granulocyte) morphology following staining
with MGG; b) cells expressing lactoferrin, a known constituent of
neutrophil secondary granules and c) cells staining with the AGF4.48
antibody, a neutrophil specific antibody of the CD15 cluster, which
identifies cells at or beyond the promyelocyte stage of differentiation.
13.1 Induction of monocyte differentiation by PMA.
PMA was added immediately after establishing cultures of purified blast
cells at 2.5 x lO^/ml. Sixteen hours after the addition of PMA, the
morphological appearance of cells in the treated cultures was already
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Plate 6. Photomicrographs of undifferentiated blast cells cultured in
medium containing fetal calf serum with ( 6a ) and without ( 6b ) the
addition of 10nM PMA. Cells in PMA-treated cultures became clumped,
adherent, spread and had produced pseudopodia - changes consistent
with the cells having undergone monocyte differentiation (x 140).
134
different from that in control cultures (Plate 6). A considerable
proportion of the cells in the PMA-treated wells had become clumped,
adherent, spread and had produced pseudopodia. Cells with these
features which are consistent with cells having undergone macrophage
differentiation were less evident in the control cultures. Monocyte
differentiation in PMA-treated cultures was confirmed following
assessment of monocytic cells seen in MGG stained cytocentrifuge
preparations. Promonocytes, which were more evident in PMA treated
cultures, had distinguishing characteristics of increased size with
increased quantities of cytoplasm which was less basophilic, often
vacuolated, and had irregular edges. Phagocytosis of a few
contaminating sheep erythrocytes, from the rosette procedure, was also
occasionally seen. The nuclear to cytoplasmic ratios was reduced in
these cells and the nucleus was eccentrically placed, reniform in shape
and contained nucleoli. More mature cells showed typical macrophage
morphology (Plate 7). At time zero, cells with these features accounted
for 4% of cells. The addition of 10 nM PMA resulted in an increase of
monocytic cells to values of 62% and 65% at 42h and 66h respectively,
compared to values of 14% and 16% in control cultures (Figure 22),
The rapid morphological differentiation towards macrophages seen with
PMA was accompanied by an increase in the number of cells expressing
a-naphthyl acetate esterase. Four percent of the initial cell population
expressed this enzyme but by 66h, 46% of cells in PMA-treated cultures
were positive compared with 8% of control cells (Figure 22; Plate 7).
When expressed in absolute numbers the number of cells expressing a-
naphthyl acetate esterase had increased from 1.0 x 10^ cells initially to
9.7 x 1C>4 in PMA-treated cultures at 66h compared to 1.8 x 10^ in
control cultures at this time point. The number of phagocytic cells
increased from <1% to 17% at 66h in PMA-treated cultures as
opposed to 6% in control cultures. In both the PMA-treated and control
cultures there was no increase in the total number of cells over the 66
hr during which analyses were undertaken and the values obtained for
the number of viable cells recovered (80-92%) and cell viability (87-
98%) were similar for the treated and untreated cultures throughout the


















































Assessment of cell proliferation by analysis of DNA synthesis was also
performed. In control cultures there was a moderate increase in [^H]
TdR uptake. Values for dpm incorporated per 10^ cells were 3.0 x 10^
at 1 2h rising to 5.1 x 10^ and 4.2 x 10^ at 60 and 84h respectively.
PMA treated cultures had proliferated to a lesser extent as shown by
[3h] TdR incorporation values of 1.7 x 1 C)4, 4.2 x 1 0^ and 3.4 x 1 0^ at
12h, 60h and 84h respectively. Thus it was unlikely that PMA had
induced rapid and extensive proliferation of a minor population of the
purified blast cells and that this together with loss of a considerable
number of cells within another cell population had maintained cell
numbers in the PMA-treated cultures. Furthermore, large numbers of
dead cells were clearly not present in the wells. Plate 7 illustrates that
the frequency of monocytic cells was considerably higher in PMA-
treated cultures than in cultures of control cells.
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Plate 7(opposite). PMA-induction of monocyte differentiation
and inhibition of granulocyte differentiation of undifferentiated blast
cells purified from human fetal liver.
Illustrations are photocpoies of colour photomicrographs. Figures a -c
are Romanowsky stained preparations; figures d - f are preparations
stained for a-naphthyl acetate esterase activity (monocytic cells);
and figures g - i are preparations stained by indirect
immunofluorescence with AGF4.48 antibody (granulocytic cells)
(magnification x 500). Figures a,d,g show cells at Oh; figures b,e,h












13.2 Inhibition of granulocyte differentiation by PMA
In PMA-treated cultures the maximum percentage of cells which could
be induced to differentiate towards monocytes was 63-67%. At 66h,
31-33% of the remaining cells, as observed in MGG stained preparations
had retained a blast cell appearance and only 1 % of total cells had
differentiated towards neutrophils. In contrast, analysis of MGG stained
preparations from control cells showed that, by 66h, 34% of cells
exhibited morphological evidence of granulocytic differentiation (Figure
23, Plate 7). To confirm that the addition of PMA had interfered with
granulopoiesis within the purified blast cell population the percentage of
cells expressing lactoferrin and the neutrophil specific cell surface
antigen AGF4.48, which is expressed at the promyelocyte stage of
differentiation, were enumerated throughout the time course of PMA-
treated and control cultures. Within the starting cell population, 10% of
cells contained lactoferrin and expressed the AGF4.48 antigen. By 66h
the numbers of lactoferrin and AGF4.48 antigen positive cells in control
cultures had increased to 33% and 39% respectively. In contrast,
throughout the time course of PMA-treated cultures, the percentage of
lactoferrin positive cells remained at the level of 5-14% and those
stained by the monoclonal antibody AGF4.48 at 9-12%. At 66h, the
mean value for the percentage of AGF4.48 positive cells represented a
level of 1.9 x 10^ mature granulocytic cells in PMA treated cultures as
compared with 9.0 x 10^ in control cultures. Initial levels of mature
granulocytic cells in the purified blast cell population were in the range
of 1.8 - 2.1 x 104. Plate 7 illustrates that the frequency of mature
granulocytic cells was considerably lower in PMA-treated cultures than
in cultures of control cells.
To exclude the possibility that the inhibition of granulopoiesis or the
promotion of monopoiesis observed was due to indirect effects whereby
PMA had induced the small percentage of contaminating lymphocytes to
release inhibitory or inductive factors, the following experiment was
undertaken. The monoclonal antibody AGF43, which stains both T and
B lymphocytes (Fisher et al, 1983), was added to the antibody mixture
used to prepare indirect rosettes and this resulted in effective depletion































































cells prepared from fetal liver following ficoll separation consisted of
56% blasts, 22% normoblasts, 4% macrophages and 19% of cells with
the morphological appearance of lymphocytes. Cells subsequently
depleted with the Ret40F and 61 D3 antibodies were comprised of 77%
blasts and 21% of cells with the morphological appearance of
lymphocytes. The fetal liver cell population which had been depleted
using the three antibodies (Ret40F, 61 D3, and AGF43) contained 86%
blast cells and only 1 % lymphocytes. Parallel studies of the effect of
PMA on the above two purified cell populations showed that removal of
the contaminating lymphocytes did not affect the rapid induction of
monocyte differentiation by PMA or the inhibition of granulopoiesis. At
61 h after PMA treatment, cultures established from fetal liver cells
depleted by lymphocytes and from those cells contaminated by
lymphocytes contained similar numbers of cells expressing a-naphthyl
acetate esterase (27% and 21% respectively). In both cultures after
treatment with PMA for 61 h there was no evidence of neutrophil
differentiation as assessed by the percentages of AGF4.48 antigen
positive cells (<1%) and cells at the promyelocyte to neutrophil stages
of maturation (< 1 %).
13.3 The effect of treatment with PMA on the expression of
cytochemical markers.
The effect of PMA treatment of undifferentiated blast cells on the
expression of other cytochemical markers was also studied. The
cytochemical stains employed were Sudan Black B, chloroacetate
esterase, butyrate esterase and periodic acid-Schiff reagent. Two
experiments were carried out where the percentage of cells expressing
each marker was assessed initially and after 66 hours in culture. Both
experiments gave similar results which are expressed as a mean of the
obtained values. To validate the experiments, control data for cell
number, viability, results of MGG staining and staining with the
AGF4.48 antibody were also assessed in parallel. Analyses for these
control data gave results similar to the previous PMA induction
experiments. The percentage of cells staining for chloroacetate esterase,
a marker for mature granulocytic cells showed good agreement with the
percentage of granulocytic cells observed following MGG staining and
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the percentage of cells staining with the AGF4.48 antibody in both
control and PMA treated cultures (Figure 24). Control cells after 66
hours in culture showed significantly increased numbers of chloroacetate
esterase positive cells (12% - 35%) whereas in PMA treated cultures,
chloroacetate esterase positive cells fell from 12% to 9%. The
percentage of cells staining for butyrate esterase, a monocyte specific
esterase, also showed good agreement with data obtained from the
previous PMA induction experiments. The percentage of butyrate
esterase positive cells increased slightly in control cultures (2% to 7%)
but showed a much larger increase in PMA treated cultures (2% to
26%) (Figure 24). These data on the expression of chloroacetate
esterase and butyrate esterase support the previous observations on the
effect of PMA on the differentiation of myeloid blast cells purified from
fetal liver. The percentage of cells staining with Sudan Black B and
periodic acid-Schiff reagent showed large increases in both control and
PMA treated populations. Sudan Black B positive cells increased from
17% to 88% in control cultures and from 17% to 87% in PMA treated
cultures. PAS positive cells increased from 15% to 39% in control
cultures and from 15% to 56% in PMA treated cultures. These data for
Sudan Black B and PAS staining are consistent with previous
observations since these markers are absent in undifferentiated blast
cells but present in cells showing evidence of either granulocytic or
monocytic differentiation. Their levels were low in the initial
undifferentiated blast cell population and increased after 66 hours in
culture, over which time period significant differentiation had occurred.
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Figure 24. Effect of PMA treatment on the expression of
chloroacetate and butyrate esterases within purified
blast cells. The percentages of granulocytic cells ( • ),
AGF4.48 positive cells ( □ ), chloroacetate positive
cells ( a ), monocytic cells ( o ), and butyrate esterase
positive cells ( ■ ) were determined. The results are
means of values (+SEM) from two experiments.
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13.4. The effect of treatment of purified blast cells with PMA on the
expression of leucocyte surface antigens.
The effect of PMA treatment of undifferentiated blast cells on the
expression of leucocyte surface antigens was also studied. The cell
surface antigens studied and the results are shown in Table 22. Two
experiments were performed where the percentage of cells expressing
each marker was assessed initially and after 66h in culture. Both
experiments gave similar results which are expressed as a mean of the
values obtained. To validate the experiments control data for cell
number and viability, and results for MGG staining and staining with the
AGF4.48 antibody were also assessed in parallel. Analyses of these
control data gave identical results to the previous PMA induction
experiments.
The percentage of glycophorin positive cells remained low in all cell
populations (<3%) indicating a low initial presence of these cells and no
increase in their numbers during culture.
The percentage of cells expressing CD15 on their surface, as detected
by the antibody, was higher in control cultures (31 %) than PMA treated
cultures (1%) and paralleled the results obtained following staining with
the AGF4.48 antibody, another antibody of the CD15 cluster (Figure
25). These data are consistent with previous observations that certain
CD15 monoclonal antibodies recognise cells of the granulocytic lineage
and therefore support the previous observations of the effect of PMA on
the differentiation of myeloid blast cells purified from fetal liver.
The CD11c antigen (pi 50,95) is a member of the CD11 family of cell
adhesion molecules which has a unique a-chain sub unit (CD11c). This
sub unit combines with a IS-chain sub unit (CD18) which is common to
other members of the CD11 family. CD11c has been shown to have
C3b receptor (CR4) activity (Myones et al, 1988) and although it is
weakly expressed in neutrophils and cells from cases of certain chronic
B-cell leukaemias, its expression is strongly linked to cells of the
monocytic lineage. CD11c is strongly expressed on monocytes and
monocyte derived macrophages (Uchiechowski and Schmidt, 1 989;
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Table 22. Effect of PMA treatment of undifferentiated myeloid blast
cells purified from human fetal liver on the expression of
leucocyte surface antigens.
% of population positive (±SEM)
Undifferentiated Blast cells Blast cells
Blasts ( - PMA)1 ( + PMA)1
Surface Antigen Time Oh 66h 66h
Erythroid
Glycophorin C 1 (0.4) 0 (0) 2.5 (2.5)
Mveloid
CD11c 7 (0.8) 11 (0.5) 67 (10.5)
CD15 8 (1.0) 31 ( 1) 7 (1)
CD14 3 (1.3) 19 (1.5) 18 (4)
Lvmphoid
CD3 (T cell) 1 (0.6) 3 (3) <1 (0.5)
CD5 (T cell, B cell
subset) 4 (1.5) 1 (1) 2 (1)
CD19 (B cell) 14 (7) 3 (0) 15 (0.5)
CD10 (B cell
progenitor) 18 (3.3) 8 (3.5) 4 (0)
2
Neaative control 2 (0.8) 5 (2) 2.5 (1.5)
1. results are mean values (±SEM) from 2 experiments
2. cells were stained using a monoclonal antibody to rotavirus.
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Myones et al, 1988). Expression of CD11c is increased on monocytes
treated with PMA (Mentizer et al, 1988) and is also increased on HL60
cells and U937 cells induced to differentiate along the monocytic
pathway by PMA (Dudley et al, 1989; Pedrinaci et al, 1989). Other
studies of acute myeloid leukaemia cells have shown a strong correlation
with CD11c expression and cells exhibiting evidence of monocytic
maturation (Master et al, 1989; Scott et al, 1990 and Tucker et al,
1990). In these experiments the percentage of cells expressing CD11c
showed a significant increase in PMA-treated cultures of blast cells from
7% to 67% whereas in control cultures there was little change (7% to
11 %) (Figure 4).
The CD 14 antigen is reported to be associated with monocytes. The
percentage of cells expressing CD 14, as detected by the antibody,
showed an equivalent moderate increase from 3% to 18% and to 19%
in control cultures. The percentages of mature T cells, which expressed
the CD3 and CD5 antigens were low in both control and PMA treated
cultures (<4%), indicating that mature T cells did not develop in these
culture conditions.
Cells which expressed the CD10 antigen, which is present on B cell
progenitors and mature granulocytes, decreased from 18% in the initial
blast cell population to 8% in control populations at 66h and to 4% in
PMA-treated cultures. Percentages of cells which expressed the CD 19
antigen fell from 14% to 3% in control cultures but showed no change
in PMA-treated cultures (15%). Therefore there was no evidence to
support the growth and differentiation of lymphoid progenitor cells
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Figure 25. Effect of PMA treatment on the expression of
CD 15 and CD 11 c antigens by purified blast cells. The
percentages of granulocytic cells ( • ), AGF.4.48
positive cells ( □ ), CD 15 positive cells ( A), monocytic
cells ( O ), ANAE positive cells ( ■ ), and CD 11 c
positive cells ( a ) were determined. The results are the
means of values from two experiments. SEM are shown
for CD 15 and CD 11 c values.
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CHAPTER 14.
CULTURE OF FETAL LIVER CELLS UNDER SERUM-FREE CONDITIONS
Studies, outlined in the previous chapters, on cells purified from human
fetal liver following erythroblast and macrophage depletions indicated
that the population of cells consisted mainly of undifferentiated myeloid
blast cells which were capable of either granulocytic or monocytic
differentiation. In this manner, the normal cell population resembled the
human cell line HL60, which is an undifferentiated myeloid cell line
capable of either granulocyte or monocyte differentiation. Previous
studies within the laboratory had delineated intracellular metabolic
events within HL60 cells which occur during either PMA-induced
monocyte differentiation or DMSO-induced granulocyte differentiation of
these cells. These studies included investigation of protein
phosphorylation and of inositol metabolism within HL60 cells (French et
al, 1 991). It was, therefore, of interest to determine whether the events
described in studies of HL60 cells occur within the normal population of
undifferentiated myeloid blast cells undergoing differentiation. To permit
studies of intracellular inositol metabolism in normal myeloid blast cells it
was necessary to maintain and grow the blast cells in culture so as to
allow incorporation of [^H]-inositol. It was also necessary to maintain
the cells in serum-free conditions so as to minimise the usage of
radiolabeled inositol. Furthermore, the studies of inositol metabolism
within HL60 cells were undertaken using cells grown under serum-free
conditions and in medium containing a low amount of inositol.
Therefore, the aim was to maintain the blast cells in the serum-free and
low inositol medium used in the HL60 studies. Once equilibrium
labelling of inositol metabolites had been achieved within blast cells, the
changes in metabolism which occur when the blast cells are induced to
differentiate by PMA could be investigated.
14.1 Culture of normal myeloid blast cells, purified following enzyme
digestion of liver tissue and erythroblast and macrophage
depletion in serum-free medium.
Preliminary experiments to determine the survival of undifferentiated









































































purified following enzyme digestion of liver tissue and erythroblast and
macrophage depletion. In order to have adequate numbers of blast cells,
with which to carry out studies of the survival of cells under serum-free
conditions, the blast cells were not further purified by counter current
elutriation. Figure 26 shows the survival of undifferentiated blast cells
when cultured under serum-free conditions in medium containing low
amounts of inositol with and without the addition of a high
concentration of IL-3 (100U/ml). The results are means of the values
obtained ( + SEM) from two experiments. Blast cells cultured in serum-
free medium in the absence of IL-3 died rapidly and surviving cells did
not proliferate after a further culture period. In contrast, blast cells
exhibited much better survival in serum-free medium containing IL-3.
Although all numbers fell off within the first two days in culture, after
this time period cells showed evidence of proliferation. In cultures
containing IL-3 on day +2 the number of cells in culture was 1.9 x
1C)5/ml, whereas, on day +5 and day +7 the average of the values
obtained for the number of cells in culture was 7.45 and 6.35 x 1C)5/ml
respectively. The mean of the values obtained for cell viability on day
+ 5 and day +7 was 90% and 85% respectively.
Equilibrium labelling of inositol metabolites with [^HJ-inositol requires
the cells to be grown for five days in culture and maintained in an
undifferentiated state. During the initial five day period of growth of
blast cells in the presence of IL-3, the cells did not differentiate to a
large extent (Figure 27). Cells classified as blasts or promyelocytes
remained high throughout the 5 days of culture. At time 0, these cells
accounted for 75% of cells and by day +5 they accounted for 85% of
cells. These cells were nearly all undifferentiated blast cells, until day
+ 5 when a significant number of cells containing azurophil granules
(31%) were observed which were classified as promyelocytes.
However, these cells had not shown marked evidence of granulocytic
differentiation as indicated by the extremely low percentage of cells
staining with the AGF4.48 antibody (2%). The extent of either
granulocyte or monocyte differentiation within the five day culture
period was limited as indicated by the following observations. The
percentage of cells classified as mature granulocytes at or beyond the




















































































population of cells, and by day +5 accounted for only 2% of cells. At
this point the percentage of AGF4.48 positive cells was 2%. The
percentage of cells classified as either promonocytes or monocytes
accounted for 9% of the starting population of cells and by day +5
accounted for 11 % cells. Cells positive for a-naphthyl acetate esterase
accounted for 8% of the starting population of cells and by day +5 this
value had increased to 22%. The percentage of cells with the
morphological appearance of lymphocytes was 5% of the starting
population of cells and by day +5 this value was <1%. By day +7 of
culture, however, further differentiation had occurred with significant
increases in the percentages of promonocytes/monocytes (46%) and
cells positive for a-naphthyl acetate esterase (50%).
These observations revealed that the presence of IL-3 was necessary for
the maintenance and growth of undifferentiated blast cells in culture.
The experiments to study inositol metabolism, presented in the following
chapter, were undertaken using elutriated blast cells so as to obtain a
more homogeneous blast cell population.
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1 4.2 Culture of normal myeloid blast cells purified after cell elutriation
in serum-free medium containing IL-3.
For the studies of inositol metabolism within blast cells they were
maintained in RPM1 1640 medium containing a low amount of inositol
(1 mg/l), serum-free additives and IL-3. It was necessary to determine
whether the elutriated blast cells could be maintained in an
undifferentiated state under these culture conditions. In 5 experiments
cells pooled from CCE fractions 13.3 and 17.8 mls/minute were cultured
for 5 days in serum-free medium containing 100 U/ml IL-3. The extent
to which the elutriated blast cells were maintained in an undifferentiated
form by culture in IL-3 is shown in Figures 28 and 29. The results at
time zero and day +5 are means ( + SEM) from 5 data points and the
intervening points are means ( + SEM) from 2 or 3 data points. Figure
28 shows that the elutriated cells were maintained in culture for 5 days
in serum-free medium containing a low amount of inositol and IL-3. Up
to day +2 of culture cell numbers fell from 4.9 x 10^/ml to 3.0 x
10^/ml. However, beyond day +2 there was a recovery in cell numbers
to a value of 4.6 x 10^/ml on day +5. Therefore, there was not
extensive growth of the elutriated blast cells in the presence of IL-3.
The mean of the values obtained for cell viability was 94% at time zero,
75% at day +2 and was 85% at day +5.
Figure 29 illustrates that the elutriated blast cells were maintained in an
undifferentiated state during the same study period. In these cultures
the percentage of the initial population classified as blast cells was 70%.
By day +5 this value was 68%. Cells containing azurophil granules
which were classified as promyelocytes accounted for < 1 % of cells up
to day +2 of culture and on day + 5 of culture accounted for 15% cells.
However, as in the previous study of non-elutriated cells, these cells had
not shown marked evidence of granulocyte differentiation as the
percentage of cells positive for the AGF4.48 antibody on day +5 was
low (3%). The percentage of cells positive for a-naphthyl acetate
esterase was 14% at time zero. By day +5 this value was 18%
indicating that monocyte differentiation had not occurred to any
significant degree during the 5 day culture period. The percentage of






























































































































time zero. By day +5, however, this value was 1%, indicating that
these cells were not maintained in the 5 day culture period. In a single
experiment the blast cells were cultured up to 7 days. At day +7 the
number of viable cells in culture was 5.44 x 10^/ml and 82% of cells
were viable. The percentage of blast cells was reduced at 47%. There
was evidence of monocyte differentiation as indicated by the percentage
of cells classified as promonocytes (17%) and positive for a-naphthyl
acetate esterase (30%). An increased percentage of cells contained
azurophil granules, most of which were classified as promyelocytes, but
the percentage of AGF4.48 positive cells remained low (2%). After
culturing the blast cells for 7 days, cells with the morphological
appearance of lymphocytes were not present. These data showed that
the elutriated blast cells could be maintained by culturing the cells in
serum- free conditions in medium containing a low amount of inositol (1
mg/L) and a high concentration of IL-3 (100 U/ml). This permitted
equilibrium labelling with labelled inositol to be undertaken so as to
identify the pattern of inositol metabolites within undifferentiated blast
cells. Furthermore, as presented in the next chapter, the changes in
inositol metabolism during monocyte induced differentiation of blast
cells, as induced by PMA, could then be studied.
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CHAPTER 15
THE PATTERN OF INOSITOL METABOLITES WITHIN NORMAL
MYELOID BLAST CELLS AND CHANGES DURING THEIR
DIFFERENTIATION TOWARDS MONOCYTES.
Inositol, which is a cyclic polyol synthesised from glucose, forms an
integral part of molecules which are key regulators of important events
within eukaryotic cells. These molecules include membrane bound
inositol lipids and intracellular inositol phosphates which are involved in
processes such as intracellular signalling pathways which regulate the
control of cell proliferation and differentiation (Michell et al, 1990). For
example, receptor activation of phosphatidyl inositol 4,5-bisphosphate
(Ptd Ins (4,5)P2> hydrolysis by membrane bound phosphoinositidase C
generates inositol 1,4,5-triphosphate and 1,2-diacylglycerol. Inositol
1,4,5-triphosphate (lns(1,4,5)P3> causes the release of calcium from
intracellular stores and its inositol phosphate metabolite inositol 1,3,4,5-
tetrakisphosphate (Ins (1,3,4,5)P4> controls the influx of calcium into
the cell from the external medium. The increase in intracellular calcium
concentration results in conformational changes in calcium binding
proteins, such as calmodulin, which activate cellular enzymes, especially
kinases. Subsequent phosphorylation events induce secondary changes,
such as cell proliferation, by mechanisms which are as yet poorly
understood. Membrane hydrolysis of Ptd Ins (4,5)P2 also releases 1,2-
diacylglycerol which activates protein kinase C, therefore inducing
further intracellular phosphorylation events. The phorbol ester, PMA
directly activates protein kinase C, and may therefore mimic key
regulatory events which are of physiological importance.
Other inositol phosphates include polyphosphorylated forms such as
inositol 3,4,5,6-tetrakisphosphate (lns(3,4,5,6)P4>, inositol 1,3,4,5,6-
pentakisphosphate (lns(1,3,4,5,6)P5> and inositol-hexakisphosphate (Ins
Pq) which are found in abundance within a number of cell types
including HL60 cells. These polyphosphates appear to be formed and
metabolised by largely unknown metabolic pathways which do not
involve lipids. (Shears, 1989). The studies on HL60 cells performed in
the laboratory (French et al, 1991) have delineated the pattern of
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inositol metabolites within HL60 cells and have documented changes in
these metabolites which occur in association with either DMSO-induced
neutrophil differentiation or PMA-induced monocyte differentiation of
these cells. It was therefore of interest to study the pattern of inositol
metabolites in normal myeloid blast cells and to determine whether
change in these metabolites occurred in association with PMA-induced
monocyte differentiation of these cells.
15.1 The pattern of inositol metabolites within normal myeloid blast
cells.
These studies of intracellular inositol metabolism in normal myeloid blast
cells were performed in collaboration with Dr P French (Department of
Biochemistry) and Dr C Bunce (Department of Immunology).
Undifferentiated myeloid blast cells purified following elutriation were
cultured in serum-free medium containing 100 U/ml IL-3, 1 mg/l inositol
and 2 pCi/ml [^HJ-inositol. After 5 days in culture to permit equilibrium
labelling of inositol metabolites with [^HJ-inositol, intracellular inositol
phosphates were extracted and quantified using high pressure liquid
chromatography (HPLC). The separation by HPLC of radiolabeled inositol
metabolites of normal human myeloid blast cells is shown in Figure 30a
and data obtained from identical studies performed on HL60 cells (kindly
provided by Dr French and Dr C Bunce) are presented for comparison
(Figure 30b). The traces show the ability of HPLC to clearly separate
various labelled inositol compounds and peaks relating to particular
inositol phosphates have been identified. The identification of individual
peaks within HL60 cells has been studied in detail by a combination of
methods involving 1) co-migration of known standard inositol
compounds and 2) degradation studies involving a) periodate oxidation,
reduction and dephosphorylation of separated fractions followed by
HPLC separation of the resulting polyols and b) ammonia hydrolysis of
separated fractions followed by HPLC separation of resulting
monophosphates. These techniques, however, were unable to
distinguish between enantiomeric forms of individual inositol
phosphates. The principles and details of these identification methods
are described in detail in French, 1990.
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Figure 30a. HPLC Separation of the inositol metabolites








0 30 60 90 120
Elution Time (minutes)








The identity of peaks separated within normal myeloid blast cells have
been assigned with respect to their co-elution with peaks containing
known inositol metabolites from HL60 cells. The first column represents
total unchanged myo-inositol and the next fraction represents a weakly
charged and as yet unidentified inositol derivative that may be
glycerophospho-inositol (GPI). Subsequent labelled peaks represent
inositol phosphates, phosphorylated at increasing numbers of sites on
the 6 carbon ring of myo-inositol. For example, the peak labelled Ins P
for HL 60 cells represents total inositol monophosphate compounds and
contains two large and one very small third peak identifying different
isomeric forms of inositol monophosphate. The first and largest peak,
identified following co-migration with the 14C-lns (3) P standard,
contained Ins (3)P or its enantiomer Ins (1)P. The second smaller peak
contained Ins (2)P and the third small peak contained 3 isomers which
could not be further separated under the conditions used - Ins (4)P or its
enantiomer pair Ins (6)P and Ins (5)P. These inositol monophosphate
peaks were similarly represented in normal myeloid blast cells.
The peak labelled Ins P2 for HL60 cells represents total inositol
biphosphate compounds and contained 3 peaks identifying different
isomeric forms of inositol biphosphate. The first small peak contains
inositol (1,3) biphosphate (Ins (1,3)P2)- The next peak and second most
abundant peak in the inositol biphosphate region contained inositol (1,4)
biphosphate (lns( 1,4) P2) or its enantiomeric form inositol (3,6)
biphosphate (Ins (3,6)P2). The third and most abundant peak in the
biphosphate region was unidentified. The peak, co-eluting with Ins
(1,4)P2/ was the dominant inositol biphosphate peak present in normal
myeloid blast cells.
The peak labelled Ins P3 represents total inositol triphosphate
compounds which are present only in small amounts in both HL60 cells
and normal myeloid blast cells. Within HL60 cells four separate peaks
within the inositol triphosphate region could be identified by HPLC
analysis. The first peak contained insufficient material to undertake
structural analysis studies and the constituents of the second and most
abundant peak could not be definitely identified. The third peak
contained inositol (1,2,3) triphosphate (Ins (1,2,3)P3) and the fourth
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peak contained inositol (1,4,5,) triphosphate (lns(1,4,5)P3> or inositol
(1,4,6) triphosphate (lns(1,4,6)P3> and/or their respective enantiomers
Ins (3,5,6)P3 or Ins (3,4,5)P3 with a small amount of inositol (3,4,5)
triphosphate (lns(3,4,5)P3> or its enantiomer inositol (1,5,6)
triphosphate (lns(1,5,6)P3>.
The fraction labelled Ins P4 for HL60 cells represents total inositol-
tetrakisphosphate compounds and separates as one large and one very
small peak containing different isomeric forms of inositol
tetrakisphosphate. The first and by far the most abundant peak of this
region contained inositol (1,3,4,5) tetrakisphosphate (lns(1,3,4,5,)P4>,
which accounted for 85% of the peak, and two other isomeric forms,
present in much smaller amounts, inositol (3,4,5,6) tetrakisphosphate
(lns(3,4,5,6)P4> and inositol(1,4,5,6) tetrakisphosphate (lns(1,4,5,6)P4>.
The minor adjacent peak contained inositol (1,2,5,6) tetrakisphosphate
(lns(1,2,5,6)P4> or its enantiomer inositol (2,3,4,5) tetrakisphosphate
(lns(2,3,4,5)P4) and either one or a mixture of the following isomers Ins
(1,2,4,5)P4, Ins (1,2,3,5)P4, Ins (1,2,4,6)P4 and Ins (2,4,5,6)P4. A
large Ins P4 peak was similarly present in normal myeloid blast cells, but
its contents were not further defined.
The peak labelled Ins P5 for HL60 cells represented a single isomer of
inositol pentakisphosphate, namely inositol (1,3,4,5,6)Pg. This was the
most abundant inositol phosphate present in normal myeloid blast cells
and was expressed in terms relative to other inositol phosphates at
higher levels in normal myeloid blast cells than in HL60 cells. In HL60
cells a small peak between Ins P5 and Ins Pg contained a small amount
of other Ins P5 isomers namely either inositol (1,2,4,5,6)Pg or Ins
(2,3,4,5,6)P5.
The peak labelled Ins Pg contained the single form of inositol
hexakisphosphate which is also known as phytic acid. This compound
was present in large amounts in both HL60 cells and in normal myeloid
blast cells.
From knowledge of the total number of undifferentiated myeloid blast
cells, calculations for mean cell volume, the specific activity of [^H]-
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inositol in the culture medium and the total radioactivity present in each
peak separated by HPLC, the total intracellular concentrations of inositol
metabolites have been calculated (Table 23). These data are means of
( + SEM) the values obtained from 10 experiments and represent total
intracellular concentrations. No allowance could be made for possible
compartmentalisation of inositol metabolites within the cell, under which
circumstances local concentrations of inositol metabolites would be
increased.
Table 23. Intracellular concentrations of inositol and inositol
metabolites in normal myeloid blast cells.
Inositol metabolite 1 Concentration (piM)
mean (±SEM) 2
Inositol 2610 (1200)
glycerophospho-inositol (GPI) 22.4 (2.1)
Ins P 16.2 (2.1)
Ins P2 9.4 (4.6)
Ins P3 0.8
Ins P4 4.2 (0.7)
Ins P5 37.2 (2.7)
Ins P6 30.5 (5.1)
1,2. Cells were cultured for six days in serum-free medium containing
100 U/ml IL-3 and [^Hl-inositol. Data are means ( + SEM) of values
obtained from ten experiments except for Ins P3 which represents one
determination only. Inositol phosphates are labelled Ins P to Ins Pg and
values represent total concentration of inositol polyphosphate isomers.
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Analysis of the total intracellular concentrations of the metabolites of
myo-inositol present in normal myeloid blast cells yielded a complex
picture. The free inositol concentration was 2600pM which was
significantly higher than the 5.55pM inositol concentration present in the
growth medium. These data suggest that inositol is accumulated by
active transport within these cells. There were significant levels of a
number of inositol metabolites within normal myeloid blast cells, namely
the putative glycerophospho-inositol(GPI) peak, the inositol
monophosphate peak (InsP), the inositol biphosphate peak (lnsP2), the
inositol tetrakisphosphate peak (lnsP4>, the inositol pentakisphosphate
peak (InsPg) and the inositol hexakisphosphate peak (InsPg). The
combined concentrations of Ins (1,3,4,5,6)Pg and InsPg accounted for
half of the aqueous soluble inositol within normal myeloid blast cells.
The concentrations of Ins (1,3,4,5,6)Pg and Ins Pg were 37.2 pM and
30.5 pM respectively. These higher inositol phosphates were also
present in high concentrations within HL60 cells. The peak containing
the Ins (1,4,5) P3 isomer could not be clearly identified in the case of
the normal blast cells. The relative amounts of inositol metabolites
contained within normal myeloid blast cells and within HL60 cells are
discussed later.
15.2. Changes in concentrations of inositol metabolites within normal
myeloid blast cells during their differentiation towards monocytes.
In view of the documented changes that occur in intracellular
concentrations of certain inositol polyphosphates during monocyte and
neutrophil induced differentiation of HL60 cells (French et al, 1991), a
comparative study was undertaken using normal myeloid blast cells.
Undifferentiated myeloid blast cells purified following elutriation were
cultured in serum-free medium containing 100 U/ml IL-3, 1 mg/l inositol
and 2 pCi/ml [^HJ-inositol. After 5 days in culture, during which time
equilibrium labelling with [^HJ-inositol had been achieved, cells were
treated with 10 nM PMA. After a further 24 hours cells were harvested
for analysis of total intracellular inositol metabolites. Control cells not
treated with PMA were harvested at the same time for comparative
study.
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The efficacy of the PMA-induced monocyte differentiation of these cells
was confirmed in each experiment by the microscopic examination of
cultures. All PMA-treated cultures contained a considerable proportion
of cells which had become pleomorphic, adherent and which were
clumped as had been previously observed in PMA-treated cultures
described in Chapter 13. Cells with these features, which are consistent
with cells having undergone macrophage differentiation, were much less
evident in control cultures. Furthermore, in three of the experiments
cytospin preparations of cells were made from control and PMA-treated
cultures and stained with May-Grunwald-Giemsa. Examination of these
cytospins confirmed that promonocytic cells were present in much
higher numbers after treatment with PMA for 24 hours than in control
cultures. In analysis of these 3 experiments the mean values obtained
for the percentage of cells showing evidence of promonocytic
differentiation in cultures after 24 hours exposure to PMA was 48%
whereas in control cultures the corresponding value was 21%.
Granulocytic differentiation was also inhibited in PMA treated cultures.
The mean of values obtained for the percentage of cells showing
evidence of granulocytic differentiation in cultures after 24 hours
exposure to PMA was 6% whereas the corresponding value for control
cultures was 30%. Therefore, these data confirm the efficacy of PMA
induction of monocyte differentiation of normal myeloid blast cells as
described in Chapter 13.
In order to conserve cells for the study of intracellular inositol
metabolites further characterisation studies of PMA induction
experiments were not undertaken. Following treatment of blast cells
with PMA there were changes in the concentrations of certain
intracellular inositol metabolites when compared with control cultures.
Figure 31 shows the HPLC traces obtained from a typical analysis of
cells from both control and PMA-treated cultures. Table 24 shows the
data obtained for total intracellular concentrations of inositol metabolites
within cells from control and PMA-treated cultures. The major visible
changes between the FIPLC traces obtained for cells from control and
PMA-treated cultures were the changes observed in the Ins P4, Ins P5
and putative GPI peaks. In the case of cells from PMA-treated cultures
the Ins P4 peak was barely visible and the level of the Ins P5 peak was
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Figure 31. HPLC Separation of the inositol metabolites
within normal human myeloid blast cells




reduced by approximately 50%. The peak provisionally labelled GPI (or
GroPlns) was larger in the traces obtained for cells from PMA-treated
cultures. The means of the values obtained after exposing cells for 24
hours to PMA for total intracellular concentrations of inositol metabolites
are listed in Table 24.
Table 24. Changes in the intracellular concentrations of inositol
metabolites during monocyte differentiation in normal







Inositol 2610 (1200) 2030 (761)
Glycerophospho-
inositol(GPI) ^ 22.4 (2.1) 73.2 (17)
Ins P 16.2 (2.1) 14.8 (1.4)
Ins P2 9.4 (4.6) 12.9 (1.2)
Ins P3 6 ND ND
Ins P4 ^ 4.2 (0.7) 1.1 (0.4)
Ins P5 ^ 37.2 (2.7) 20.7 (3.5)
Ins Pg 30.5 (5.1) 27.2 (3.5)
1. Inositol phosphates are labelled Ins P to Ins Pg and values represent total
concentrations of inositol phosphate isomers.
2. Cells treated with 10 nM PMA for 24 hours; number of experiments = 4.
3. P = 0.04, 2 sample paired T test.
4. P = 0.01, 2 sample paired T test.
5. P = 0.02, 2 sample paired T test.
6. ND = not determined.
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There was no significant difference between control and PMA-treated
cells in their total intracellular concentrations of unchanged myo-inositol.
The intracellular concentration of inositol remained at high levels. The
concentration of putative GPI was higher in cells from PMA-treated
cultures than in control cells (p = 0.04, 2 sample paired T test). The
concentrations of Ins P and Ins P2 were not significantly different
between cells from control and PMA-treated cultures. The Ins P3 peak
contained minimal numbers of disintegrations per minute in the case of
cells from both control and PMA-treated cultures and therefore the
concentration of Ins P3 could not be accurately quantified. As shown in
Figure 31, there were clear changes in the concentrations of Ins P4 and
Ins (1,3,4,5,6) P5 when blast cells were treated with PMA. At 24
hours, the concentration of Ins P4 in cells from PMA-treated cultures
was 1.1 pM as compared with a value of 4.2 pM obtained for control
cells (p = 0.01, 2 sample paired T test). The concentration of Ins
(1,3,4,5,6) P5 was reduced by 44% following PMA treatment of blast
cells (p = 0.02, 2 sample paired T test). The concentrations of Ins Pg
within PMA-treated and control cells were not significantly different.
Therefore, following treatment of undifferentiated myeloid blast cells
with PMA for 24 hours there were significant reductions in the
intracellular concentrations of Ins P4 and Ins (1,3,4,5,6) P5 and an
increase in the inositol metabolite provisionally identified as
glycerophospho-inositol. The significance of these findings and the
comparison of these data with that generated from the study of HL60
cells are discussed later.
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CHAPTER 16.
STUDIES ON A CASE OF PRIMARY MYELOFIBROSIS
An individual case of primary myelofibrosis was selected for further
study for two reasons; firstly, to determine the potential of such
patients as a source of haemopoietic precursor cells to develop model
systems which can be used to characterise biochemical and molecular
events associated with lineage commitment, proliferation and
differentiation in the human haemopoietic system; and secondly to
confirm clinical and morphological features in the patient suggesting an
intrinsic defect in erythropoiesis and by further karyotypic and molecular
study to determine the possible chromosomal location of genes which
encode key regulators of erythroid lineage development. The clinical,
haematological and morphological features of the case are described in
more detail in the material and methods section (p61).
16.1 Immunophenotypic analysis of peripheral blood mononuclear cells.
The patient with primary myelofibrosis was studied with respect to
cytogenetic analysis of peripheral blood cells and characterisation of
peripheral blood mononuclear cells separated following ficoll-hypaque
fractionation of whole peripheral blood. The initial studies included
assessment of the MGG differential, the expression of cell surface
antigens and the ability of cells to form colonies when plated in semi¬
solid media. When the initial studies were undertaken the patient's full
blood count was as follows: Hb = 11.4 g/dl (post transfusion), WBC =
7.9 x 10^/1 and platelet count = 169 x 10^/1. The differential white
cell count was lymphocytes 1.2 x 10^/1, monocytes 0.6 x 10^/1,
neutrophils 5.2 x 10^/1, basophils <0.1 x 10^/1, myelocytes 0.6 x
10^/1, metamyelocytes 0.2 x 10^/1 and blast cells 0.2 x lO^/l.
Nucleated red cells were not seen on this occasion in the peripheral
blood. Following ficoll-hypaque fractionation of 40 mis of peripheral
blood, 15% of the leucocytes were recovered. The MGG differential of
the mononuclear cell population was as follows: lymphocytes 48%,
granulocytic cells (cells from promyelocyte to neutrophil stages of
differentiation) 25%, monocytes 13%, blast cells 10%, normoblasts 0%
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and unidentified cells 4%. The results obtained following
immunophenotypic analysis of this population are shown in Table 25.
Table 25 Immunophenotypic analysis of peripheral blood
mononuclear cells isolated from a patient with primary
myelofibrosis.
1





Lymphoid CD3 (T cell) 35
CD19 (B cell) 1 1
CD10 (B cell progenitor,
mature granulocyte) 16
Other CD7 (T cell, T cell/
myeloid precursor) 53
HLA class II (progenitors,
B cells, macrophages) 38
1. Percentages of positive cells were determined by use of the
direct rosette technique.
The percentages of positive cells for the mature myeloid antigens
CD11 b, CD11 c, CD1 5 and CD14 were in the range of 1 5 - 25%. These
values were consistent with the percentages of granulocytic cells (25%)
and monocytic cells (13%) observed following staining of the same cell
population with MGG. The percentages of mature lymphocytes (43%)
as assessed by the combination of CD3 (T cell) positive (32%) and
CD1 9 (B cell) positive (11%) cells also showed good agreement with the
percentage of lymphocytes observed following staining with MGG
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(48%). The values for CD3 positive cells (32%) and CD5 positive cells
(35%) were in close agreement. Both antigens are markers of mature T
cells but CD5 does recognise, in addition a subset of B cells. The
percentage of CD10 positive cells was 16%. The discrimination
between CD 10 positive B cell progenitors and CD 10 positive mature
granulocytes was not further elucidated. Other antigens studied
included the CD7 and class II HLA antigens. These antigens are known
to be expressed on both mature and precursor haemopoietic cell
populations. For example HLA class II antigen expression is a feature of
B cells and macrophages and also of progenitor cells. CD7 antigen
expression is a feature of mature T cells and also T cell and myeloid
precursors. Both these antigens were expressed to a higher degree than
the percentages of the corresponding mature cell populations present,
indicating that a significant population of precursor cells was present in
the fractionated cell population. The finding of 10% blast cells in the
MGG differential supported this observation.
These data on the characterisation of the fractionated mononuclear cell
population by MGG differential and immunophenotypic analysis indicated
that the cell population consisted mainly of mature myeloid and
lymphoid cells and that the haemopoietic precursor population
constituted only a small minority of cells. Studies of the cytogenetic
abnormalities and colony forming ability of peripheral blood mononuclear
cells isolated from this patient were undertaken and are described
below.
16.2 Colony forming ability of peripheral blood mononuclear cells.
Fresh peripheral blood mononuclear cells isolated from the above patient
were assayed for their ability to form erythroid and granulocyte
macrophage colonies in semi-solid medium. The results are shown in
Table 26 and are expressed as CFU/ml of peripheral blood. Similar
results were demonstrated on 3 different occasions which revealed
greatly increased numbers of circulating CFU-GM with the complete
absence of erythroid colonies. The nature of GM colonies was
confirmed following staining of cytocentrifuge preparations of sample
single colony contents. Positive control erythroid colonies were grown
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in appropriate numbers from fractionated human fetal liver cells (Toksoz
and Brown, 1984) and from normal bone marrow cells, indicating that
the failure to detect erythroid progenitors was not due to technical
reasons.
Table 26 Number of colony forming cells grown from PMF peripheral
blood mononuclear cells and from normal cells.
PMF PBMNC FETAL LIVER BONE MARROW
CFU/ml of blood CFU/105 cells
Time CFLJ-GM BFU-E/CFU-F CFU-GM BFU-E CFU-GM BFU-E
Point
1 2,644 0 103 153 33 22
2 7,912 0 122 155 70 28
3 7,605 0 300 90 27 ND1
1. ND = not determined.
16.3 Cytogenetic studies
Cytogenetic analysis of peripheral blood cells from the patient with
myelofibrosis was undertaken to detect abnormalities present in
haemopoietic cells. Analysis of 20 metaphases from unstimulated
cultures of peripheral blood cells revealed 3 cell lines: 1 metaphase
showed a normal male karyotype: 13 cells showed 46 chromosomes
with the loss of one chromosome 2 and one 11, the presence of an
abnormal chromosome 2 derived from a 2; 11 translocation and an
additional unidentified marker chromosome (46, XY, -2, -11, + der(2) t
(2; 11) (q24/31 ;q1 3), + mar); and 6 cells showed the above karyotype
along with the loss of one chromosome 17 and a deletion of part of the
long arm of one chromosome 7 (45,XY,-2,-11, +der(2)t
(2;1 1 )(q24/31 ;q1 3), + mar,-1 7,del(7q)). This complex karyotypic
abnormality has not been reported previously in primary myelofibrosis.
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Pooled GM colonies grown from peripheral blood mononuclear cells were
also subjected to karyotypic analysis. Analysis of the progeny of pooled
colony forming cells showed the third karyotype described above in 8/10
metaphases. The other two metaphases described the same karyotype
with the addition of another unidentified marker chromosome, implying
some further clonal evolution (Plate 8).
The primary fibroblast cultures harvested from a skin biopsy from the
above patient were also subjected to karyotypic analysis. Analysis of all
these metaphases revealed a normal male karyotype. This evidence
supports the fact that the patient exhibited a normal constitutive
karyotype and had acquired an abnormal karyotype in haemopoietic
lineages in association with the development of primary myelofibrosis.
Epstein-Barr virus transformed B cell lines were also generated from this
patient (in collaboration with Dr C Gregory, Department of Immunology)
and then subjected to karyotypic analysis to determine whether any of
the cell lines isolated carried the same karyotypic abnormality as the
patient's other haemopoietic cells. Twenty lymphoblastoid cell lines
were derived and cloned from this patient. Cells from all the lines,
designated EBoy 1-20, exhibited a normal male karyotype. This last
observation suggested that either 1) the clonal disorder giving rise to
myelofibrosis did not involve B lineage precursors or 2) the more likely
possibility that the lymphoblastoid cell lines had been generated from
long lived B cells that had themselves been generated from normal B cell
progenitors.
The patient's peripheral blood cells were further studied at the terminal
stage of his disease. A more complex karyotype had evolved which was
45, XY, t( 1 p, 1 8p),-2,-11, + der(2)t(2;1 1 ),-4,del(7q),-1 6, +der(1 6)t(1 6;?),
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16.4 Initiation of haemopoiesis by PMF peripheral blood mononuclear
cells on irradiated stroma grown from long term bone marrow
cultures.
The finding of absent circulating erythroid progenitor cells in PMF is an
uncommon event, which in the patient described above may have been
due to an intrinsic defect in the capacity of haemopoietic stem cells to
undergo commitment to the erythroid lineage or the ability of committed
erythroid progenitors to undergo erythropoiesis. Previous studies have
shown that in PMF patients, CFU-GM can be maintained in liquid
suspension culture of peripheral blood mononuclear cells in the absence
of a substantial stromal layer over a 10 week period, indicating that
primitive stem cells may circulate in PMF patients (Douay et al, 1987).
In the following experiment fresh peripheral blood mononuclear cells
harvested from the patient with PMF were co-cultured with irradiated,
allogeneic normal bone marrow stroma (Plate 9) to maintain circulating
primitive stem cells and to assess whether they were able to give rise to
erythroid progenitors in a normal and appropriate microenvironment.
Cultures were established which contained 1) irradiated normal bone
marrow stroma alone; 2) peripheral blood mononuclear cells from the
patient with PMF alone and 3) Co-cultures which contained peripheral
blood mononuclear cells from the patient with primary myelofibrosis and
irradiated allogeneic normal bone marrow stroma. After 5 weeks in
culture the cells were harvested and assayed for CFU-GM and BFU-E
numbers. These results are shown in Table 27.
Table 27. Mean number (+ SEM) of CFU isolated after culture of PMF
PBMNC on irradiated bone marrow stroma.
Culture condition CFU-GM BFU-E/CFU-E
per 105 cells per total culture
stroma alone 0 0 0
PMF cells alone 14(1.1), 1 1(1.7) 156(12), 101(16) 0
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No GM or erythroid colonies were grown from the culture containing
irradiated allogeneic normal bone marrow stroma alone. In cultures
containing PMF peripheral blood mononuclear cells only GM colonies
were isolated. However, co-cultures containing both irradiated stroma
and PMF peripheral blood mononuclear cells yielded much greater
numbers of GM colonies than cultures containing PMF PBMNC alone
whether numbers were expressed in terms of total CFU per culture or
per 1C)5 inoculating cells. When the patient's cells were co-cultured
with normal allogeneic bone marrow stroma, the average values ( + SEM)
for the numbers of GM-CFC generated per culture in two experiments
were 405 (31) and 348 (11) respectively. However, when the PMF
PBMNC were cultured alone the corresponding values for the numbers of
GM-CFC per culture were 156 (12) and 101 (16) respectively. No
erythroid colonies were grown from these cultures. MGG stained
cytocentrifuge preparations of cells taken from cultures at the time of
clonogenic assay did not show any cells of the erythroid lineage. The
finding of increased numbers of CFU-GM following incubation of PBMNC
with marrow stroma as compared with control PBMNC cultured in the
absence of stroma supported the existence of circulating stem cells in
PMF and the inability to generate erythroid progenitor cells in this culture
system further supported an intrinsic defect of erythropoiesis in this
case.
1 6.5 Determination of the involvement of pSEA locus in the t(2:1 1)
translocation noted in this patient.
The proto-oncogene pSEA, which is the human homologoeof the viral
oncogene SEA of the S13 avian erythroblastosis virus, maps to the
region of 11 q 1 3 which was involved in the chromosomal translocation
noted in PBMNC isolated from this patient with PMF. As this case was
associated with defective erythropoiesis it was of interest to study the
potential involvement of the proto-oncogene in the t(2:11) translocation
observed in this patient. This was performed by comparing Southern
blots of DNA which had been prepared from sources of both normal
(skin fibroblast) and abnormal (PBMNC) DNA and which had been
qo
hybridised with a P labelled cDNA probe to pSEA. Three different
restriction endonucleases were employed to digest the DNA. The
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autoradiographs of the hybridised Southern blots are shown in Plate 10.
The pattern of bands visualised was identical using DNA derived from
either peripheral blood mononuclear cells or skin fibroblasts. This
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Plate 10. Southern blot analysis of DNA obtained from
peripheral blood mononuclear cells (PBMNC) and skin
fibrolasts (FIB) isolated from the patient with primary
myelofibrosis. The DNA was digested with BamH1, EcoR1
and Sst1 restriction endonucleases and the filters were
hybridised with a 4.5kb cDNA probe to pSEA.
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SECTIOM 4. DISCUSSION
CHAPTER 17. STUDIES USING BLAST CELLS PURIFIED FROM
HUMAN FETAL LIVER
The principal objective of this thesis was to purify normal human
myeloid cells at a very early stage of differentiation in sufficient numbers
for the subsequent study of intracellular biochemical events related to
myeloid differentiation. Such a model system would permit comparative
studies with abnormal cells or cell lines to be undertaken which might
delineate events pertinent to malignant transformation. Human fetal
liver, which is known to be a rich source of haematopoietic progenitor
cells (Champlin and Gale 1980; Toksoz and Brown 1984; Emerson et al
1985), was used as the source of haemopoietic cells and a population
of undifferentiated myeloid blast cells, with a similar differentiation
status to HL60 cells, was purified. Treatment of the blast cells with
PMA was shown to promote rapid monocyte differentiation and to
inhibit spontaneous granulocyte differentiation which was present in
control cultures of these cells. Studies of intracellular inositol
metabolites within undifferentiated normal myeloid blast cells and
changes during PMA-induced monocyte differentiation of these cells
were then performed and the results were compared with those
obtained from previous studies performed using HL60 cells. The
observations suggest a possible, but as yet unidentified, role for inositol
polyphosphates in myeloid differentiation. The ability to purify
homogeneous populations of undifferentiated normal haemopoietic cells
for biochemical and molecular studies of differentiation is a significant
achievement.
It was very important in this study to aim to purify undifferentiated
haemopoietic cells from fetal liver using negative selection techniques.
Negative selection methods for enriching cell populations have the
advantage that the required cell population is not directly stimulated by
binding of antibodies to their surface and are therefore unperturbed.
This approach was preferred over positive selection methods since the
cells were required for in vitro biochemical studies. The positive
selection of cells by antibody labelling may interfere with cells'
physiological properties by effecting intracellular biochemical changes
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occurring as a result of antibody binding or alternatively, antibody bound
to the cell surface has the potential to interfere stoichally with the
binding of normal external factors. Furthermore, the positive selection
of cells by rosetting with CrCI3-coupled erythrocytes and the negative
selection of cells using antibody combined with complement mediated
lysis have not been recommended because of non-specific damage to
the desired population of haemopoietic precursor cells (Emerson et al,
1985).
In this study cells were initially purified following density separation and
unwanted cells were removed after coating these cells with a mixture of
two monoclonal antibodies which identify glycophorin C and a monocyte
associated antigen respectively. The subsequent separation of cells by
counterflow cell elutriation (CCE) allowed further purification of primitive
cells without direct interference with the desired cell population. Thus,
the blast cells obtained were not subjected to either antibody coating or
possible damage by CrCI3-coupled erythrocytes. Furthermore, since the
fetal liver cells were first purified as light density cells using ficoll-
hypaque and then by subsequent negative selection using ficoll-
hypaque, the initial fractionation procedure depended only on the
criterion of antigen expression. As an alternative, negative selection by
panning out the unwanted cell populations has been recommended for
the isolation of haemopoietic progenitor cells from human fetal liver
(Emerson et al, 1985). However in these circumstances, when antibody
coated cells adhere to plastic surfaces coated with anti-immunoglobulin,
both antigen expression and non-specific adherence are factors involved
and the process may selectively remove some adherent myeloid blast
cells of interest. A minimal combination of two antibodies was used to
coat unwanted cell populations to avoid the possibility that the
combined effects of a large cocktail of monoclonal antibodies, each
binding to haemopoietic cell surface antigens expressed at uncertain
and/or low levels on undifferentiated myeloid blast cells, may generate
indirect rosettes and eliminate some cells of interest.
Previous studies describing the growth and differentiation in liquid
suspension culture of mononuclear cells isolated from human fetal liver
(Toksoz and Brown, 1984) had shown that these cultures generated
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large numbers of mature neutrophils and macrophages and sustained
GM-CFC for 4 weeks indicating that the initial cell population contained
cells at early stages of myeloid differentiation. In this study the cell
population obtained from fetal liver following mechanical disruption of
tissue, density gradient fractionation and rosette depletion of unwanted
cells (Chapter 11.1, p95) was composed mainly of undifferentiated
myeloid blast cells and a few containing lymphocytes and more mature
myeloid cells (table 12, p103). The purified blast cells lacked features
of differentiation such that they could not be identified as either
precursors of neutrophils or monocytes (Plate 1b, p 104). When
cultured in medium containing fetal calf serum these cells differentiated
towards either neutrophils or macrophages. However, as reported
previously for the light density fetal liver cells (Toksoz and Brown,
1984), the terminal differentiation of the population as a whole occurred
over a protracted time course. Both the slow changes in the
differentiation status of the population and the fact that both
granulocytes and monocytes are generated, presented difficulties in
using these cells to analyse biochemical events pertinent to either
neutrophil or macrophage differentiation.
The phorbol ester, PMA is known to induce the rapid terminal
differentiation of various cell types, including keratinocytes (Parkinson
and Emerson, 1982) and rapid differentiation of the human promyeloid
cell line, HL60 towards monocytes (Rovera et al, 1979). When PMA
was added to cultures of undifferentiated blast cells purified from human
fetal liver (fig. 22, p136), 62% of the cells differentiated towards
macrophages within 42 hours as revealed by increased numbers of cells
with an appropriate morphological appearance and by cells which
expressed the enzyme a-naphthyl acetate esterase. Thus the addition of
PMA provided a reduced time course for the differentiation of a
population of the blast cells towards macrophages. An unexpected
finding was that PMA inhibited granulopoiesis within the cultures,
possibly by affecting the 31-51% of blast cells which underwent
neutrophil differentiation in the control cultures. This inhibition of
granulopoiesis in the PMA-treated cultures was revealed by the lack of
increased numbers of cells at or beyond the promyelocyte stage of
differentiation (AGF4.48 positive) and by the lack of cells expressing
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lactoferrin (fig. 23, p 141.). The studies of other cytochemical markers
(fig 24, p144) and the expression of other leucocyte surface antigens
(table 22, p 146) confirmed the finding that PMA promoted the rapid
monocyte differentiation of the undifferentiated myeloid blast cells
purified from human fetal liver whilst concomitantly inhibiting
granulocyte differentiation. The practical benefit from the rapid
promotion of monopoiesis and simultaneous inhibition of granulopoiesis
is that a population of normal cells is provided which is undergoing
macrophage differentiation only. This is advantageous to studies of
biochemical events during monopoiesis since, as suggested above, a
mixture of blast cells undergoing macrophage differentiation and
neutrophil differentiation would display events pertinent to both
pathways of maturation but which could not be studied in isolation. An
alternative solution to this problem would be to separate the two blast
cell populations. However the means to achieve this are not presently
available.
The capacity of PMA to promote monopoiesis and inhibit granulopoiesis
has important implications in relation to intracellular processes which
regulate these two pathways of differentiation. The purified blast cell
population is most likely to be a mixture of cells which are already
committed to either neutrophil or macrophage differentiation, since a
maximum number of 65% of the cells were induced to mature towards
monocytes by PMA and in control cultures 34% of the cells were able
to spontaneously differentiate towards neutrophils. The 34% of cells
able to differentiate towards neutrophils correlates well with the
percentage of blast cells which did not differentiate in PMA-treated
cultures (32%). Thus, PMA would not appear to interfere with
granulopoiesis by diverting cells towards the monocyte pathway of
maturation. This conclusion leads to the view that the opposing effects
of PMA on granulopoiesis and monopoiesis are related to a reciprocal
interaction between intracellular processes which regulate the capacities
for the two pathways of maturation. In other words, intracellular events
effected by PMA which facilitate monopoiesis concomitantly lead to a
reduced capacity for granulopoiesis. For example, PMA is known to
activate protein kinase C (PKC) which may phosphorylate proteins and
confer functional activity which is essential for monocyte differentiation.
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As irreversible commitment of progenitor cells to a particular pathway of
differentiation is involved, these proteins would presumably include
DNA-binding proteins, the PMA-responsive elements identified as
modulators of gene activity in several cell types (Lee et al, 1987). The
reciprocal enhancement and silencing of genes required for monocyte
and neutrophil differentiation respectively in this system, could thus be
achieved through activation of the PKC pathway and the ultimate
modulation of specific DNA-binding proteins.
The above general consideration as to the effect of PMA also accords
with previous proposals that expressions of the potentials for both
neutrophil and monocyte differentiation are closely linked. Brown et al,
1985 have interpreted data from various studies to suggest that the
above two differentiation potentials are expressed in a progressive and
linear manner, in that as cells lose the capacity for neutrophil
differentiation they then acquire the potential for monocyte
differentiation. If this hypothesis is correct, then only one or two
choices are available to developing haemopoietic progenitor cells at any
given time and lineage potentials can be viewed as sequential partially
overlapping differentiation options (p 11; Brown et al, 1989). The
notion that PMA promotes monopoiesis and inhibits granulopoiesis by
virtue of a reciprocal interaction between intracellular events, which
regulate commitment to these two pathways of differentiation, provides
a mechanism whereby regulation of differentiation potentials can be
achieved. Further support for such a model, that lineage potentials are
sequentially expressed, can be proposed as follows. At the molecular
level, the modulation of gene expression required for all diversification
may be effected via a relatively small group of transcriptional regulators,
governed by the major intracellular signalling pathways, including protein
kinase C. Specificity is introduced at the level of modulation of the
activity of these gene regulators and the accessibility of these gene loci.
The minimal activation of one signalling pathway, leading to the
enhancement and silencing of particular genes, would necessitate the
availability of only two differentiation options as regards the expression
of lineage potentials. In contrast, a multipotent model of haemopoiesis
in which cells can differentiate directly along any one of at least five
maturation pathways (Heyworth et al, 1988), is likely to require the
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involvement of several intracellular signalling pathways, which modulate
a panel of DNA-binding proteins, so as to select one differentiation
option and close down the others.
In parallel to the studies of the effects of PMA on the differentiation of
purified blast cells, the purified blast cells were further characterised
with respect to their cytochemistry, the expression of cell surface
antigens and their ability to form colonies when plated in semi-solid
medium. (Ch. 12.1, p120). The pattern of cytochemical staining
observed did confirm that this was a population of cells showing limited
evidence of myeloid differentiation. However previous staining with
MGG did show that the cells exhibited variable morphological features
(p104) and indicated that they were not an entirely homogeneous
population. Analysis of their colony forming ability indicated that only a
small minority of cells (0.5%) were able to give rise to colonies under
the culture conditions used in the assay. Immunophenotypic analysis of
the purified undifferentiated blast cells did confirm that the cells were
haemopoietic in nature as 99% of the cells reacted with the antibody to
common leucocyte antigen. The percentage of cells expressing
glycophorin C, an erythroid antigen, was low (1%) illustrating the
efficiency of the erythroblast depletion procedure. The percentages of
cells positive for the mature myeloid antigens CD11c, CD15 and CD14
were all low (<8%) and these values were consistent with the findings
observed following cytochemical and MGG staining. The number of
mature T cells present, as identified by CD3 staining, was also low
(1%) but a significant percentage of cells were positive for the CD10
(18%) and CD 19 (14%) antigens indicating that B cell progenitors were
present within the purified population. Very much larger percentages of
cells were positive for HLA Class II (59%), CD7 (46%) and CD34 (32%)
antigens indicating that the population consisted largely of
undifferentiated haemopoietic cells.
However, to enhance the yield of undifferentiated blast cells obtained
from each fetal liver the purification procedure was modified to
incorporate initial enzyme digestion of fetal liver tissue, susbsequent
ficoll-hypaque separation of light density cells, which was performed
twice, and finally rosette depletion of fetal liver cells using the Ret40F
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and 61 D3 monoclonal antibodies (Ch 11.3, p 111). The enzyme digest
procedure did result in significantly increased cell yields from each fetal
liver but the new procedure also highlighted qualitative differences
between the mononuclear cell populations obtained when using the two
purification methods. In addition to an increase in cell yields, the
percentages of normoblasts and macrophages were considerably higher
in interface populations obtained following enzyme digestion of fetal
tissue. For example, following enzyme digestion and the second ficoll-
hypaque fractionation the percentage of normoblasts in the interface
population was 55% whereas this value was 27% in the interface
population obtained following mechanical disruption of fetal tissue;
following enzyme digestion and the second ficoll-hypaque fractionation
the percentage of monocytes and macrophages in the interface
population was 11.3%, whereas this figure was only 2.2% in the
interface population obtained following mechanical disruption of fetal
tissue. The modified method therefore, enhanced total cell yields but
also enriched for the proportion of fragile normoblasts and adherent
macrophages possibly because they were not removed in a cotton wool
filtration step.
This qualitative difference in the purified populations obtained using the
two different methods was also apparent following the rosette depletion
step. For the same reasons as outlined above, the final purified
population obtained after enzyme digestion and rosette depletion using
Ret40F and 61 D3 contained a much higher proportion of promonocytes
(13.9%) than the final population obtained following mechanical
disruption of tissue (4.6%). The percentage of mature macrophages
was low in both purified populations indicating the efficiency of the
rosette depletion procedure in removing mature macrophages but this
figure was again slightly higher in the enzyme digest population (0.5%)
than in the mechanical disruption population (0.1%). Mainly as a result
of the increased proportion of promonocytes, the enzyme digested final
purified population contained fewer undifferentiated blast cells (59.2%)
than the population obtained following mechanical disruption of tissue
(76.5%). Flowever despite the lower percentage value for
undifferentiated blast cells, the enzyme digestion method produced a far
greater yield of cells from each fetal liver (7.3 x 10® cells v 3.6 x 10®
186
cells) than that obtained following mechanical disruption of tissue.
Therefore the modified procedure gave approximately twice the number
of blast cells than obtained previously using mechanical disruption.
In an attempt to obtain a more homogeneous blast cell population from
the enzyme digested liver material the 61D3 and Ret40F depleted
mononuclear cells were further purified by counterflow cell elutriation
(CCE). This procedure separates cells according to their size and
buoyant density and has been successfully used to separate murine
CFU-S from PHSC (Jones et al, 1990; Material and Methods p72).
Following this procedure it was discovered that the collection and
pooling of two CCE fractions obtained at flow rates of 13.3 and 17.8
ml/minute with a rotor speed of 1950 rpm gave the optimal combination
of cell yield and separation of undifferentiated blast cells from other cell
types including promonocytes and lymphoid progenitor cells. These
fractions also contained the highest percentages and the greatest
absolute numbers of cells positive for the CD34 antigen. These cells
were also more homogeneous in nature with respect to their MGG
staining characteristics (Plates 3 c-d, p1 17) than the blast cells observed
prior to the elutriation step (Plate 2d, p110). Approximately 20% of the
cells placed in the elutriation chamber were recovered in these two
fractions. In five experiments a mean of 1.75 x 10® cells was
recovered from each fetal liver representing a yield of 0.07% of the cells
obtained following enzyme digestion of liver tissue.
The studies previously outlined indicated that the population of cells
purified from human fetal liver consisted mainly of undifferentiated
myeloid blast cells which were capable of maturing to become either
granulocytes or monocytes. In this manner the cell population provides
a new normal cell model system which is parallel to the human cell line
HL60. HL60 is an undifferentiated myeloid cell line which is also
capable of either granulocyte or monocyte differentiation. Previous
studies had delineated changes in intracellular metabolites of inositol in
association with PMA-induced monocyte differentiation of HL60 cells
(French et al, 1991) and it was of interest to determine whether the
same changes occurred during PMA-induced monocyte differentiation of
undifferentiated normal myeloid blast cells. To perform these
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experiments in comparable conditions to the HL60 cell experiments it
was necessary to maintain the myeloid blast cells in an undifferentiated
state in serum-free medium containing low amounts of inositol for a long
enough period to permit equilibrium labelling of the inositol metabolites
within the cells. Once the equilibrium labelling of inositol metabolites
had been achieved, the changes in metabolism which occur when the
blast cells differentiate in response to PMA could then be investigated.
When placed in serum-free medium, as used in the earlier HL60 cell
studies, the blast cells died rapidly. However, when IL-3 was
incorporated into the culture medium (100 U/ml), the cells survived,
increased in number and maintained an undifferentiated phenotype. The
survival of these undifferentiated blast cells in high concentrations of IL-
3 is consistent with the known factor dependence of early myeloid
precursor cells and is analogous to the maintenance of the
undifferentiated status of murine IL-3 dependent cell lines (Heyworth et
al, 1990).
The labelling of blast cells in medium with a known specific activity of
[^HJ-inositol and measurement of the mean cell volume permitted the
determination of the concentrations of inositol metabolites within the
cells. The levels of several inositol phosphates within undifferentiated
normal myeloid blast cells were similar to those observed within the
promyeloid cell line HL60 (French et al, 1991). The concentrations of
Ins P, Ins P2, Ins P4 and Ins P5 observed in undifferentiated normal
myeloid blast cells and HL60 cells, respectively, were as follows: Ins P,
1 6pM versus 24pM; Ins P2, 9.4pM versus 14pM; Ins P4 4.2pM versus
4.4pM and Ins P5 37pM versus 27|aM. Other compounds displayed
marked differences in concentration between the two cell populations.
HL60 cells contained more Ins Pg than the fetal liver blast cells (63pM
versus 31pM) and less glycerophospho-inositol (GPI) (11pM versus
22pM). A particularly striking difference between the two cell
populations was the concentration of free intracellular inositol. Within
the undifferentiated normal myeloid blast cells the concentration of
inositol was 261OpM which is much higher than the 39pM observed
within HL60 cells. This difference may in part be explained by the fact
that the normal blast cells were obtained from fetal tissue which has a
high extracellular concentration of inositol in the surrounding fluids
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(125pM, Lewin et al, 1978; Quirk and Bleasdale, 1983). In contrast,
the HL60 cells had been maintained long term in medium containing
much lower amounts of inositol (5pM). However the higher level for
intracellular inositol within the cells as opposed to the external medium
suggests that inositol is actively transported within both cell types.
Differences in inositol pools may indeed reflect a different rate of inositol
transport in each cell type. Also, the similar values for the higher
inositol phosphates found in cells with different sized pools of free
intracellular inositol suggests that cells actively control their levels of
highly phosphorylated derivatives even when the level of intracellular
inositol is restricted. This further supports the hypothesis that these
compounds have an important role within cells.
The changes previously described in inositol phosphates during PMA-
induced monocyte differentiation of HL60 cells included rapid and
sequential declines in Ins P4 and Ins P5 and a slower fall in Ins Pg
(French et al, 1991). In HL60 cells treated for 24 hours with PMA there
was a 75% decrease in the level of Ins P4 and an 80% decrease in the
level of Ins P5. Similar changes in these two compounds were observed
at 24 hours when the fetal blast cells had differentiated towards
monocytes in response to PMA: Ins P4 had declined by 75% and Ins P5
by 50%. The slow decline in the level of Ins Pg within HL60 cells was
noted at 48 hours and was not significant at 24 hours. The fetal blast
cells had been harvested 24 hours after the addition of PMA and
therefore may not have reached the point when a change in the level of
Ins Pg might have been observed.
The significance of the decreases in the levels of both Ins P4 and Ins P5
which occurred in association with monocyte differentiation of both
normal myeloid blast cells and HL60 cells remains to be determined. It
is possible that these changes may be a key feature of cells undergoing
monocyte maturation or alternatively they may represent epiphenomena
related to the effects of treatment of cells with PMA. It would therefore
be of particular interest to determine whether similar changes occur in
normal myeloid blast cells as they undergo differentiation in response to
physiological stimuli. This might be achieved by permitting cells to
spontaneously differentiate in serum containing culture medium or by
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the addition of M-CSF to the culture medium. However, as the blast
cells are a mixed population of cells committed to neutrophil and
monocyte differentiation, it is probable that such cultures would contain
a mixture of mature granulocytes and mature monocytes. Therefore to
perform the analysis of intracellular inositol phosphates one would have
to separate the two populations of cells. It is not possible, at present,
to separate the blast population into those committed to either
granulocyte or monocyte differentiation but it may prove possible to
separate more mature populations. For example, cells undergoing
granulocyte differentiation begin to express the CD15 antigen on their
cell surface at the promyeloid stage of maturation and cells expressing
CD 15 could be rosette depleted using sheep red cells or magnetic beads
bound to an antibody directed against the CD15 antigen. This should
leave behind a population of cells which are negative for the CD 15
antigen and which should therefore be enriched with cells which have
undergone monocyte maturation. This population of normal cells which
have undergone physiological monocyte differentiation could therefore
be used for analysis of intracellular inositol phosphates.
A complementary approach would be to study the effects of PMA on
the intracellular inositol metabolites within variant HL60 cells which
arrest their growth in response to PMA but which do not undergo
monocyte differentiation (Bunce, 1987). If the same changes in Ins P4
and Ins P5 occur in these circumstances they must be related either to
growth arrest or epiphenomena related to treatment of cells with PMA.
The reason for the changes in these inositol metabolites observed during
PMA-induced monocyte differentiation remains unresolved. If these
events are related to PMA, it is possible that the fall in Ins P4 seen in
both cell types is related to protein kinase C activation of the 5-
phosphatase which degrades Ins (1,3,4,5) P4, the likely major
component of the Ins P4 peak (Bansal and Majerus, 1990). However
this 5-phosphatase also degrades Ins (1,4,5) P3 and in the HL60 studies
no depletion of Ins (1,4,5) P3 was observed in response to PMA which
therefore argues against this possible explanation for the depletion of Ins
P4.
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The remaining major change which occurred as the normal myeloid blast
cells underwent differentiation towards monocytes was a large increase
in the putative glycerophospho-inositol (GPI) peak (from 22^M to
73pM). This was not observed as HL60 cells differentiated towards
monocytes and the reason for this discrepancy between the two
promyeloid cell populations during the differentiation towards
monocytes is not clear. Glycerophospho-inositol is formed following the
serial deacylation of phosphatdyl-inositol by the enzymes phospholipase
A2 (PLA2) and a subsequent lysophospholipase. These steps result in
the removal of the two fatty acid side chains of the glycerol backbone of
phosphatidyl-inositol. An important difference between the cell
populations might therefore lie in the control of membrane bound
phospholipase A2.
As these data have highlighted both similarities and differences between
normal undifferentiated myeloid blast cells and HL60 cells it would also
be of interest to study similar phenomena in cells from patients with
acute myeloblastic leukaemia (AML). Such comparative studies by
showing similarities in HL60 and AML cells but not in normal myeloid
blast cells might indicate phenomena which directly relate to the cells'
transformed status.
In this study recombinant human IL-3 was used to maintain the purified
blast cells in serum-free medium. However, more recently other
multipotent factors have become available and it is likely that the use of
such factors will increase the potential for using such cells as model
systems for the study of haemopoiesis. For example, it has been shown
that the use of both IL-3 and SCF results in the extensive proliferation of
undifferentiated myeloid blast cells purified from fetal liver and that a
subsequent change in the culture medium to a high concentration of G-
CSF and to low concentrations of IL-3 results in the cultures generating
granulocytes alone (C Bunce, Personal Communication). Such a
physiological model system for the study of human granulopoiesis is a
significant advance and it is likely that further manipulations of the
purified cells will generate additional knowledge of considerable value.
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In addition to their use in model systems to study events in
haemopoiesis fetal liver cells have been investigated as a source of
pluripotent haemopoietic stem cells for experimental and clinical
allogeneic transplantation. The stimulus for this research has been a
search for sources of PHSCs with a decreased capacity to induce graft-
versus-host-disease (GVHD). The fetal liver is the prominent site of
haemopoiesis in mid-gestation and contains large numbers of PHSCs
but, unlike adult bone marrow or neonatal cord blood, the fetal liver
contains few if any immunocompetent lymphocytes and is therefore
associated with a decreased risk of inducing GVHD (Chaplin and Gale,
1980). However, fetal liver transplants in this regard may resemble
adult bone marrow transplants depleted of T cells which are associated
with an increased risk of graft failure and leukaemia relapse.
Early studies in rodents indicated that fetal liver transplantation using
histocompatible donors readily results in the successful haemopoietic
engraftment and immune reconstitution of irradiated recipients without
the induction of GVHD (Uphoff, 1958). Further studies, including those
in other mammal model systems, suggested that successful fetal liver
transplantation could also be achieved across major histocompatibility
barriers but that this required larger numbers of donor cells and more
intensive pre-transplant conditioning of the host. It was also noted that
older fetal livers provided more cells and were associated with a higher
rate of engraftment but also with more GVHD (Rogo et al, 1987).
However, studies using dogs have indicated that both host conditioning
and matching for major histocompatibility antigens are crucial factors
required for the prevention of rejection of fetal liver grafts (Champlin et
al, 1 985; Primmer et al, 1 985).
These experimental findings are consistent with the results which have
been observed with the empirical use of fetal liver grafts in man. Most
such transplants have been unsuccessful due to graft failure resulting
from a combination of factors including the use of mismatched grafts,
inadequate numbers of transplanted cells and inadequate pre-transplant
conditioning regimes (Gale, 1987). However successful transplantation
using mismatched fetal liver cells has been achieved in recipients with
192
severe combined immunodeficiency (SCID) where graft rejection is not a
major problem and where pre-transplant immunosuppression is not
required (Gale et al, 1987).
Fetal liver transplantation may have a future in the areas of
immunodeficiency, aplastic anaemia and inherited and metabolic
disorders if the problems of graft rejection can be overcome. A role for
the treatment of leukaemias would appear unlikely as the beneficial
effect associated with allogeneic bone marrow transplantation (the
graft-versus-leukaemia effect) typically occurs in the context of GVHD,
and is therefore less likely to develop to a significant degree following
fetal liver transplantation. The data also suggest that full matching for
major histocompatibility antigens may be required and that recipients
will require adequate pre-transplant immunosuppressive conditioning
regimens. However, the recent improvements in cryopreservation
techniques and methods for histocompatibility testing permit such
procedures to be undertaken and furthermore, the recent availability of
cytokines which expand early haemopoietic precursor cells in vitro, such
as stem cell factor (Brandt, et al, 1990; Srour et al, 1991; Brandt et al,
1 992; Srour et al, 1 993; Brugger et al, 1 993; Muench et al, 1 993), may
enhance the engraftment capability of such donor cells. Such
transplants indeed may ultimately prove superior to current attempts
using bone marrow donations, depleted of T cells, from unrelated
individuals matched for the major histocompatibility loci.
A recent imaginative use of fetal liver cells has been their transplantation
in utero. Fetal tolerance, which leads to permanent chimerism, occurs
naturally in non-identical animal and human twins which share a
placental circulation. This observation suggests that the fetus is both
an ideal donor and recipient of PHSCs as no graft rejection or GVHD
occurs under these conditions. Such a strategy, which would not
require matching for histocompatibility antigens, could be used for the
treatment of major genetic disorders, such as haemoglobinopathies,
which could be diagnosed and treated antenatally. Such experimental in
utero transplants of fetal liver haemopoietic stem cells have already
been carried out successfully in rhesus monkeys (Harrison et al, 1989)
and three such recent transplants performed in humans have also been
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partially successful (Touraine, 1992). Furthermore, the recent
demonstration of successful transplantation of human PHSCs in utero
into sheep fetuses (Srour et al, 1 992) has provided more evidence of the
potential of this therapy and the further development of human in utero
transplantation is eagerly awaited.
Neonatal umbilical cord blood has also been proposed as an alternative
source of PHSCs for allogeneic transplantation and indeed such cells
have been used to successfully transplant HLA-identical siblings with
Fanconi's anaemia (Broxmeyer et al, 1989; Gluckman et al, 1989).
However these individual cases have been highly unusual, in being HLA-
identical sibling transplants and the technique suffers from other
disadvantages which are likely to limit its broader application. For
example, in addition to the limited numbers of cells available for
infusion, such grafts are likely to be associated with a greatly increased
risk of GVHD due to the presence of mature T cells of both donor and
maternal origin (Linch and Brent, 1989; Nathan, 1989). However, this
form of transplantation is also the subject of ongoing investigation.
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CHAPTER 18. STUDIES ON A CASE OF PRIMARY MYELOFIBROSIS
This study also included investigation of an individual case of primary
myelofibrosis. The patient's peripheral blood mononuclear cells
(PBMNC) were initially examined for their expression of surface antigens
and to enumerate colony forming cells present in order to assess
whether such cells might be profitably used as a source of haemopoietic
precursor cells for experiments on haemopoiesis. The surface antigens
expressed by these cells (p 169) indicated that, although primitive cells
were present, they represented only a small minority of the total
population which contained large percentages of mature cell types e.g.
granulocytes, monocytes, T cells and B cells. Therefore to obtain these
low frequency cells by negative selection would require a more complex
antibody cocktail than that successfully used in the studies on human
fetal liver. However, the purification of haemopoietic precursor cells
from PBMNC of patients with primary myelofibrosis is worthy of further
consideration in the longer term.
Analysis of the colony forming ability of P&MNC from the above patient
consistently showed greatly increased numbers of CFU-GM which is
commonly observed in primary myelofibrosis but a complete absence of
circulating erythroid progenitors which are only rarely observed in these
patients. For example studies of circulating erythroid progenitors in
myelofibrosis patients have showed normal or increased levels in 18/18
cases studied by Carlo-Stella et al, 1987, 17/18 cases studied by
Partenen et al, 1982 and 2/2 cases studied by Douer et al, 1983.
However, other cases of PMF have been reported in which erythroid
progenitor cells were absent. In the study of Hibbin and co-workers
erythroid progenitors were absent in four splenectomised patients
(Hibbin et al, 1984) and Croizat et al, 1983 observed an absence of
erythroid progenitors in four patients two of which had been
splenectomised. The absence of circulating erythroid progenitors in PMF
patients is not invariably linked to splenectomy since the patient
reported in this study and the one identified by Partenen and co-workers
with absent BFU-E (Partenen et al, 1982) were not splenectomised.
Furthermore, the two larger studies of 18 patients showed normal or
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increased levels of circulating BFU-E in many splenectomised patients
(Partenen et al, 1982; Carlo-Stella et al, 1987).
The absence of circulating erythroid progenitors in this case suggested a
basic defect in erythropoiesis which was supported by other clinical,
morphological and experimental features. The morphological features of
the trephine biopsy indicated that the patient belonged to an uncommon
but distinct subgroup of patients with PMF and red cell aplasia (Barosi et
al, 1983) and the subsequent clinical course of blast transformation was
entirely consistent with that previously reported for patients with this
particular condition (Bentley et al, 1977; Barosi et al, 1983). Previous
observations have suggested that circulating committed progenitors in
PMF arise largely from the spleen (Douay et al, 1987; Craig et al, 1991)
and, therefore, an alternative explanation for the failure to detect
circulating erythroid progenitors in this case may be due to the fact that
they were generated and sequestered in the spleen.
In this case an intrinsic defect in erythropoiesis due either to a defect in
the capacity of haemopoietic stem cells to undergo commitment to the
erythroid lineage or the ability of committed erythroid progenitors to
undergo erythropoiesis, is more likely for the following reasons. Douay
and co-workers have shown that in PMF patients, CFU-GM can be
maintained in liquid suspension culture in the absence of a substantial
stromal layer over a 10 week period and concluded that primitive stem
cells circulated in PMF patients (Douay et al, 1987). In our study,
PBMNC were cultured with normal marrow stroma to maintain
circulating primitive stem cells and to assess whether they were able to
give rise to erythroid progenitors in an appropriate microenvironment.
Erythroid progenitor cells, were not generated in these experiments but
the presence of circulating stem cells in the patient's blood was
demonstrated by the generation of increased numbers of CFU-GM
following incubation with marrow stroma as compared with control
PMF PBMNC cultured in the absence of stroma. The failure to detect
circulating erythroid progenitors for technical reasons could be excluded
since the assays were controlled by the demonstration of erythroid
progenitors in appropriate numbers of both normal fetal liver and bone
marrow cells.
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Of those PMF patients previously studied with absent circulating
erythroid progenitors, cytogenetic data is available for only one other
case which exhibited a complex karyotype - 47, XX, 5q-,1 1 q-,-20,
+ mar 1, + mar 2 (Partenen et al, 1982). In the case reported in this
thesis, a previously unreported complex karyotype was recorded (p 171)
involving a translocation between chromosome 2 and chromosome 1 1
to (2; 1 1 )(q24/31 ;q1 3). However, a common abnormality involving the
long arm of chromosome 11 was present in both the previous case and
the one studied. This may suggest a causal relationship between an
abnormality on the long arm of chromosome 1 1 and defective
erythropoiesis. The breakpoint observed in the case studied here was
11 q 13 [t(2; 11)(q24/31 ;q 1 3)] and an abnormality at 11 q 1 3 has been
reported once previously in PMF but whether erythropoiesis was
defective in this case is unknown (Sessarego et al, 1983). A review of
the literature with regard to oncogene associations at the relevant
breakpoints in the case described in this thesis revealed that proto-
oncogene SEA (S13 avian erythroblastosis oncogene homology maps to
the 1 1 q 13 region (Williams et al, 1987; Nordenskjold et al, 1989;
Hayman et al, 1985). As this, therefore, may have highlighted a key
gene in the regulation of erythropoiesis, which may have been altered in
this patient, it was of interest to explore its involvement at the
molecular level. However, subsequent DNA analysis using a probe for
pSEA (p 176) indicated that this locus had not been disrupted by the
(2; 11) translocation. Other candidate genes for involvement in this
patient's disease include - a virus integration site, int 2 which, is also
located in the region of the 11 q 13 breakpoint and the gene for
glycophorin C and a homeobox gene are both located in the region of
the breakpoint on chromosome 2.
Cytogenetic analysis of additional patients with an absence of
circulating erythroid progenitors is worthy of further study. This
approach may reveal a common chromosome abnormality and point to
the location of genes which encode key intrinsic regulators of erythroid
lineage development. Furthermore, studies of the lesions in the
generation of other various committed progenitor cells in PMF patients in
relation to possible karyotypic abnormalities offers a useful approach to
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the analysis of the chromosomal location and organisation of genes
which control the generation and differentiation of haemopoietic
progenitor cells.
Of additional interest in this case was the documentation of karyotypic
abnormalities in pooled GM colonies isolated from the patient, the
attempt to demonstrate the cytogenetic abnormalities in EBV-
transformed lymphocytes and the co-culture experiments of PMF
PBMNC with irradiated allogeneic marrow stroma. Cytogenetic
abnormalities have been reported previously in pluripotent haemopoietic
progenitor cells isolated from patients with PMF (Ruutu et al, 1983;
Sato et al, 1986; Sugiyama et al, 1989). Along with the finding of G-6-
PD isoenzyme restriction in patients' peripheral blood cells but not in
fibroblasts, this strongly supports the hypothesis that the primary defect
in PMF is a clonal expansion of pluripotent haemopoietic progenitor cells
associated with reactive marrow fibrosis (Jacobson et al, 1978).
The observation that increased numbers of CFU-GM were generated
following incubation of PMF PBMNC with normal marrow stroma as
compared with control PMF PBMNC cultured in the absence of stroma
supports the concept that pluripotent haemopoietic stem cells may
circulate in PMF patients. This concept was originally suggested by
Douay et al in 1987, who observed that CFU-GM obtained from PMF
PBMNC can be maintained in liquid suspension culture in the absence of
a substantial stromal layer over a 10 week period. To test this
hypothesis further Epstein-Barr virus transformed B cell lines were
generated from the patient with PMF and then subjected to karyotypic
analysis to determine whether any cells of the B lineage carried the
same karyotype abnormality as the patients myeloid progenitor cells.
Twenty lymphoblastoid cell lines were derived and cloned from B cells
from this patient but cells from all the lines exhibited a normal male
karyotype. This observation suggests that either 1) the clonal disorder
giving rise to myelofibrosis did not involve B lineage precursors in this
patient or 2) the lymphoblastoid cell lines had been generated from long
lived B cells that had themselves been generated from normal B cell
progenitors. However this approach, which has not been used before, is
worthy of further study in other patients with PMF.
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In conclusion the central problem in understanding haemopoiesis is now
the endeavour to describe the events within developing blood cells
which regulate the complex and integrated processes of their
proliferation, lineage commitment and maturation. As outlined in this
study many of the microenvironmental factors which regulate these
processes have been identified. In particular many haemopoietic growth
and/or differentiation factors have been molecularly cloned and are now
available as research tools and, increasingly, as potential therapeutic
agents. Furthermore, in parallel to our improved knowledge of the
cytokines and microenvironmental factors which regulate haemopoiesis,
it is becoming possible to recognise, characterise and purify
haemopoietic progenitor cells in both mouse and man.
Taken together, these advances make it possible to execute key in vitro
culture experiments designed to shed light on intracellular events related
to haemopoiesis. The studies outlined in this thesis highlight this
concept and show how studies of both normal primitive myeloid cells
and those from patients with diseases such as PMF can be used to seek
out and study the genes and metabolic pathways which are involved in
the regulation of lineage commitment, proliferation and differentiation
with haemopoietic cells. As yet it is not possible to undertake detailed
studies on pluripotent haemopoietic stem cells, but as I hope this thesis
has illustrated, the field is making rapid progress towards this goal.
199
APPENDIX A BIBLIOGRAPHY
Abramson S, Miller R G, Phillips R A (1977). The identification in
adult bone marrow of pluripotent and restricted stem cells of the
myeloid and lymphoid systems. J.Exp.Med. 145: 1567-1579.
Ash R C, Detrick R A, Zanjani E D (1981). Studies of human
pluripotential hemopoietic stem cells (CFU-GEMM) in vitro. Blood
58: 309-316.
Alitalo R (1990). Induced differentiation of K562 leukaemia cells:
a model for studies of gene expression in early megakaryoblasts.
Leukaemia Research 14: 501-514.
Andrews R G, Singer J W, Bernstein I D (1989). Precursors of
colony-forming cells in humans can be distinguished from colony-
forming cells by expression of the CD33 and CD34 antigens and
light scatter properties. J. Exp. Med. 169: 1721-1731.
Andrews R G, Knitter G H, Bartelmez S H, Langley K E, Farrar D,
Hendren R W, Appelbaum F R, Bernstein I D, Zsebo K M (1991).
Recombinant human stem cell factor, a c-kit ligand, stimulates
hematopoiesis in primates. Blood 78: 1975-1980.
Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K,
Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku F,
Akiyama Y (1990). In vivo effects of recombinant human
interleukin 6 in primates: stimulated production of platelets. Blood
75: 1602-1605.
Axelrad A A (1990). Mini Review. Some hemopoietic negative
regulators. Exp.Hematol. 18: 143-150.
Bagby G C Jr (1989). Interleukin 1 and hematopoiesis. Blood
Reviews 3: 152-161.
Bajorin D F, Cheung N-K, Houghton A N (1991). Macrophage
colony-stimulating factor: Biological effects and potential
applications for cancer therapy. Semin.Hematol. 28, No.2
Suppl.2: 42-48.
Bansal V S, Majerus P W (1990). Phosphatidylinositol-derived
precursors and signals. Ann.Rev.Cell Biol. 6: 41-67.
200
Barosi G, Baroldi A, Cazzola M, Spriano P, Magrini U (1983). Red
cell aplasia in myelofibrosis with myeloid metaplasia. A distinct
functional and clinical entity. Cancer 52: 1290-1296.
Bentley S A, Murray K H, Lewis S M, Roberts P D (1977).
Erythroid hypoplasia in myelofibrosis: a feature associated with
blastic transformation. Br.J.Haematol. 36: 41-47.
Berenson R J, Andrews R G, Bensinger W I, Kalamasz D, Knilter G,
Buckner C D, Bernstein I D (1988). Antigen CD34 + marrow cells
engraft lethally irradiated baboons. J.Clin.Invest. 81: 951-955.
Berger R (1992). The cytogenetics of haematological
malignancies. In The molecular genetics of haematological
malignancy , Ed Young B D, Clinical Haematology, 5: no 4:
Bailliere Tindall, London, pp791-814.
Bernard A, Boumsell L, Dausset J (1984). Joint report of the first
international workshop on human leucocyte antigens by the
investigators of the participating laboratories: T2 protocol. In
Leucocyte Typing, Human leucocyte differentiation antigens
detected by monoclonal antibodies. Eds. Bernard A, Boumsell L,
Dausset J, Milstein C, Schlossman SF. Springer-Verlag, New York,
pp25-60.
Bernstein A, Forrester L, Reith A D, Dubreiul P, Rottapel R (1991).
The murine W/c-kit and Steel loci and the control of
hematopoiesis. Semin.Hematol.28: 138-142.
Bernstein I D, Andrews R G, Zsebo K M (1991). Recombinant
human stem cell factor enchances the formation of colonies by
CD34+ and CD34+ lin" cells, and the generation of colony-
forming cell progeny from CD34+ lin" cells cultured with
interleukin-3, granulocyte colony-stimulating factor, or granulocyte-
macrophage colony-stimulating factor. Blood 77: 2316-2321.
Berridge M J and Irvine R F (1989). Inositol phosphates and cell
signalling. Nature 341: 1 97-205.
Biondi A, Rambaldi A, Alcalay M, Pandolfi P P, Lo Coco F, Diverio
D, Rossi V, Mencarelli A, Longo L, Zangrilli D, Masera G, Barbui T,
Mandelli F, Grignani F, Pelicci P G (1991). RAR-a gene
rearrangements as a genetic marker for diagnosis and monitoring in
acute promyelocytic leukaemia. Blood 77: 1418-1422.
201
Borrow J, Solomon E (1992). Molecular analysis of the t (1 5; 1 7)
translocation in acute promyelocytic leukaemia. In The molecular
genetics of haematological malignancy , Ed Young B D, Clinical
Haematology, 5: no 4: Bailliere Tindall, London, pp791-814.
Boyum A (1968). Separation of leucocytes from blood and bone
marrow. Scand. J. Clin. Lab. Invest. 21 (supplement 97): 21-77.
Bradford M M (1976). A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal. Biochem. 72: 248-254.
Bradley T R and Metcalf D (1966). The growth of mouse bone
marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci. 44: 287-300.
Brandt J, Baird N, Lu L, Srour E, Hoffmann R (1988).
Characterization of a human hematopoietic progenitor cell capable
of forming blast cell containing colonies in vitro. J. Clin. Invest.
82: 1017-1027.
Brandt J, Srour EF, van Besian K, Briddell RA, Hoffman R (1990).
Cytokine-dependent long-term culture of highly enriched precursors
of hematopoietic progenitor cells from human bone marrow. J.
Clin. Invest. 86: 932 - 941.
Brandt J, Briddell R A, Srour E F, Leemhuis T B, Hoffman R
(1992). Role of c-kit ligand in the expansion of human
hematopoietic progenitor cells. Blood 79: 634-641.
Brenner M K (1988). Tumour necrosis factor. Br.J.Haematol.. 69:
149-152.
Brown G, Kourilsky F M, Fisher A G, Bastin J, MacLennan I C M
(1981). Strategy for screening for monoclonal antibodies against
cellular antigens expressed on minor cell populations or in low
amounts. Human Lymphocyte Differentiation 1: 167-182.
Brown G, Bunce C M, Guy G R (1985). Sequential determination
of lineage potentials during haemopoiesis. Br.J.Cancer 52: 681-
686.
Brown G, Bunce C M.( Lord J M and McConnell F M (1989). The
development of cell lineages: A sequential model. Differentiation
39: 83-89.
202
Brown G, Bunce C M, Lord J M (1990). Open Forum. Models of
haemopoiesis. Leuk.Res. 14: 495-499.
Broxmeyer H E, Douglas G W, Hangoc G et al (1989). Human
umbilical cord blood as a potential source of transplantable
hematopoietic stem/progenitor cells. Proc.Natl.Acad.Sci.USA 86:
3828-3832.
Broxmeyer H E, Williams D E, Lu L, Cooper S, Anderson S L, Beyer
G S, Hoffman R, Rubin R Y (1986). The suppressive influences of
human tumour necrosis factors on bone marrow hematopoietic
progenitor cells from normal donors and patients with leukaemia:
synergism of tumour necrosis factor and interferon-gamma.
J.Immunol.1 36: 4487-4495.
Brugger W, Mocklin W, Heimfeld S, Berenson J, Mertelsmann R,
Kanz L (1993). Ex vivo expansion of enriched peripheral blood
CD34 + progenitor cells by stem cell factor, interleukin-1 (3 (IL-1P),
IL-6, IL-3, interferon-y, and erythropoietin. Blood 81: 2579-2584.
Bruno E, Briddell R A, Cooper R J, Hoffman R (1991). Effects of
recombinant interleukin 11 on human megakaryocyte progenitor
cells. Exp. Hematol. 19: 378-381.
Bunce C M (1987). The use of variant HL60 cell lines in studies
of myelopoiesis. Ph. D. Thesis, University of Birmingham.
Cannistra S A and Griffin J D (1988). Regulation of the production
and function of granulocytes and monocytes. Semin.Hematol. 25:
173-188.
Carlo-Stella C, Cazzola M, Gasner A and 6 others (1987). Effects
of recombinant alpha and gamma interferons on the in vitro growth
of circulating haematopoietic progenitor cells (CFU-GEMM, CFU-
Mk, BFU-E and CFU-GM) from patients with myelofibrosis and
myeloid metaplasia. Blood 70: 1014-1019.
Carnot P, Deflandre C (1906). Sur I'activite hemopoietique des
differents organes au cours de la regeneration de sang. Comptes
Rendus de Seances de L'Academie des Sciences, Paris 143: 432-
435.
Cashman J D, Eaves A C, Raines E W, Ross R, Eaves C J (1990).
Mechanisms that regulate the cell cycle status of very primitive
hematopoietic cells in long-term human marrow cultures. 1.
203
Stimulatory role of a variety of mesenchymal cell activators and
inhibiting role of TGFG. Blood 75: 96-101.
Catlett J, Leftwich J, Westin E, Grant S, Hoff T F (1990).
Expression of c-kit by CD34 + bone marrow progenitors and
response to rh IL-3 following exposure to anti-sense
oligonucleotides to c-kit. Blood 76 (Suppl.1): 86 (abstract).
Chan L C, Furley A J, Ford A M, Yardumian D A, Greaves M F
(1986). Clonal rearrangement and expression of the T cell
receptor gene and involvement of the breakpoint cluster region in
blast crisis of chronic granulocytic leukaemia. Blood 67: 533-536.
Chaplin R E, Cain G, Stitzel K A, Gale R P (1985). Fetal liver cell
transplantation in dogs: Results with DLA-compatible and
incompatible grafts. In Fetal Liver Transplantation. Eds. Gale R P,
Touraine J-L, Lucarelli G. Alan R Liss, Inc.New York 1985: pp195-
204.
Chaplin R E and Gale R P (1980). Hematopoiesis and immune
reactivity of human fetal liver cells. In Fetal Liver Transplantation.
Eds. Lucarelli G, Fliedner T M, Gale R P. Elsevier, Amsterdam,
1980, pp117-125.
Civin C I, Strauss L C, Brovall C, Fackler M J, Shwartz J F, Shaper
J H (1984). Antigenic analysis of hematopoiesis III. A
hematopoietic progenitor cell surface antigen defined by a
monoclonal antibody raised against KG1a cells. J.Immunol. 133:
157-165.
Civin C I, Banguenigo M L, Strauss L S, Loken M R (1987).
Antigenic analysis of hematopoiesis VI. Flow cytometric
characterization of My10-positive progenitor cells in normal human
bone marrow. Exp.Haematol. 15: 10-17.
Civin C I et al, (1989). Report on the CD34 cluster workshop. In
Leucocyte Typing IV, White cell differentiation antigens. Eds.
Knapp W et al. Oxford University Press, pp 818-825.
Clark B R, Gallagher J T, Dexter TM (1992). Cell adhesion in the
stromal regulation of haemopoiesis. In Growth factors in
haemopoiesis, Eds. Lord B I, Dexter TM, Clinical Haematology 5;
no 3, BailliereTindall, London, pp 619-652.
Clark S C and Kamen R (1987). The human hematopoietic colony-
stimulating factors. Science 236: 1229-1237.
204
Clarke B J and Housman D (1977). Characterisation of an
erythroid precursor cell of high proliferative capacity in normal
human peripheral blood. Proc.Natl.Acad.Sci.USA. 74: 1105-1109.
Cohen P (1982). The role of protein phosphorylation in neural and
hormonal control of cellular activity. Nature 296: 613-620.
Collins S J, Gallo R C, Gallagher R E (1977). Continuous growth
and differentiation of human myeloid leukaemia cells in suspension
culture. Nature 270: 347-349.
Command Paper CM 762 HMSO (1989). Review of the guidance
on the research use of fetuses and fetal material.
Coulombel L, Eaves A C, Eaves C J (1983). Enzymatic treatment
of long-term human marrow cultures reveals the preferential
location of primitive hemopoietic progenitors in the adherent layer.
Blood 62: 291-297.
Craig J I 0, Anthony R S, Parker A C (1991). Circulating
progenitor cells in myelofibrosis: the effect of recombinant a2b
interferon in vivo and in vitro. Br. J. Haematol. 78: 155-160.
Croizat H, Amato D, McLeod D L, Eskinazi D, Axelrad A A (1983).
Differences among myeloproliferative disorders in the behaviour of
their restricted progenitor cells in culture. Blood 62: 578-584.
Curry J L and Trentin JJ (1967). Hemopoietic spleen colony
studies 1. growth and differentiation. Development Biology 15:
395-413.
Dacie J V, Lewis SM (1984). Blood-cell cytochemistry and
supplementary techniques. In Practical Haematology, sixth edition,
Eds Dacie J V, Lewis S M, Churchill Livingstone, Edinburgh, pp 84-
116.
D'Andrea A D and Jones S J (1991). Activation of the
erythropoietin receptor in stable lymphoid and myeloid
transfectants. Semin.Hematol. 28: 152-157.
Davis I, Morstyn G (1992). Clinical uses of growth factors. In
Growth factors in haemopoiesis, Eds Lord B I, Dexter TM, Clinical
Haematology 5; no 3, BailliereTindall, London, pp 753-786.
Dexter T M and White H (1990). Growth without inflation.
Nature 344: 380-381.
205
Dexter T M, Allen T D, Lajtha L G (1977). Conditions controlling
the proliferation of haemopoietic stem cells in vitro. J. Cell.
Physiol. 91: 335-344.
Dexter T M (1982). Stromal cell associated haemopoiesis. J. Cell
Physiol. 96: Suppl.1: 87-94.
di Giovine F S and Duff G W (1980). Interleukin 1: the first
interleukin. Immunology Today 11: 13-20.
Dick J E, Magli M C, Huszar D, Phillips R A, Bernstein A (1985).
Introduction of a selectable gene into primitive stem cells capable
of long-term reconstitution of the hemopoietic system of W/Wv
mice. Cell 42: 71-79.
Donahue R E, Emerson S G, Wang E A, Wong G G, Clark S C,
Nathan D G (1985). Demonstration of burst-promoting activity of
recombinant human GM-CSF on circulating erythroid progenitors
using an assay involving the delayed addition of erythropoietin.
Blood 66: 1479-1481.
Donahue R E, Yang Y-C, Clark S C (1990). Human P40 T-cell
growth factor (interleukin-9) supports erythroid colony formation.
Blood 75: 2271-2275.
Dorshkind K (1990). Regulation of hemopoiesis by bone marrow
stromal cells and their products. Ann.Rev.Immunol. 8: 111-137.
Douay L, Laporte J P, Lefrancois G and 5 others (1987). Blood
and spleen haematopoiesis in patients with myelofibrosis. Leuk.
Res. 1 1: 725-730.
Douer D, Fabian I, Cline M J (1983). Circulating pluripotent
haemopoietic cells in patients with myeloproliferative disorders.
Br.J.Haematol. 54: 373-381.
Dudley D, Baker D M, Hickey M J, Hickstein D D (1989).
Expression of surface antigen and mRNA for the CD11c (alpha
X,p150) subunit of the human leucocyte adherence receptor family
in hematopoietic cells. Biochem.Biophys.Res.Commun. 160: 346-
353.
Emerson S G, Sieff C A, Wang E A, Wong G G, Clark S C, Nathan
D G (1985). Purification of fetal hematopoietic progenitors and
demonstration of recombinant multipotential colony-stimulating
activity. J.Clin.Invest. 76: 1286-1290.
206
Erber W N, Pinching A J, Mason D Y (1984).
Immunocytochemical detection of T and B cell populations in
routine blood smears. Lancet 1: 1042-1043.
Erslev A J (1991). Erythropoietin. New Eng.J.Med. 324: 1339-
1344.
Fauser A A and Messner H A (1979). Identification of
megakaryocytes, macrophages and eosinophils in colonies of
human bone marrow containing neutrophilic granulocytes and
erythroblasts. Blood 53:1023-1027.
Feinberg A P, Vogelstein B (1983). A technique for radiolabelling
DNA restriction endonuclease fragments to high specific activity.
Anal. Biochem. 132: 6-13.
Ferguson M A J and Williams A F (1988). Cell-surface anchoring
of proteins via glycosyl-phosphatidylinositol structures.
Ann.Rev.Biochem. 57: 285-320.
Fialkow P J (1980). Clonal and stem cell origin of blood cell
neoplasms. In Contemporary Haematology and Oncology, J Lobve,
A S Gordon, R Silken, F M Muggia, Eds. (New York: Plenum Press)
pp 1-46.
Fisher A G, Kumaratne D S, Khan M, Ismail S, Harper A-M, Brown
G (1983). Antigen shared by human haemopoietic precursor cells
and T and B lineage cells. Hybridoma 2: 413.
Fisher A G, Bunce C M, Tokosz D, Stone P C W, Brown G (1982).
Studies of human myeloid antigens using monoclonal antibodies
and variant line from the promyeloid cell line HL60.
Clin.Exp.Immunol. 50: 374-381.
Ford C E, Hamerton J L, Barnes D W and Loutil J F (1956).
Cytological identification of radiation-chimaeras. Nature; 177:
452-454.
French P J (1990). Inositol metabolism in the human promyelocytic
cell line, HL60. Ph.D. Thesis, University of Birmingham.
French P J, Bunce C M, Lord J M, McConnell F M, Brown G, Creba
J A, Michell R H (1991). Changes in the levels of inositol lipids
and phosphates during the differentiation of HL60 promyelocytic
cells towards neutrophils and monocytes. Proc.Roy.Soc.Biol.Sci.
245: 193-201.
207
Gale R P, Touraine J-L, Kochupillai V (1987). Synopsis and
perspectives on fetal liver transplantation. Thymus 10: 1-4.
Gale R P (1 987). Fetal liver transplantation in aplastic anaemia and
leukaemia. Thymus 10: 89-94.
Gallagher R, Collins S, Trugillo J, McCredie M, Ahearn M, Tsai S,
Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R (1979).
Characterization of the continuous differentiating myeloid cell line
(HL60) from a patient with acute promyelocytic leukaemia. Blood
54: 713-733.
Gatter K C, Cordell J L, Turley H, Fleryet A, Kieffer N, Anstee D J,
Mason D Y (1988). The immunohistological detection of platelets,
megakaryocytes and thrombin in routinely processed specimens.
Histopathology 13: 257-267.
Gartner S and Kaplan PI (1980). Long-term culture of human bone
marrow cells. Proc.Natl.Acad.Sci.USA. 77: 4756-4759.
Gluckman E, Broxmeyer H E, Averbach A D et al (1989).
Hematopoietic reconstitution in a patient with Fanconi's anaemia
by means of umbilical-cord blood from an F(LA-identical sibling.
N.Eng.J.Med. II: 1174-1 178.
Gordon M Y, Hibbin J A, Kearney L V, Gordon-Smith E C, Goldman
J M (1985a). Colony formation by primitive haemopoietic
progenitors in co-cultures of bone marrow cells and stromal cells.
Br.J.Haematol 60: 129-136.
Gordon M Y, Goldman J M, Gordon-Smith E C (1985b). 4-
hydroperoxycyclophosphamide inhibits proliferation by human
granulocyte-macrophage colony-forming cells (GM-CFC) but spares
more primitive progenitor cells. Leuk.Res. 9: 1017-1021.
Gordon M Y, Dowding C R, Riley G P, Greaves M F (1987a).
Characterisation of stroma-dependent blast colony-forming cells in
human marrow. J.Cell.Physiol. 130: 150-156.
Gordon M Y, Riley G P, Watt S M, Greaves M F (1987b).
Compartmentalization of a haematopoietic growth factor (GM-CSF)
by glycosaminoglycans in the bone marrow microenvironment.
Nature 326: 403-405.
Gordon M Y (1988). Extracellular matrix of the bone marrow
microenvironment. Br.J.Haematol. 70: 1-4.
208
Gough N M, Gearing D P, King J A, Wilson T A, Hilton D J, Nicola
N A, Metcalf D (1988). Molecular cloning and expression of the
human homologue of the murine gene encoding myeloid leukaemia-
inhibitory factor. Proc. Natl. Acad. Sci. USA 85: 2623 - 2627.
Graham G J, Wright E G, Hewick R, Wolfe S D, Wilkie N M,
Donaldson D, Lorimore S and Pragnell I B (1990). Identification
and characterisation of an inhibitor of haemopoietic stem cell
proliferation. Nature 344: 422-444.
Griffin J D, Trantravali R, Canellos G et al (1983). T cell surface
antigens in a patient with blast crisis of chronic myelogenous
leukaemia. Blood 61: 640-644.
Hambley H and Mufti G J (1990). Erythropoietin: an old friend
revisited. Br.Med.J. 300: 621-622.
Hamblin A S (1988). Biochemistry of lymphokines. In
Lymphokines. Eds. Male D, Rickwood D 1988. IRL Press, Oxford
pp1 3-34.
Hamblin T (1991). E Donnal Thomas MD. Nobel Laureate 1990.
Leuk. Res.1 5: 71.
Harrison M R, Slotnick R N, Crombleholme T M, Golbos M S,
Tarantal A F, Zanjani E D (1989). In-utero transplantation of fetal
liver haemopoietic stem cells in monkeys. Lancet 11:1425-1427.
Haworth C (1989). Multifunctional cytokines in haemopoiesis.
Blood Reviews 3: 263-268.
Hayman M J, Kitchener G, Vogt P K, Beug H (1985). The putative
transforming protein of S13 avian erythroblastosis virus is a
transmembrane glycoprotein with an associated protein kinase
activity. Proc.Natl.Acad.Sci.USA. 82: 8237-8241.
Henney C S (1989). lnterleukin-7: effects on early events in
lymphopoiesis. Immunology Today 10: 170-173.
Hernandez P, Carrot J, Cruz C (1982). Chronic myeloid leukaemia
blast crisis with T cell features. Br.J.Haematol. 51: 175-176.
Heyworth C M, Dexter T M, Kan O, Whetton A D (1990). The role
of hemopoietic growth factors in self-renewal and differentiation of
IL-3 dependent multipotent stem cells. Growth Factors 2: 197-
21 1.
209
Heyworth C M, Pointing I L O, Dexter T M (1988). The response
of haemopoietic stem cells to growth factors: developmental
implications of synergistic interactions. J.Cell Science 91: 239-
247.
Hibbin J A, Njoku 0 S, Matutes E, Lewis S M, Goldman J M
(1984). Myeloid progenitor cells in the circulation of patients with
myelofibrosis and other myeloproliferative disorders.
Br.J.Haematol. 57: 495-503.
Hilton DJ, Nicola NA, Metcalf D (1988). Purification of a murine
leukaemia inhibitory factor from Krebs ascites cells. Anal.
Biochem. 173: 359 - 367.
Hino M, Tojo A, Miyazono K, Urabi A, Takaku F (1988). Effects of
type beta transforming growth factors on haematopoietic
progenitor cells. Br.J.Haematol. 70: 143-147.
Hirano T, Akira S, Taga T, Kishimoto T (1990). Biological and
clinical aspects of Interleukin 6. Immunology Today 11: 443-449.
Hoelzer D, Seipelt G, Ganser A (1991). Interleukin 3 alone and in
combination with GM-CSF in the treatment of patients with
neoplastic disease. Semin. Hematol. 1991; 28, No.2 (Suppl.2):
17-24.
Hogg N, Horton M A (1987). Myeloid antigens: new and
previously defined clusters. In Leucocyte Typing III, White cell
differentiation antigens. Ed. Mc Michael AJ, Oxford University
Press, pp577-602.
Hollen C W, Henthorn J, Koziol J A, Burstein S A (1991). Elevated
serum interleukin-6 levels in patients with reactive thrombocytosis.
Br.J.Haematol.79: 286-290.
Ikebuchi K, Wong G C, Clark S C, Ihle J N, Hirai Y, Ogawa M
(1987). Interleukin 6 enhancement of interleukin 3 - dependent
proliferation of multipotential haemopoietic progenitors. Proc. Natl.
Acad. Sci. USA 84:9035-9039.
Ikebuchi K, Ihle J N, Hirai Y, Wong G C, Clark S C, Ogawa M
(1988). Synergistic factors for stem cell proliferation: Further
studies of the target stem cells and the mechanism of stimulation
by interleukin-1, interleukin-6 and granulocyte colony-stimulating
factor. Blood 72: 2007-2014.
210
Imai T, Koike K, Kubo T, Kikuchi T, Amano Y, Takayi M, Okumura
N, Nakahata T (1991). lnterleukin-6 supports human
megakaryocytic proliferation and differentiation in vitro. Blood 78:
1968-1974.
Iscove N N, Sieber F and Winterhalter K H (1974). Erythroid
colony formation in cultures of mouse and human marrow: analysis
of the requirement for erythropoietin by gel filtration and affinity
chromatography on agarose-concanavalin A. J Cell Physiol. 83:
309-320.
Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyore S, Hirano T,
Kishimoto T, Takatsuki F, Akiyama Y (1989b). lnterleukin-6 is a
potent thrombopoietic factor in vivo in mice. Blood 74: 1241-
1244.
Ishibashi T, Kimura H, Uchida T, Kariyore S, Frese P, Burstein S A
(1989a). Human interleukin 6 is a direct promotor of maturation of
megakaryocytes in vitro. Proc.Natl.Acad.Sci.USA. 86: 5953-
5957.
Ishibashi T, Koziol J A, Burstein S A (1987). Human recombinant
erythropoietin promotes differentiation of murine megakaryocytes
in vitro. J.Clin.Invest. 79: 286-289.
Jacobson R J, Salo A, Fialkow P J (1978). Agnogenic myeloid
metaplasia: a clonal proliferation of haematopoietic stem cells with
secondary myelofibrosis. Blood 51: 189-194.
Jones R J, Wagner J E, Celano P, Zicha M S, Sharkis S J (1990).
Separation of pluripotent hematopoioetic stem cells from spleen
colony-forming cells. Nature 347: 188-189.
Kaczmarski R S and Mufti G J (1991). The cytokine receptor
superfamily. Blood Reviews 5: 193-203.
Kaizer H, Stuart R, Brookmeyer R, Beschorner W, Braine H G,
Burns W, Fuller D J, Korbling M, Mangan K F, Saral R,
Sensenbrenner L L, Shadduck R K, Shende A C, Tutschka P,
Yeager A, Zinkham W H, Colvin O M, Santos G W (1985).
Autologous bone marrow transplantation in acute leukaemia: A
phase 1 study of in vitro treatment of marrow with 4-hydroxy
cyclophosphamide to purge tumour cells. Blood 65: 1504-1510.
Kan 0, Evans C A, Whetton A D (1992). Cellular signalling events
stimulated by myeloid haemopoietic growth factors. In Growth
211
factors in haemopoiesis, Eds Lord B I, Dexter TM, Clinical
Haematology 5; no 3, BailliereTindall, London, pp 653-679.
Keating A, Powell J, Takahashi M, Singer J W (1984). The
generation of human long-term marrow cultures from marrow
depleted of la (HLA-DR) positive cells. Blood 64: 1 1 59-1 1 62.
Kehrl J H, Wakefield L M, Roberts AB et al, (1986). Production of
transforming growth factor-beta by human T lymphocytes and its
potential role in the regulation of T cell growth. J. Exp. Med.
163: 1037-1046.
Keller G, Paige C, Gilboa E, Wagner E F (1985). Expression of a
foreign gene in myeloid and lymphoid cells derived from
multipotent hematopoietic precursors. Nature 318: 149-154.
Kobayashi M, Imamura M, Gotohda Y, Maeda S, Iwasaki H,
Sakurada K et al, (1991). Synergistic effects of interleukin-1 p and
interleukin-3 on the expansion of human hematopoietic progenitor
cells in liquid cultures. Blood 78: 1947-1953.
Koeffler H P, Billings R, Lusis A J, Sparkes R, Golde D W (1980).
An undifferentiated variant derived from the human acute
myelogenous leukaemia cell line (KG-1). Blood 56: 265-273.
Lang R A and Burgess A W (1990). Autocrine growth factors and
tumorigenic transformation. Immunology Today 1 1: 244-249.
Leary A G and Ogawa M (1987). Blast cell colony assay for
umbilical cord blood and adult bone marrow progenitors. Blood
69: 953-956.
Leary A G, Ikebuchi K, Hirai Y, Wong G G, Yang Yu-Chung, Clark
S C, Ogawa M (1988). Synergism between lnterleukin-6 and
lnterleukin-3 in supporting proliferation of human hematopoietic
stem cells: comparison with lnterleukin-1 a. Blood 71:1759-1763.
Lebacq A M, Ravoet A M, Bazin H M, De Bruyere M, Rodhain J,
Sokal G (1984). Complementary anti-calla like monoclonal
antibodies. In Leucocyte Typing, Human leucocyte differentiation
antigens detected by monoclonal antibodies. Eds. Bernard A,
Boumsell L, Dausset J, Milstein C, Schlossman SF. Springer-
Verlag, New York, p680.
212
Lee W, Mitchell P, Tijan R (1987). Purified transcription factor AP-
1 interacts with TPA-inducible enhancer elements. Cell 49: 741-
752.
Lemischka I R, Raulet D H, Mulligan R C (1986). Developmental
potential and dynamic behaviour of hematopoietic stem cells. Cell
45: 917-927.
Lewin L M, Melmed S, Passwell J H, Yanna I Y, Brish M, Orda S,
Boichis H, Bank H (1978). Myo-inositol in human neonates: Serum
concentrations and renal handling. Pediat.Res. 12: 3-6.
Linch D C and Brent L (1989). Can cord blood be used? Nature
340: 676.
Ling N R and Richardson P R (1981). A critical appraisal of the
direct rosette test for the detection of cell surface antigens.
J.Immunol.Methods 47: 265-274.
Ling N R, MacLennan I C M, Mason D Y (1987). B-cell and plasma
cell antigens: new and previously defined clusters. In Leucocyte
Typing III, White cell differentiation antigens. Ed. McMichael A J,
Oxford University Press, pp302-335.
Lord B I, Mori K J, Wright E G and Lajtha L G (1976). An inhibitor
of stem cell proliferation in normal bone marrow. Br.J.Haematol.
34: 441-445.
Lord B I, Mori K J, Wright E G (1977). A stimulator of stem cell
proliferation in regenerating bone marrow. Biomedicine 27: 223-
226.
Lowe J, Ling N R, Forrester J A, Cumber A J (1986). Studies on
the reappearance of MHC class II antigens on cells of a variant
human lymphoblastoid line. Immunol. Lett. 12: 263-269.
Lozzio C B and Lozzio B B (1975). Human chronic myelogenous
leukaemia cell line with positive Philadelphia chromosome. Blood
45: 321-334.
Lu L, Walker D, Broxmeyer H E, Hoffman R, Hu W, Walker E
(1987). Characterization of adult human hematopoietic
progenitors highly enriched by two-colour sorting with My 10 and
major histocompatibility Class II monoclonal antibodies.
J.Immunol. 139: 1823-1829.
213
Lubbert M and Koeffler H P (1988). Myeloid cell lines: Tools for
studying differentiation of normal and abnormal hematopoietic
cells. Blood Reviews 2: 121-133.
Marsh J C W and Geary C G (1991). Annotation. Is aplastic
anaemia a pre-leukaemic disorder? Br.J.Haematol. 77: 447-452.
Marshall C J (1989). Oncogenes and cell proliferation: an
overview. In Oncogenes Eds. Glover D M, Hames B D. IRL press
Oxford, pp1 -1 9.
Master P S, Richards S J, Kendall J, Roberts B E, Scott C S
(1989). Diagnostic application of monoclonal antibody KB90
(CD1 1c) in acute myeloid leukaemia. Blut. 59: 221-225.
Mayer P, Geissler K, Ward M, Metcalf D (1993). Recombinant
human leukaemia inhibitory factor induces acute phase proteins
and raises the blood platelet counts in nonhuman primates. Blood
81: 3226 - 3233.
McCulloch E A, Siminovitch L, Till J E, Russell E S, Bernstein S E
(1965). The cellular basis of the genetically determined
hemopoietic defect in anemic mice of genotype SI/SI^. Blood 26:
399-410.
McNiece I K, McGrath H E, Quesenberry P J (1988). Granulocyte
colony-stimulating factor augments in vitro megakaryocyte colony
formation by interleukin 3. Exp.Hematol. 1 6: 807-810.
McNeice I K, Bertoncello I, Kneigler A B, Quesenberry P J (1990).
Colony forming cells with a high proliferative potential (HPP-CFC).
Int. J. Cell Cloning 8:146.
McNiece I K, Langley K E, Zsebo K M (1991b). Recombinant
human stem cell factor synergies with GM-CSF, G-CSF, IL-3 and
Epo to stimulate human progenitor cells of the myeloid and
erythroid lineages. Exp.Hematol. 1 9: 226-231.
McNiece I K, Langley K E, Zsebo K M (1991a). The role of
recombinant stem cell factor in early B cell development.
Synergistic interaction with IL-7. J.Immunol. 1 46: 3785-3790.
Mentzer S J, Herrman S H, Crimmins M A, Burakoff S J, Faller D V
(1983). The role of CD18 in phorbol ester-induced human
monocyte-mediated cytotoxicity. Cell.Immunol. 1 15:66-77.
214
Messner H A, Jamal N and Izaguirre C (1982). The growth of
large megakaryocyte colonies from human bone marrow. J Cell
Physiol. 96: Suppl.1, 45-51.
Metcalf D, Johnson G R and Burgess A W (1980). Direct
stimulation by purified GM-CSF of the proliferation of
multipotential and erythroid precursor cells. Blood 55: 138-147.
Metcalf D (1986). The molecular biology and functions of the
granulocyte-macrophage colony stimulating factors. Blood 67:
257-267.
Michell R H, Conroy L A, Finney M, French P J, Brown G, Creba J
A, Bunce C M, Lord J M (1990). Inositol lipids and phosphates in
the regulation of growth and differentiation of haemopoietic and
other cells. Phil Trans. R. Soc. London B 327: 193-207.
Micklem H S, Ford C E, Evans E P and Gray J (1966). Inter¬
relationships of myeloid and lymphoid cells: studies with
chromosome-marked cells transplanted into lethally irradiated mice.
Proc.R Soc. Lond. B. Biol. Sci. 165: 78-102.
Miller G, Lipman M (1973). Release of infectious Epstein-Barr
virus by transformed marmoset leucocytes. Proc. Natl. Acad. Sci
USA 70:190-94.
Mock B A, Krall M, Kozak C A, et al, (1990). IL-9 maps to mouse
chromosome 13 and human chromosome 5. Immunogenetics 31:
265-270.
Moore MAS, Sheridan A P C, Allen T D, Dexter T M (1979).
Prolonged hematopoiesis in a primate bone marrow culture system:
Characteristics of stem cell production and the hematopoietic
microenvironment. Blood 54: 775-793.
Moore MAS (1991a). The clinical use of colony stimulating
factors. Ann.Rev.Immunol. 9: 159-191.
Moore MAS (1991b). Clinical implications of positive and
negative hematopoietic stem cell regulators. Blood 78: 1-18.
Morris S W, Valentine M B, Shapiro O N, Sublett J E, Reaven L L,
Foust J T, Roberts W M, Ceretti D P, Look A T (1991).
Reassignment of the human CSF 1 gene to chromosome 1 p 1 3-
p21. Blood 78: 2013-2020.
215
Moss D J, Pope J H. (1972). Assay of the infectivity of Epstein-
Barr virus by transformation of human leucocytes in vitro. J. Gen.
Virol. 17: 233-236.
Muench M 0, Firpo M T, Moore MAS (1993). Bone marrow
transplantation with interleukin-1 plus c-kit ligand ex vivo
expanded bone marrow accelerates hematopoietic reconstitution in
mice without the loss of stem cell lineage and proliferative
potential. Blood 81; 3463-3473.
Myones B L, Dalzell J G, Hogg N, Ross G D (1988). Neutrophil
and monocyte cell surface p150,95 has iC3b-receptor (CR4)
activity resembling CR3. J.Clin.Invest.82: 640-651.
Namen A E (1990). Interleukin 7: a new haemopoietic growth
factor. Prog.Clin.Biol.Res. 338: 65-73.
Nathan D G (1989). The beneficience of neonatal hematopoiesis.
N.Eng.J.Med. II: 1190-1191.
Nathan D G (1990). Regulation of hematopoiesis. Pediatric
Research 27: 423-431.
Neta R (1990). Radioprotection and therapy of radiation injury
with cytokines. Prog.Clin.Biol.Res.352: 375-384.
Nicola N A and Johnson G R (1982). The production of
committed hemopoietic colony-forming cells from multipotential
precursor cells in vitro. Blood 60: 1019-1029.
Nishizuka Y N (1988). The molecular heterogeneity of protein
kinase C and its implications for cellular regulation. Nature 334:
661-665.
Nordenskjold M, Jones C A, Glaser T, Werelius B, Larsson C,
Jansson M C (1989). Mapping of chromosome 11 q probes on
somatic cell hybrids. Cytogenet. Cell. Genet. 51: 1054 (abstract).
Nunez G, Ugolini V, Capra J D, Stastny P (1982). Monoclonal
antibodies against human monocytes II. Recognition of two
distinct cell surface molecules. Scand.J.Immunol 16: 515-523.
Ogawa M, Porter P N and Nakahata T (1983). Renewal and
commitment to differentiation of hemopoietic stem cells (An
interpretive review). Blood 61: 823-829.
216
Olofsson T and Olsson I (1980). Biochemical characterization of a
leukaemia associated inhibitor (LAI) suppressing normal
granulopoiesis in vitro. Blood 55: 983-991.
Paquette R L, Zhou J-Y, Yang Y-C, Clark S C, Koeffler H P (1988).
Recombinant gibbon lnterleukin-3 acts synergistically with
recombinant human G-CSF and GM-CSF in vitro. Blood 71: 1596-
1600.
Parkinson E K and Emerson A (1982). The effects of tumour
promotors on the multiplication and morphology of cultured human
epidermal keratinocytes. Carcinogenesis 1982: 3: 525.
Partenen S, Ruutu T, Vuopio P (1982). Circulating haematopoietic
progenitors in myelofibrosis. Scand.J.FIaematol. 29: 325-330.
Paul W E (1991). lnterleukin-4: a prototypic immunoregulatory
lymphokine. Blood 77: 1859-1870.
Patton W N, Holyoake T M, Yates J M, Boughton B J, Franklin I M
(1992). Accelerated recovery from drug-induced agranulocytosis
following treatment with granulocyte colony-stimulating factor. Br
J. Haematol. 80: 564-565.
Paul S R, Bennett F, Calvetti J A, Kelleher K, Wood C R, O'Hara R
M Jr, Leary A C, Sibley B, Clark S C, Williams D A, Yang Y -C
(1990). Molecular cloning of a cDNA encoding interleukin 11, a
stromal cell-derived lymphopoietic and hematopoietic cytokine.
Proc. Natl. Acad. Sci. USA 87: 7512-7516.
Peault B, Weissman I L, Baum C, McCune J M, Tsukamoto A
(1991). Lymphoid reconstitution of the human fetal thymus in
SCID mice with CD34+ precursor cells. J. Exp. Med. 174: 1283-
1286.
Pedrinaci S, Huelin C, Patarroyo M, Ruiz-Cabello F, Garrido F
(1989). Studies on CD11a and CD18 molecules with two new
monoclonal antibodies: differential myelomonocytic antigen
expression of PMA treated HL60 and U937 cell lines. Hybridoma
8: 13-23.
Pedrinaci S, Ruiz-Cabello F, Gomez O, Collado A, Garrido F (1990).
Protein kinase C-mediated regulation of the expression of CD14
and CD1 1/CD18 in U937 cells. Int.J.Cancer 45: 294-298.
217
Peschel C, Broxmeyer H E, Campos L, Konwolinka G, Strauss L C,
Tabilo A (1989). Reactivity of selected new myeloid workshop
antibodies with haemopoietic cells. In Leucocyte Typing IV.
White cell differentiation antigens, Knapp W, Borben B, Gilks W R,
Rieber E P, Schmidt R E, Stein H, von dem Borne A E G Kr, Eds.
(Oxford University Press) pp 906-909.
Peschel C, Paul W E, Ohara J, Green I (1987). Effects of B cell
stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells.
Blood 70: 254-263.
Pierce J H (1989). Oncogenes, growth factors and hematopoietic
cell transformation. Biochimica et Biophysica Acta 989: 179-208.
Pike B L and Robinson W A (1970). Human bone marrow colony
growth in agar-gel. J.Cell Physiol.76: 77-84.
Pluznik D H and Sachs L (1966). The induction of clones of
normal mast cells by a substance from conditioned medium.
Exp.Cell Res. 43: 553-563.
Prchal J T, Throckmorton D W, Carroll A J, Fuson E W, Gams R A,
Prchal J F (1978). A common progenitor for human myeloid and
lymphoid cells. Nature 274: 590-591.
Prummer 0, Calvo W, Werner C, Carbonell F, Fliedner T (1985).
Haemopoiesis and immune functions in dogs following fetal liver
transplantation. In Fetal Liver Transplantation. Eds. Gale R P,
Touraine J-L, Lucarielli G , Alan R Liss, Inc. New York 1985; pp
175-194.
Pryzwansky K B, Raush P G, Spitznagel J K, Herion J C (1979).
Immunocytochemical distinction between primary and secondary
granule formation in developing neutrophils with Romanowsky
stains. Blood 53: 179-185.
Quesenberry P J, McGrath H E, Williams M E, Robinson B E,
Deacon D H, Clark S, Urdal D, McNiece I K (1991). Multi-factor
stimulation of megakaryocytopoiesis. Effects of Interleukin 6.
Exp.Hematol. 1 9: 35-41.
Quirk J G and Bleasdale J E (1983). Myo-inositol homeostasis in
the human fetus. Obstetrics and Gynaecology 62: 41-48.
Rabbitts T H, Rabbitts P H (1989). Molecular pathology of
chromosomal abnormalities and cancer genes in human tumours.
218
In Oncogenes Eds. Glover D M, Hames B D. IRL press Oxford,
pp67-112.
Rayter S I, Iwata K K, Michitsch R W, Sorvillo J M. Valenzuela D
M, Foulkes J G (1989). Biochemical functions of oncogenes. In
Oncogenes Eds. Glover D M, Hames B D. IRL press Oxford, pp
1 13-190.
Rees R C (1990). The biology and clinical applications of
Interleukin 2. Ed. Rees R C. IRL Press, Oxford.
Reinherz E L, Kung P C, Goldstein G, Schlossman S F (1979). A
monoclonal antibody with selective reactivity with functionally
mature human thymocytes and all peripheral human T cells. J.
Immunol. 123: 1312-1317.
Reinherz E L, Hossey R E, Schlossman S F (1980). A monoclonal
antibody blocking human T cell function. Eur. J. Immunol.
10:758-762.
Renauld J C, Goethals A, Houssiau F, Merz H, van Roost E, van
Snick J (1990). Human P40/IL-9. Expression in activated CD4 +
T cells, genomic organisation, and comparison with the mouse
gene. J. Immunol. 144: 4235-4241.
Richman C M, Rowley J D, Golomb H M (1984). Chronic
granulocytic leukaemia: epidemiology and aetiology, pathogenesis,
cytogenetics, in vitro studies and clinical features. In Leukaemias,
Butterworths International Medical Reviews Haematology 1, J M
Goldman, H D Preisler, Eds. Butterworths, London, pp 208-238.
Roberts R, Gallagher J, Spooncer E, Allen T D, Bloomfield F,
Dexter T M (1988). Heparin sulphate bound growth factors: A
mechanism for stromal cell mediated haemopoiesis. Nature 332:
376-378.
Rogo C, Touraine J-L, Veyron P, Aitouche A (1987). Survey of
experimental data on fetal liver transplantation. Thymus 10: 5-12.
Rosenberg C L, Wong E, Petty E M (1991). PRAD1, a candidate
BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Proc. Natl. Acad. Sci. USA. 88: 9638-9642.
Rosse W F (1989). Paroxysmal nocturnal hemoglobinuria: The
biochemical defects and the clinical syndrome. Blood Reviews 3:
192-200.
219
Rosse W F (1990). Phosphatidylinositol-linked proteins and
paroxysmal nocturnal hemoglobinuria. Blood 75: 1595-1601.
Rovera G, Santoli D, Damsky C (1979). Human promyelocytic
leukaemia cells in culture differentiate into macrophage-like cells
when treated with a phorbol ester. Proc.Natl.Acad.Sci.USA 76:
2779-2783.
Rowley P T, Ohlsson-Wilhelm B M, Farly B A (1978). Erythroid
colony formation from human fetal liver. Proc. Natl. Acad. Sci.
USA 75: 984-988.
Rowley S D, Sharkis S J, Hattenbury C, Sensenbrenner LL (1987).
Culture from human bone marrow of blast progenitor cells with an
extensive proliferative capacity. Blood 69: 804-808.
Ruutu T, Partenen S, Knuutila S (1983). Clonal karyotype
abnormalities in erythroid and granulocyte-monocyte precursors in
polycythaemia vera and myelofibrosis. Scand.J.Haematol. 31:
253-256.
Sanderson C J, Campbell H D, Young I G (1988). Molecular and
cellular biology of eosinophil differentiation factor (Interleukin 5)
and its effects on human and mouse B cells. Immunol.Rev. 1 02:
29-50.
Santos G W (1987). History of bone marrow transplantation.
Clinics in Haematology 12: 61 1-639.
Sato Y, Suda T, Suda J, Ohsaka A, Kubota K, Saito M and Miura Y
(1986). Multi-lineage expression of haemopoietic precursors with
an abnormal clone in idiopathic meylofibrosis. Br.J.Haematol. 64:
657-667.
Scott C S, Richards S J, Master P S, Kendall J, Limbert H J,
Roberts B E (1990). Flow cytometric analysis of membrane
CD11b, CD11c and CD14 expression in acute myeloid leukaemia:
relationships with monocytic subtypes and the concept of relative
antigen expression. Eur.J.Haematol. 44: 24-29.
Sessarego M, Ajmar F, Ravazzolo R, Bianchi Scarra G L, Garre C,
Boccaccio P (1983). Coincidence between fragile site expression
and interstitial deletion of chromosome 11 in a case of
myelofibrosis. Hum.Genet. 63: 299-301.
220
Sieff C A, Emerson S G, Donahue R E, Nathan D G, Wang E A,
Wong G G, Clark S C (1985). Human recombinant granulocyte-
macrophage colony stimulating factor: a multi-lineage
haematopoietin. Science 230: 1171-1173.
Sieff C A, Niemeyer C M, Nathan D G, Ekern S C, Bieber F R, Yang
Y C, Wong G, Clark S C (1987). Stimulation of human
hematopoietic colony formation by recombinant gibbon multi-
colony-stimulatory factor or lnterleukin-3. J.Clin.Invest. 80: 818-
823.
Siena S, Castro-Malaspina H, Gulati S, Lu L, Colvin MO, Clarkson
BD, O'Reilly RJ, Moore MAS (1985). Effects of in vitro purging
with 4-hydroperoxycyclophosphamide on the hematopoietic and
microenvironmental elements of human bone marrow. Blood 65:
655-662.
Sing C K, Keller J R, Ellingsworth L R, Ruscetti F W (1988).
Transforming growth factor-B selectively inhibits normal and
leukaemic bone marrow cell growth in vitro. Blood 72: 1504-
1511.
Singer J W, Fialkow P J, Dow L W, Ernst C, Steinmann L (1979).
Unicellular or multicellular origin of human granulocyte-macrophage
colonies in vitro. Blood 54: 1395-1399.
Spangrude G J, Smith L, Uchida N, Ikuta K, Heimfeld S, Friedman
J, Weissman I L (1991). Mouse hematopoietic stem cells. Blood
78: 1395-1402.
Spooncer E, Heyworth C M, Dunn A, Dexter T M (1986). Self-
renewal and differentiation of Interleukin 3 dependent multipotent
stem cells are modulated by stromal cells and serum factors.
Differentiation 31: 111-118.
Srour EF, Brandt JE, Briddell RA, Leemhuis T, van Besien K,
Hoffman R (1991). Human CD34+ HLADR- bone marrow cells
contain progenitor cells capable of self-renewal, multilineage
differentiation, and long-term in vitro hematopoiesis. Blood Cells
17: 287-295.
Srour E F, Zanjani E D, Brandt J E, Cornetta K, Traycoff C, Cooper
R, Heerema N A, Leemhuis T, Hoffman R (1992). Adult human
CD34+ HLA-DR" bone marrow cells transplanted in utero into
sheep fetuses display multipotential lymphohaemopoietic
221
differentiation and self-renewal capacities. Blood 80, Suppl 1:13
(abstract).
Srour EF, Brandt JE, Briddell RA, Grigsby S, Leemhuis T, Hoffman
R (1993). Long-term generation and expansion of human primitive
hematopoietic progenitor cells in vitro. Blood 81: 661-669.
Starnes H F (1991). Biological effects and possible clinical
applications of lnterleukin-1. Semin.Hematol. 28, Supp.2: 34-41.
Strong R C, Korsemeyer S J, Parkin J L, Arthur D C, Kersey J H
(1985). Human acute leukaemia cell line with the t(4; 11)
chromosomal rearrangement exhibits B lineage and monocytic
characteristics. Blood 65: 21-31.
Suda T, Suda J, Ogawa M, Ihle J N (1985). Permissive role of
interleukin 3 (IL-3) in proliferation and differentiation of
multipotential haematopoietic progenitors in culture. J. Cell.
Physiol. 124: 182-190.
Sugiyama H, Ichiba S, Okuno Y and 7 others (1989). Cytogenetic
evidence for a clonal disorder involving CFU-GEMM, BFU-E and
CFU-C in patients with myeloproliferative disorders. Nippon
Ketsueki Gakkai Zasshi 52: 1022.
Sundstrom C, Nilsson K (1976). Establishment and
characterization of a human histiocytic lymphoma cell line (U-937).
Internat.J.Can. 17: 565-577.
Sutherland H J, Eaves C J, Eaves A C, Dragowska W, Lansdorp P
M (1989). Characterization and partial purification of human
marrow cells capable of initiating long-term hematopoiesis in vitro.
Blood 74: 1563-1570.
Tepperman A D, Curtis J E and McCulloch E A (1974).
Erythropoietic colonies in cultures of human marrow. Blood 44:
659-669.
Teramura M, Kobayshi S, Hoshino S, Oshimi K, Mizoguchi H.
(1992). Interleukin 11 enhances human megakaryocytopoiesis in
vitro. Blood 79: 327-331.
Terstappen L W M H, Huang S, Safford M, Lansdorp P M, Loken M
R (1991). Sequential generations of haematopoietic colonies
derived from single nonlineage-committed CD34+ CD38"
progenitor cells. Blood 77: 1218-1227.
222
Thomas E D, Storb R, Clift R A, Fefer A, Johnson F L, Neiman P E,
Lerner K G, Glucksberg H, Buckner C D (1975). Bone marrow
transplantation. New Engl.J.Med. 292: 832-843; 895-902.
Till J E and McCulloch EA (1961). A direct measurement of the
radiation sensitivity of normal mouse bone marrow cells. Rad.Res.
14: 213-222.
Till J E, McCulloch E A, Siminovitch L (1964). A stochastic model
of stem cell proliferation, based on the growth of spleen colony
forming cells. Proc.Natl.Acad.Sci.USA. 51: 29-36.
Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton D M, Mufti G J
(1990). Mutation of the human FMS gene (M-CSF receptor) in
myelodysplastic syndromes and acute myeloid leukaemia.
Leukaemia 4: 486-489.
Toksoz D, Dexter T M, Lord B I, Wright E G and Lajtha L G (1 980).
The regulation of haemopoiesis in long-term bone marrow cultures
II. Stimulation and inhibition of stem cell proliferation. Blood 55:
931-936.
Toksoz D, Bunce C M, Stone P C W, Michell R H, Brown G (1982).
Variant cell lines from the human promyelocyte line HL60. Leuk.
Res. 6: 491-498.
Toksoz D and Brown G (1984). Maintenance of granulocyte-
monocyte progenitor cells in liquid cultures of human fetal liver.
J.Cell.Physiol. 119: 227-233.
Torok-Storb B (1 988). Cellular Interactions. Blood 72: 373-385.
Touraine J-L (1992). Transplantation of fetal haemopoietic and
lymphopoietic cells in humans, with special reference to in utero
transplantation. In Fetal Tissue Transplants in Medicine, Ed.
Edwards RG, University Press, Cambridge, pp155-176.
Trainor C D, Wong-Staal F, Reitz M S (1982). Comparative
restriction endonuclease maps of proviral DNA of the primate type
C simian sarcoma-associated virus and gibbon age leukaemia virus
group. J. Virol. 41:298-308.
Tsai S, Patel V, Beaumont E, Lodish H F, Nathan D G, Seiff C A
(1987). Differential binding of erythroid and myeloid progenitors
to fibroblasts and fibronectin. Blood 69: 1587-1594.
223
Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Noweli P C,
Croce C M (1984). Molecular cloning of the chromosomal
breakpoint of B cell lymphomas and leukaemias with the t( 11; 14)
chromosome translocation. Science 224: 1403-1406.
Tucker J, Dorey E, Gregory W M, Simpson A P, Amess J A, Lister
T A, Horton M A (1990). Immunophenotype of blast cells in acute
myeloid leukaemia may be a useful predictive factor for outcome.
Haematol. Oncol. 8: 47-58.
Uchiechowski P and Schmidt R E (1 989). Cluster report: CD1 1. In
Leucocyte Typing IV, White cell differentiation antigens. Eds.
Knapp W et al, Oxford University Press, pp543-551.
Uphoff D E (1958). The preclusion of secondary phase of
irradiation syndrome by inoculation of fetal haemopoietic tissue
following total body irradiation. J.Nat.Cancer Inst. 20: 625-632.
Vairo G and Hamilton J A (1991). Signalling through CSF
receptors. Immunology Today 12: 362-369.
Van Snick J (1990). Interleukin 6: an overview.
Ann.Rev.Immunol 8: 253-278.
Verfaillie C, Blakolmer K, McGlave P (1990). Purified primitive
human hematopoietic progenitor cells with long-term in vitro
repopulating capacity adhere selectively to irradiated bone marrow
stroma. J.Exp.Med. 172: 509-520.
Visser J W M, Bauman J G J, Mulder A H, Eliason J F, de Leeuw A
M (1984). Isolation of murine pluripotent haemopoietic stem cells.
J.Exp.Med.159: 1576-1590.
Warrell R P, Frankel S R, Miller W H, Scheinberg D A, Itri L M,
Hittelman W N, Vyas R, Andreeff M, Tafuri A, Jakubowski A,
Gabrilove J, Gordon M S, Dmitrovsky E (1991). Differentiation
therapy of acute promyelocytic leukaemia with tretinoin (all-trans-
retinoic acid). New Eng.J.Med. 324: 1385-1393.
Waterfield M D, Scrace G T, Whittle N, Stroobant B P, Johnson A,
Wasteson A, Westermark B, Heldin C H, Hvang J S, Duel T F
(1983). PDGF is structurally related to the putative transforming
protein P28s's of simian sarcoma virus. Nature 304: 35.
Whetton A D and Dexter T M (1989). Myeloid haemopoietic
growth factors. Biochemica et Biophysica Acta 989: 111-132.
224
Whitlock C A and Witte 0 N (1982) Long-term culture of B
lymphocytes and their precursors from murine bone marrow.
Proc.Natl.Acad.Sci.USA 79: 3608-3612.
Williams B P, Goodfellow P N, Shipley J M, Spurr N K, Smith D R,
Hayman M J (1987). Assignment of SEA, a putative human
oncogene, to chromosome 11 q 1 3. Cytogenet. Cell Genet . 46:
717 (abstract).
Williams N, Bertoncello I, Kaynouclinas H, Zsebo K, McNiece I K
(1992). Recombinant rat stem cell factor stimulates the
amplification and differentiation of fractionated mouse stem cell
populations. Blood 79: 58-64.
Winton E F and Colenda K W (1987). Use of long-term human
bone marrow cultures to demonstrate progenitor cell precursors in
marrow treated with 4-hydroperoxycyclophosphamide.
Exp.Hematol. 1 5: 710-714.
Wolf N S (1979). The haemopoietic microenvironment. In Lajtha
L G ed: Clinics in Haematology, London, Philadelphia, Toronto: WB
Saunders Co., Vol.8: 469-500.
Wreggett K A, Irvine R F (1987). A rapid separation method for
inositol phosphates and their isomers. Biochem. J. 245: 655-660.
Wright E G, Pragnell I B (1992). Stem cell proliferation inhibitors.
In Growth factors in haemopoiesis, Eds Lord B I, Dexter TM,
Clinical Haematology 5; no 3, pp 723-739, BailliereTindall,
London.
Wright E G, Sheridan P and Moore MAS (1980). An inhibitor of
murine stem cell proliferation produced by normal bone marrow.
Leuk.Res. 4: 309-319.
Wu A M, Till J E, Siminovitch L, McCulloch EA (1968).
Cytological evidence for a relationship between normal
hematopoietic colony-forming cells and cells of the lymphoid
system. J.Exp.Med. 1 27: 455-463.
Yam L T, Li CY, Crosby W W (1971). Cytochemical identification
of monocytes and granulocytes. Am.J.Path. 55: 283-294.
Yang Y C, Ricciardi S, Ciarletta A, Calvetti J, Kelleher K, Clark S C
(1989). Expression and cloning of a cDNA encoding a novel
225
human haemopoietic growth factor: human homologue of murine
T-cell growth factor P40. Blood 74:1880-1884.
Yarden Y (1988). Growth factor receptor tyrosine kinases.
Ann.Rev.Biochem. 57: 443-478.
Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Takatsuki K
(1993). Effect of recombinant human interleukin-11 on rat
megakaryopoiesis and thrombopoiesis in vivo: comparative study
with interleukin-6. Br. J. Haematol. 84:16-23.
Yoshimura A, Longmore G, Lodish H F (1990). Point mutation in
the exoplasmic domain of the erythropoietin receptor resulting in
hormone-independent activation and tumorigenicity. Nature 348:
647-649.
Zsebo K M, Wypach J, McNiece I K, Lu H S, Smith K A, Karkave S
B, Sachdev R K, Yuschenkoff V N, Birkett N C, Williams L R,
Satyagal V N, Jung W, Bosselman R A, Mendiaz E A, Langley K E
(1990). Identification, purification and biological characterization
of hematopoietic stem cell factor from buffalo rat liver-conditioned
medium. Cell 63:1 95-201.
226
APPENDIX B. PUBLICATIONS RELATED TO THESIS
(i) Patton W N, Bunce C M. Scott S A. Lord J M, Brown G (1 990).
Phorbol myristate acetate induction of monocyte differentiation of
normal myeloid blast cells isolated from human fetal liver.
Br.J.Haematol. 74 (Suppl.1): 41 (abstract).
(ii) Bunce C M, Patton W N. Pound J D, Lord J M, Brown G (1 990).
Phorbol myristate acetate treatment of normal human myeloid blast
cells promotes monopoiesis and inhibits granulopoiesis. Leukaemia
Research 14: 1007-1017.
(iii) Patton W N. Bunce C M, Larkins S, Brown G (1991). Defective
erythropoiesis in primary myelofibrosis associated with a
chromosome 11 abnormality. Br.J.Cancer 64: 128-131.
(iv) Patton W N. Bunce C M. Larkins S, Brown G (1991). Defective
erythropoiesis in myelodysplastic syndromes. J.Clin.Pathol. 44:
965 (correspondence).
(v) Bunce C M, French P J, Patton W N. Turnell A S, Scott S A,
Michell R H, Kirk C J, Brown G (1992). Levels of inositol
metabolites within normal myeloid blast cells and changes during
their differentiation towards monocytes. Proc. R . Soc.Lond. B
247: 27-33.
227
PHORBOL MYRISTATE ACETATE INDUCTION OF MONOCYTE
DIFFERENTIATION OF NORMAL MYELOID BLAST CELLS
ISOLATED FROM HUMAN FOETAL LIVER. Patton WN. Bunce
CM, Scott SA, Lord JM, Brown G. Department of
Immunology, Medical School, Birmingham, B15 2TJ.
The molecular events associated with the
proliferation, lineage committment and
differentiation of normal haemopoietic cells are
relevant to the perturbations involved in
leukaemias and myelodysplastic syndromes. However,
studies of these events have been difficult to
perform as they require the purification of
homogeneous haemopoietic precursors in large numbers
for the relevant biochemical and molecular analyses.
We have purified an undifferentiated myeloid blast
cell population from 16-20 wk human foetal liver.
The procedure involves ficoll gradient fractionation
of the initial cell suspension and subsequent
removal of contaminating erythroblasts and
macrophages by indirect erythrocyte rosette
sedimentation using monoclonal antibodies directed
against glycophorin and a macrophage associated
surface antigen. Total yields of 7-9x10^ cells
were obtained depending on the age and size of the
liver. The purified population consisted mainly of
undifferentiated blast cells(70-80%) which where
negative for Sudan Black B, chloroacetate esterase,
a-naphthyl acetate esterase(ANAE) and markers of
mature B and T cells. During 3 weeks in culture the
cells spontaneously differentiated into both mature
granulocytes (as identified by morphology and
expression of lactoferrin and a granulocyte
associated antigen) and macrophages (as identified
by morphology and ANAE expression). When cultures
were treated with lOnM phorbol myristate acetate,
terminal monocyte differentiation occurred within
48hr in 60% of the blast cell population. The
purified blast cells offer a model system for the
study of molecular and other events associated with
normal myeloid and particularly monocyte maturation.
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PHORBOL MYRISTATE ACETATE TREATMENT OF NORMAL
HUMANMYELOID BLAST CELLS PROMOTES MONOPOIESIS AND
INHIBITS GRANULOPOIESIS
Christopher M. Bunce, W. Nigel Patton, John D. Pound, Janet M. Lord and
Geoffrey Brown
Department of Immunology, The Medical School, University of Birmingham, Birmingham B15 2TT,
U.K.
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Abstract—Fractionation of mononuclear cells from human fetal liver provides a cell population at
early stages of myeloid differentiation which, when cultured, generates neutrophils and macrophages
for up to a month. These studies describe the further purification of an undifferentiated myeloid blast
cell population by rosette sedimentation of unwanted cells, after coating these cells with monoclonal
antibodies which identify macrophages and erythroblasts. In culture, the purified blast cells generated
only neutrophils and macrophages. When treated with 10 nM PMA, 62% of the purified cells were
induced to differentiate towards macrophages within 48 h. PMA-induced cells acquired morphological
features of macrophages and synthesized a-naphthyl acetate esterase. The differentiation of the
remaining blast cells towards neutrophils, seen in untreated cultures, was completely inhibited by
PMA, as revealed by the absence of increases in the numbers of cells expressing lactoferrin and an
antigen which appears at the promyelocyte stage of differentiation. Thus, PMA effects intracellular
changes which both promote monopoiesis and inhibit granulopoiesis, suggesting a reciprocal inter¬
action between intracellular processes which regulate the capacity for the two pathways of maturation.
The purified blast cell population provides a good model system for studies of molecular events which
regulate the expression of macrophage characteristics.
Key words: Myelopoiesis, phorbol esters, macrophages, fetal liver.
INTRODUCTION
Studies of the cellular events during myeloid cell dif¬
ferentiation have most often involved the use of cell
lines as model systems. However, human promyeloid
cell lines such as HL60 [1], KG-1 [2] and ML-1 [3]
have all been derived from leukaemia cells and present
abnormal karyotypes. Therefore, there is a difficulty
as to whether the cellular processes described from
studies of transformed myeloid cell lines reflect either
events during normal myelopoiesis or some aspect of
the lines' abnormal status. To confirm that intra¬
cellular changes defined in studies ofmyeloid cell lines
are a feature of normal myelopoiesis and also to delin¬
eate events pertinent to malignant transformation, it
Abbreviations: PMA, phorbol myristate acetate; FCS,
fetal calf serum; BSA, bovine serum albumin; GM-CFC,
< granulocyte/macrophage colony forming cell; PHA-LCM,
phytohaemagglutinin stimulated leucocyte conditioned
medium; CSF, colony stimulating factor; 3[H]TdR, tri-
tiated thymidine.
Correspondence to: G. Brown, Department of Immu¬
nology, The Medical School, University of Birmingham,
Birmingham B15 2TT, U.K.
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is essential to purify myeloid cells at a very early stage
of differentiation in sufficient numbers for biochemi¬
cal and molecular biological studies.
In a previous study,we used a one-step fractionation
procedure to obtain a mononuclear cell population
from human fetal liver which was capable of gen¬
erating all stages of neutrophil and macrophage dif¬
ferentiation [4], This cell population provided a good
source of myeloid precursor cells but was contami¬
nated with erythroblasts and mature macrophages.
In this study, we have further purified an
undifferentiated myeloid blast cell population by
rosette sedimentation of the above contaminating
cell populations. The myeloid blast cell population
was purified by negative rather than positive selection
so as to avoid interference with surface properties
which may elicit events which, in turn, confuse sub¬
sequent physiological studies. The purified myeloid
blast cells are described in terms of theirmorphology,
phenotype and capacity to differentiate towards neu¬
trophils and monocytes. In particular, the effect on
this purified myeloid population of PMA, which is
used to induce HL60 cells to differentiate rapidly
towards monocytes [5], was studied in detail.
1008 C. M. Bunce et al.
MATERIALS AND METHODS
Purification of blast cells
Light-density cells were harvested from whole human
fetal liver as previously described [4]. Normoblasts and
macrophages were removed by an indirect rosetting tech¬
nique [6] using mouse monoclonal antibodies against gly-
cophorin C, Ret 40F (Dr D. Y. Mason, Oxford, [7]) and
a monocyte specific surface antigen, 61D3 [8]. Cells were
resuspended in 500 |xl aliquots at 4 x 106/ml and incubated
with antibody to glycophorin C (500 pi of undiluted tissue
culture supernatant) and 61D3 antibody (20 pi of undiluted
ascitic fluid) for 15 min at room temperature. Following two
washes with RPMI 1640 medium (GIBCO, Paisley) sup¬
plemented with 2% FCS (GIBCO), 250 pi of sheep eryth¬
rocytes coated with anti-mouse immunoglobin [9] were
added and the cells centrifuged at 300 g for 3 min. After a
final 5 min incubation at 4°C the cells were resuspended and
pooled. An aliquot was taken for enumeration of rosette
positive cells. The remaining cells were made up to 6 ml with
RPMI 1640medium supplementedwith2% FCS, the rosette
positive cells and excess sheep erythrocytes were removed
by further fractionation on 3 ml of Ficoll-Hypaque (Phar¬
macia, Milton Keynes). The light-density cells were har¬
vested and washed three times with RPMI 1640 containing
5% FCS. Aliquots were removed to provide cytospin prep¬
arations (Cytospin 2, Shandon Scientific Ltd, Runcorn) for
Romanowsky, cytochemical and immunostaining, for
assessment of phagocytosis and indirect rosette assays for
glycophorin C and 61D3 positive cells. The rosette assays
were performed as described above.
For culture, cells were aliquoted, in 1 ml volumes at
2.5 x 105/ml into individual wells of 24-well tissue culture
plates (Nunc Ltd, Paisley) in RPMI 1640 medium sup¬
plemented with 20% heat inactivated FCS (GIBCO),
10 |xM hydrocortisone sodium succinate (Organon,
London), 5 pg/ml vitamin D3 (cholecalciferol, Sigma,
Poole) and lOOU/ml penicillin-50 pg/ml streptomycin
(GIBCO). PMA-treated wells contained 10 nM PMA
(Sigma). Individual wells of untreated and PMA-treated
cells were harvested after 16, 42 and 66 h for assessment
of cell number, viability, numbers of phagocytic cells and
cytospin preparation for subsequent Romanowsky, cyto¬
chemical and immunocytochemical analyses.
Assessment of colony forming ability
The number of cells within the purified blast cell popu¬
lation able to form colonies in semi-solid medium was
determined by using a GM-CFC assay similar to the method
described by Ash et al. [10]. Briefly, 5 x 104 purified fetal
liver cells were seeded in triplicate in a 1 ml volume of
Iscove's Modified Dulbecco's Medium (GIBCO) con¬
taining 1.2% methylcellulose (Sigma), 20% FCS, 1%
deionized BSA (Sigma), 5 x 10 5 M 2-mercaptoethanol
(Sigma) and 5% PHA-LCM as a source of growth factors.
Colonies containing >40 cells were enumerated at day 12
and the experiment was performed in duplicate.
Assessment of DNA synthesis
DNA synthesis was assessed by pulsing cultures of puri¬
fied blast cells in flat-bottomed 96-well microtitre plates.
Cells were seeded at 105 per well in 100 pi of the above
medium, PMA-treated wells contained 10 nm PMA. Half
a pCi of 3[H]TdR (25 Ci/mM) was added in 50 pi ofmedium
at 0, 12, 36, 60 and 84 h and cultures were harvested 6 h
later on a Skatron automatic harvester. 3[H]TdR incor¬
poration was measured by scintillation counting. Incor¬
poration determinations were performed in triplicate and
the experiment was undertaken twice.
Assessment of differentiation
In all analyses a minimum of 400 cells were assessed. Dif¬
ferential cell counts were performed by light microscopy
following staining of cytospin preparations withMay-Grun-
wald-Giesma. Staining for monocyte specific esterase was
performed using ar-naphthyl acetate as the substrate [11].
Granulocyte differentiation was assessed by staining cells
with the monoclonal antibody AGF4.48, which recognizes
cells at the promyelocyte to neutrophil stages ofmaturation
[12], and by immunocytochemical staining for lactoferrin, a
consistuent of neutrophil secondary granules [13]. AGF4.48
stainingwas by indirect immunofluorescence. Unfixed cyto¬
spin preparations were incubated with AGF4.48 tissue cul¬
ture supernatant for 30 min at room temperature, followed
by a fluorescein conjugated sheep anti-mouse immuno¬
globulin, diluted 1 in 50 in a mixture of 10% normal sheep
serum and 5% FCS. Lactoferrin staining was performed by
an indirect immunoperoxidase technique. Fixation and
blocking of endogenous peroxidase activity was achieved by
incubation for 20 min in methanol-formalin (1:1) con¬
taining 0.6% hydrogen peroxide. After washing, incubation
for 20 min at room temperature with a mixture of 20% nor¬
mal human AB serum and 20% swine serum was used to
prevent non-specific binding. Cytospin preparations were
then incubated for 30 min at room temperature with a 1 in
50 dilution of a polyclonal sheep IgG antibody to lactoferrin
(PC062, The Binding Site Ltd, Birmingham) and for a
further 30 min with horseradish peroxidase conjugated
swine anti-sheep IgG (PP361, The Binding Site Ltd) at a 1
in 100 dilution. Following colour development with 3,3'-
diaminobenzidine, the nuclei were counterstained with
Mayer'sHaemalum. Phosphate buffered saline, pH 7.1 con¬
taining 0.1% BSA (Sigma)was used as the diluting and wash¬
ing buffer for the above two staining procedures.
Immunocytochemical staining for mature T and B lym¬
phocytes was performed by the immunoalkaline phos¬
phatase technique using monoclonal antibodies to the CD3
and CD22 antigens as previously described [14]. To prevent
non-specific binding, 0.1% BSA was added to the wash and
dilution buffers and dilutions of the primary and second anti¬
body were supplemented with 10% normal rabbit serum.
The CD3 antibody (M756, diluted 1 in 100), CD22 antibody
(M738, diluted 1 in 200), rabbit anti-mouse immunoglobulin
(Z259, diluted 1 in 25) and alkaline phosphatase-anti-alka-
line phosphatase complexes (D651, diluted 1 in 50) were
purchased from Dako Ltd (High Wycombe). In all
immunostaining procedures positive, negative and sub¬
stitution controls were included.
Phagocytic function was assessed by the ability of cells to
phagocytose complement-coated yeast cells as previously
described [15].
RESULTS
Purification of myeloid blast cells
A one-step Ficoll-Hypaque density separation of
human fetal liver cells provided light-density cells con¬
sisting of similar percentages of blasts (46%) and nor¬
moblasts (29%). The remaining 25% of the cells were
Granulocyte and macrophage differentiation
Table 1. Purification of undifferentiated blast cells from fetal liver
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Pre-rosette Post-rosette
Characteristic separation (%)* separation (%)*
Differential:
Normoblasts 29 ± 3.2 <1
Blasts 46 ± 6.0 73 ± 4.0
Promyleocytes/myelocytes/metamyelocytes 4± 1.5 8 ± 3.2
Neutrophils 1 ± 0.3 1 ± 0.4
Promonocytes 2 ±0.4 3 ± 1.4
Macrophages 4 ± 1.4 <1
Lymphocytes! 2 ±0.4 4± 1.1
Others 12 ± 1.9 11 ±2.2
61D3/Ret 40F positive cells! 33 ± 0.6 4 ±0.1
Yield — 25 ±2.1
* Data are the mean ± S.E. of values obtained from four separate experiments,
t Combined percentages of CD3 (T) and CD22 (B) positive cells,
t Determined by indirect rosetting.
mostly macrophages (4%), cells at the promyelocyte
to neutrophil stages ofmaturation (5%), lymphocytes
(2%), as identified by the expression of the CD3 and
CD22 antigens, and cells whichwere not readily ident¬
ifiable and were classed as others (12%). The growth
and differentiation of these cells in liquid suspension
culture has already been described in detail [4]. Pro¬
liferation wasmaintained for up to amonth and during
this time the number of normoblasts declined rapidly
andmature neutrophils and macrophages appeared in
culture. By day 8, neutrophils and macrophages each
accounted for 10% of the viable leucocytes and, by
day 24, 25% and 30% of these cells were neutrophils
and macrophages, respectively.
Normoblasts and macrophages were removed from
the light-density fetal liver cells using Ficoll-Hypaque
to separate rosetting cells, prepared after labelling the
above cellswith monoclonal antibodies which identify
glycophorin C (Ret 40F) and a monocyte-associated
antigen (61D3), respectively. The percentage of cells
rosetting when a combination of the two antibodies
was used (33%) agree with the combined percentages
of normoblasts and macrophages as identified by their
morphology (33%). Table 1 shows the differential
obtained for the Ficoll-Hypaque interface population
after sedimentation of rosettes. Normoblasts and
macrophages were successfully removed as shown by
the percentages of these cells observed in Romanow-
sky stained preparations (<1%) and the combined
percentages of cells rosetting after relabelling with the
monoclonal antibodies Ret 40F and 61D3 (4%). The
purified cell population consisted mostly of undif¬
ferentiated blast cells (73%) which were pleomorphic
exhibiting variation in cell size and both nuclear and
cytoplasmic characteristics (see Fig. 2). The chroma¬
tin pattern was open with multiple nucleoli and the
nuclear outline varied from regular and round to
mainly irregular convoluted forms. The cytoplasmwas
either scanty ormoderate in quantity, weak to strongly
basophilic and often vacuolated. Azurophilic granu¬
lation was absent. The remaining contaminating cells
were at the promyelocyte to neutrophil stages of dif¬
ferentiation (9%), lymphocytes (4%) and unidenti¬
fied cells (11%). A cell yield of 25% was routinely
obtained, providing 7-9 x 106 cells from each fetal
liver, depending on the age and size of the liver.
When the purified blast cells were assayed for
their ability to form colonies in semi-solid medium,
containing PHA-LCM as a source of CSF, the num¬
ber of colonies observed in two experiments was
234 and 264 per 105 cells. The colonies consisted of
granulocytes and/or macrophages and their pre¬
cursors as revealed by staining of cytocentrifuged
preparations of single colony contents. The initial
frequency of GM-CFC in the light-density cells from
fetal liver in this and the previous study [4] was
between 100 and 200 GM-CFC per 105 cells. Thus,
significant enrichment of GM-CFC was not observed
within the purified blast cell population and the
majority of these cells do not form colonies.
Promotion ofmacrophage differentiation within puri¬
fied blast cells
The myeloid cell population obtained from fetal
liver has been shown previously to expand into all
stages of differentiation during one month in culture
[4]. However, the maturation is gradual such that
mature macrophages are only present at appreciable
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levels (10% of cells) by day 10. Similarly, the purified
blast cells gradually matured when cultured and after
six days only 12% of cells expressed the enzyme a-
naphthyl acetate esterase, amarker formacrophages.
Thus, the further purification of the myeloid blast
cells made no difference to the generation per se of
mature macrophages and also granulocytes. As in
the case of the light-density mononuclear cell fraction
initially described from fetal liver [4], granulocyte
maturation occurred in cultures of purified blast cells
such that after six days 41% of cells were at the
promyelocyte to neutrophil stages of maturation.
The possibility that the purified blast cell population
comprises to any appreciable degree of primitive
erythroblasts is excluded by the observation that the
blast cells survived well in culture. By 48 h, 51% of
cells had retained a blast cell morphology giving
rise to a value for the total number of blast cells
maintained of 58% of the initial population isolated.
The reduction in blast cell numbers can be accounted
for by cells gradually progressing to later stages of
differentiation. In contrast, normoblasts and eryth¬
roblasts present in the unpurified light-density popu¬
lation from fetal liver die very rapidly in culture [4].
PMA was added immediately after establishing
cultures of purified blast cells at 2.5 x 105/ml. In
both the PMA-treated and control cultures there was
no increase in the total number of cells over the 66-h
period during which analyses were undertaken and
values obtained for the number of viable cells
recovered (80-92%) and cell viability (87-98%) were
similar for the treated and untreated cultures
throughout the entire course of each experiment.
Assessment of cell proliferation by analysis of DNA
synthesis revealed that cells within the PMA-treated
cultures had proliferated to a lesser extent than those
in control cultures. In control cultures there was a
moderate increase in 3[H]TdR uptake. Values for
dpm incorporated per 105 cells were 3.0 X 104 at time
12 h rising to 5.1 x 104 and 4.2 x 104 at 60 and 84 h,
respectively. At 12 h PMA-treated cultures showed
an incorporation of 1.7 x 104 dpm per 105 cells rising
to values of 4.2 x 104 and 3.4 x 104 per 105 cells at
60 and 84 h, respectively. Thus, it is unlikely that
PMA had induced rapid and extensive proliferation
of a minor population of the purified blast cells and
that this together with loss of a considerable number
of cells within another cell population had maintained
cell numbers at a constant level in the PMA-treated
cultures. Furthermore, large numbers of dead cells
were clearly not present in the wells.
Twenty-four hours after the addition of PMA,
the morphological appearance of cells in the treated
cultures was already different from that of cells in
control cultures. A considerable proportion of the
cells in PMA-treated cultures had become pleo¬
morphic, spread, adherent and produced pseudo-
podia. Cells with these features, which are consistent
with cells having undergone macrophage differenti¬
ation, were less evident in the control cultures.
To what extent the blast cells had rapidly dif¬
ferentiated towards macrophages, was assessed by
determining the percentage of cells classed as pro¬
monocytes and macrophages in Romanowsky stained
preparations, those expressing cr-naphthyl acetate
esterase and the capacity of cells to phagocytose
complement coated yeasts. The cells enumerated as
promonocytes in stained preparations had dis¬
tinguishing characteristics of increased size with
increased quantities of cytoplasm which was less
basophilic, vacuolated and had irregular edges.
Phagocytosis of a few contaminating sheep eryth¬
rocytes, from the rosette procedure, was also
occasionally evident. The nuclear to cytoplasm ratio
was reduced with an eccentrically placed nucleus
which was reniform in shape and contained nucleoli.
More mature forms showed typical macrophage mor¬
phology. At time zero, cells with these features were
present at the level of <1%. As shown in Fig. 1 and
Fig. 2, the addition of 10 nM PMA resulted in an
increase in the percentage of cells classed as pro¬
monocytes and macrophages to values of 62% and
65% at 42 h and 66 h, respectively, compared with
values of 14% and 16% in control cultures. The rapid
morphological differentiation towards macrophages
seen with PMA was accompanied by an increase in
the number of cells expressing ar-naphthyl acetate
esterase. Four percent of the initial cell population
expressed this enzyme. By 66 h, 46% of cells in PMA
treated cultures were positive as compared with 8%
of control cells (see Figs 1 and 2). The percentage of
cells expressing cr-naphthyl acetate esterase, together
with no increase in cell numbers over 66 h and a high
recovery of cells from wells, reveals an increase in
the total number of mature macrophages from
1.0 x 104 at time zero to 9.7 x 104 in PMA-treated
cultures at 66 h as compared with 1.8 x 104 in control
cultures at this time point. The number of phagocytic
cells, which includes both mature macrophages and
neutrophils, increased from <1% to 17% at 66 h in
PMA-treated cultures as opposed to 6% in control
cultures.
Effect of PMA on granulopoiesis
In PMA-treated cultures the maximum percentage
of cells which could be induced to differentiate
towards macrophages was 63-67%. At 66 h, 31-33%
of the remaining cells, as observed in Romanowsky
stained preparations, had retained a blast cell appear¬
ance and only 1% of total cells had differentiated
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Fig. 1. Induction of monocyte differentiation by PMA.
Monocyte differentiation was assessed by the percentage of
promonocytes and monocytes/macrophages, as identified
morphologically by Romanowsky staining, (■—■) and by
the percentage of cells positive for ar-naphthyl acetate
esterase (•—•). Results are means ± S.E. of values
obtained from four separate experiments.
towards neutrophils. In contrast, the analysis of
stained preparations of cells from control cultures
showed that, by 66 h, 34% of cells were at the pro¬
myelocyte to neutrophil stages of differentiation.
To confirm that the addition of PMA had inter¬
fered with granulopoiesis within the purified blast
cell population, the percentage of cells expressing
lactoferrin and a neutrophil cell surface antigen
AGF4.48, which is expressed at the promyelocyte
stage of differentiation [12], were enumerated
throughout the time course of PMA-treated and con¬
trol cultures. Within the starting cell population 10%
of cells contained lactoferrin and expressed the
AGF4.48 antigen. As shown in Fig. 3, by 66 h the
numbers of lactoferrin positive and AGF4.48 antigen
positive cells in control cultures had risen to 33%
and 39%, respectively. Throughout the time course
of the PMA-treated cultures, the percentage of lac¬
toferrin positive cells remained at the level of 5-14%
and those stained by the monoclonal antibody
AGF4.48 at 9-12%. The mean of values for the
percentages of AGF4.48 positive cells represent a
level of 1.9 x 104 mature granulocytes in total in
PMA-treated cultures as compared with 9.0 x 104 in
control cultures. Initial levels ofmature granulocytes,
in the purified blast cell population, were in the range
1.8-2.1 x 104. Figure 2 shows that the frequency of
AGF4.48 positive cells was considerably lower in
cultures of PMA-treated cells than in cultures of
control cells.
To exclude the possibility that the inhibition of
granulopoiesis or promotion of monopoiesis
observed were due to indirect effects whereby the
PMA had induced the small percentage of con¬
taminating lymphocytes (4%) to release inhibitory
or inductive factors, the following experiment was
undertaken. The monoclonal antibody AGF43,
which stains both T and B lymphocytes [16], was
added to the antibody mixture used to prepare
indirect rosettes which resulted in effective depletion
of lymphocytes. In the case of this experiment, light
density cells prepared from fetal liver using Ficoll-
Hypaque consisted of 56% blasts, 22% normoblasts,
4% macrophages and a considerable contamination
by lymphocytes of 19%. Light-density fetal liver cells
which had subsequently been depleted of glycophorin
C positive and 61D3 positive cells comprised of 77%
blasts and 21% lymphocytes. The fetal liver cell
population which had been depleted of the above
cells and AGF43 positive cells, was enriched in blast
cells (86%) and contained only 1% lymphocytes.
Parallel studies of the effect of PMA on the above
two purified cell populations showed that removal of
the contaminating lymphocytes did not affect the
rapid induction of monocyte differentiation by PMA
or inhibition of granulopoiesis. At 61 h after PMA
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Fig. 3. Inhibition of granulocyte differentiation by PMA.
Granulocyte differentiation was assessed by: the per¬
centage of granulocyte cells (promyelocytes, myelocytes,
metamyelocytes and granulocytes) as identified mor¬
phologically by Romanowsky staining (■—■); the per¬
centage of cells positive after staining, by indirect
immunofluorescence, with AGF4.48 antibody (A—A);
and by the percentage of cells positive for the immu-
nohistochemical localisation of lactoferrin (•—•). Results
are means ± S.E. of values obtained from four separate
experiments.
treatment, cultures established from fetal liver cells
depleted of lymphocytes and from those cells con¬
taminated by lymphocytes contained similar numbers
of cells expressing cr-naphthyl acetate esterase. Val¬
ues obtained for the positive cells were 27% and
21%, respectively. In both cultures after treatment
with PMA for 61 h there was no evidence of neu¬
trophil differentiation as assessed by the percentages
of AGF4.48 antigen positive cells (<1%) and cells at
the metamyelocyte to neutrophil stages of maturation
(<1%).
DISCUSSION
Negative selection techniques for enriching cell
populations have the advantage that the required
cell population is unperturbed and they are thus
preferred over positive selection methods when cells
are required for in vitro physiological studies. For
example, B lymphocyte purification by eliminating T
cells, after rosetting with sheep erythrocytes, avoids
antibody labelling of the desired cells and inter¬
ference with their surface properites [17], Similarly,
negative selection by panning out the unwanted cells
has been recommended for the isolation of haemo-
poietic progenitor cells which are susceptible to non¬
specific damage by CrCl3-coupled erythrocytes used
to purify these cells by rosetting [18]. In this study
we have used a simple two-step Ficoll-Hypaque pro¬
cedure to purify myeloid blast cells from fetal liver
so as to obtain large numbers of these normal cells
for biochemical analyses. Unwanted cell populations
were eliminated by rosette sedimentation after coat¬
ing these cells with a mixture of two monoclonal
antibodies which identify glycophorin C and a mono-
cyte-associated antigen, respectively. Thus, the blast
cells obtained were not subjected to either antibody
coating or possible damage by CrCl3-coupled eryth¬
rocytes as suggested previously. Furthermore, since
the fetal liver cells were first purified as light-density
cells using Ficoll-Hypaque, then subsequent negative
selection by Ficoll-Hypaque, the fractionation de¬
pended only on the criterion of antigen expression.
In contrast, when panning for negative selection after
coating cells with antibody, both antigen expression
and non-specific adherence are factors involved and
the process may selectively remove some adherent
myeloid blast cells. A minimal combination of two
antibodies was used to coat unwanted cell popu¬


























inhibition of granulocyte differentiation of undifferentiated
blast cells from human fetal liver. Parts (A-C) show cells
at 0 h; (D-F) cells treated with PMA for 66 h; (G-I) control
cells at 66 h. Parts (A, D, G) are Romanowsky stained
preparations; (B,E,H) are preparations stained for a-
napthyl acetate esterase activity and (C, F, I) are prep¬
arations stained by indirect immunofluorescence with




possibility that the combined effects of a large cock¬
tail of monoclonal antibodies, each binding to hae-
mopoietic cell surface antigens expressed at uncertain
and/or low levels on undifferentiated myeloid cells,
may generate indirect rosettes and eliminate some
cells of interest.
The cell population obtained from fetal liver con¬
sisted of undifferentiated myeloid blast cells and a
few contaminating lymphocytes. The majority of the
purified blast cells lacked features of differentiation,
such that they could not be identified as either pre¬
cursors of neutrophils or monocytes. When cultured,
the cells differentiated towards either neutrophils or
macrophages. However, as reported previously for
the light-density fetal liver cells [4], the terminal
differentiation of the population as a whole occurred
over a protracted time course. Both the slow change
in the differentiation status of the population and that
both granulocytes and macrophages are generated,
presented difficulties in using these cells to analyse
biochemical events pertinent to either neutrophil or
macrophage differentiation.
PMA has been used to induce rapid terminal dif¬
ferentiation of various cell types, for example, the
promyeloid cell line HL60 [5] and keratinocytes [19].
When added to cultures of purified blast cells in this
study, 42-65% of the cells differentiated towards
macrophages within 42 h, as revealed by increased
numbers of cells with an appropriate morphological
appearance and cells which expressed the enzyme a-
naphthyl acetate esterase and phagocytosed yeasts.
Thus, the addition of PMA provided a reduced time
course for the differentiation of a population of the
blast cells towards macrophages. An unexpected
finding was that PMA inhibited granulopoiesis within
the cultures, presumably by affecting the 31-51% of
blast cells which underwent neutrophil differenti¬
ation in the control cultures. The inhibition was
revealed by the lack of increased numbers of cells at
or beyond the promyelocyte stage of differentiation
(AGF4.48 positive) in PMA-treated cultures. The
practical benefit from the rapid promotion of mono-
poiesis and simultaneous inhibition of granulo¬
poiesis is that a population of normal cells is
provided which is undergoing macrophage dif¬
ferentiation only. This is advantageous to studies
of biochemical events during monopoiesis since, as
suggested above, a mixture of blast cells undergoing
macrophage differentiation and those differentiating
towards neutrophils would be less suitable. An
alternative solution to this problem would be to sep¬
arate the two blast cell populations. However, appro¬
priate markers are not presently available.
The capacity ofPMA to both promote monopoiesis
and inhibit granulopoiesis has important implications
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in relation to intracellular processes which regulate
these two pathways of differentiation. The purified
blast cell population is, to a large extent, a mixture
of cells which are already committed to either neu¬
trophil or macrophage differentiation, since a maxi¬
mal number of 65% of the cells were induced to
mature towards monocytes by PMA and, in control
cultures 34% of the cells were able to spontaneously
differentiate towards neutrophils. The 34% of cells
able to differentiate towards neutrophils correlates
well with the percentage of blast cells which did not
differentiate in PMA-treated cultures (32%). Thus,
PMA does not interfere with granulopoiesis by
diverting cells towards the monocyte pathway of
maturation. This conclusion leads to the view that
the opposing effects of PMA on granulopoiesis and
monopoiesis is related to a reciprocal interaction
between intracellular processes which regulate the
capacities for the two pathways of maturation. In
other words, intracellular events effected by PMA
which facilitate monopoiesis concomitantly lead to a
reduced capacity for granulopoiesis. For example,
PMA is known to activate protein kinase C (PKC)
which may phosphorylate proteins and confer func¬
tional activity which is essential for monocyte
differentiation. As irreversible commitment of
progenitor cells to a particular pathway of dif¬
ferentiation is involved, these proteins would pre¬
sumably include DNA-binding proteins, the PMA-
responsive elements [20] identified as modulators of
gene activity in several cell types. The reciprocal
enhancement and silencing of genes required for
monocyte and neutrophil differentiation respectively
in this system, could thus be achieved through acti¬
vation of the PKC pathway and the ultimate modu¬
lation of specific DNA-binding proteins.
The above general consideration as to the effect
of PMA also accords with our previous proposal
that expression of the potentials for neutrophil and
macrophage differentiation is linked in the following
way. Data from various studies were interpreted to
suggest that the above two differentiation potentials
are expressed in a progressive and linear manner, in
that as cells lose the capacity for neutrophil dif¬
ferentiation they then acquire the potential formono¬
cyte differentiation [21]. If this hypothesis is correct,
then only one or two choices are available at any
given time and lineage potentials are viewed as par¬
tially overlapping differentiation options [22]. The
notion that PMA promotes monopoiesis and inhibits
granulopoiesis by virtue of a reciprocal interaction
between intracellular events, which regulate com¬
mitment to these two pathways of differentiation,
provides a mechanistic expansion of the previous
considerations. Furthermore, support for the model
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proposed, that lineage potentials are sequentially
expressed, is provided as follows. At the molecular
level, the modulation of gene expression required for
cell diversification may be effected via a relatively
small group of transcriptional regulators, governed
by the major intracellular signalling pathways,
including protein kinase C. Specificity is introduced
at the level of modulation of the activity of these
gene regulators, such that they bind to their specific
loci, and the accessibility of these loci, which may
require the removal of repression. The minimal acti¬
vation of one signalling pathway, leading to enhance¬
ment and silencing of particular genes, would
necessitate the availability of only two differentiation
options as regards the expression of lineage poten¬
tials. In contrast, a multipotent model of haemo¬
poiesis in which cells can differentiate directly along
any one of at least five maturation pathways [23], is
likely to require the involvement of several intra¬
cellular signalling pathways, which modulate a panel
of DNA-binding proteins, so as to select one dif¬
ferentiation option and close the others.
In conclusion, a simple procedure for purifying
myeloid blast cells in considerable numbers from
fetal liver is described, together with the use of PMA
to promote monopoiesis whilst inhibiting gran¬
ulopoiesis, providing a model system which can be
used to study biochemical and genetic events in nor¬
mal myeloid precursor cells undergoing monocyte
differentiation. For example, changes in the phos¬
phorylation status of proteins have been observed
which relate to differentiation in HL60 cells towards
monocytes [24]. Whether these proteins are phos-
phorylated during normal monopoiesis is an impor¬
tant issue. Furthermore, it would be worthwhile to
screen a variety of agents, which are used to induce
cell lines to differentiate towards neutrophils, to
investigate whether, conversely, granulopoiesis can
be promoted and monopoiesis inhibited so as to
extend the model system to encompass studies of
granulocyte differentiation.
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Defective erythropoiesis in primary myelofibrosis associated with a
chromosome 11 abnormality
W.N. Patton', C.M. Bunce2, S. Larkins3 & G. Brown2
Departments of 1 Haematology and 2Immunology, The Medical School, University of Birmingham, Birmingham B15 2TT and
'Department of Cytogenetics, Birmingham Maternity Hospital, Birmingham B15 2TH, UK.
Summary A case of primary myelofibrosis was identified with a previously unreported complex karyotype
with two abnormal clones in addition to a proportion of normal cells: 46,XY, — 2, — 11,+ der(2)t(2;l 1)
(q24/31 ;q 13), + mar and 45,XY, - 2, - 11,+ der(2)t(2; 11 )(q24/31 ;q 13), + mar, — 17,del(7q). Study of circulating
committed progenitors from this patient consistently showed (1) an absence of erythroid progenitors which is
uncommon and (2) greatly increased granulocyte-monocyte progenitors (CFU-GM) which is generally
observed in myelofibrosis. Further study showed that peripheral blood mononuclear cells co-cultured with
irradiated normal bone marrow stroma generated increased numbers of CFU-GM compared with controls but
failed to generate erythroid progenitors, providing evidence for an intrinsic defect in erythropoiesis. Only once
previously has the absence of erythroid progenitors in primary myelofibrosis been studied in relation to
cytogenetic abnormalities. This case also revealed a complex karyotype which, however, shared with our case a
defect on chromosome 11. The identification of two cases of primary myelofibrosis which lack committed
erythroid progenitor cells and which show in common a chromosomal defect on chromosome 11 point to the
existence of genes on this chromosome which play a key role during erythropoiesis.
Primary myelofibrosis (PMF) is a form of chronic myelopro¬
liferative disease characterised by bone marrow fibrosis,
hepatosplenomegaly and the presence of leucoerythroblastic
changes and tear drop poikilocytes in the peripheral blood.
The finding of G-6-PD isoenzyme restriction in patients'
peripheral blood cells, but not fibroblasts and the demonstra¬
tion of clonal cytogenetic abnormalities in pluripotent
haemopoietic progenitor cells support the hypothesis that the
primary defect is a clonal expansion of pluripotent
haemopoietic progenitor cells associated with reactive mar¬
row fibrosis (Jacobson et al., 1978; Ruutu el al., 1983; Sato et
al., 1986; Sugiyama et al., 1989). Reported cytogenetic aber¬
rations have been varied but abnormalities of chromosome
13 have been the most common. (Borgstrom et al., 1984;
Johnson et al., 1985). PMF is also associated with extra-
medullary haemopoiesis and increased levels of circulating
haemopoietic progenitors including multilineage progenitors
(CFU-GEMM), megakaryocyte progenitors (CFU-Mk),
erythroid progenitors (BFU-E) and granulocyte-macrophage
progenitors (CFU-GM). Many cases have even shown ery¬
thropoietin independent erythroid colony formation (Hibbin
et al., 1984; Carlo-Stella et al., 1987).
We report on a case of PMF in whom defective erythro¬
poiesis, characterised by the absence of circulating erythroid
progenitors and the inability to generate erythroid colonies
on irradiated normal marrow stroma, was associated with a
complex cytogenetic abnormality. Comparison of the
karyotype in this case with that observed in a previously
reported case in whom erythropoiesis was defective (Partenen
et al., 1982) reveals a common abnormality involving
chromosome 11. The significance and possible linkage
between defective erythropoiesis and the karyotypic abnor¬
mality is discussed.
Case report
A 71 year old man presented with anaemic symptoms, 8 cm
hepatomegaly and 12 cm splenomegaly. His Hb was 43 g 1"',
Wbc 2.8 x 1091~' with neutrophils 2.2xI09l_l including
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hypersegmented forms, lymphocytes 0.3 x 1091~', monocytes
0.2 x 1091_1, myelocytes <0.1 x 109C, blasts 0.1 x 109l_l,
normoblasts 1 per 100 w.b.c. and platelet count 95 x 1091"'.
His blood film showed tear drop poikilocytes but infrequent
normoblasts which were rarely seen on subsequent blood
films. His reticulocyte count was 33 x 109 F' and both the
serum and red cell folate were reduced. Bone marrow aspira¬
tion was unsuccessful and a trephine biopsy was hypercel-
lular showing marked granulocytic hyperplasia, absent
normoblasts, megakaryocytes of increased size with irregular
nuclei and increased reticulin fibrosis, consistent with features
in cases reported by Barosi et al., 1983. He was initially
supported with folic acid, allopurinol and blood transfusion
and was subsequently treated with hydroxyurea and oxy-
methalone. He remained transfusion dependent but after 7
months developed an increasing leukocyte count with an
increasing proportion of blast cells which was refractory to
therapy with hydroxyurea. He died 9 months after presenta¬
tion having followed a course similar to patients reported by
Bentley et al., 1977.
Materials and methods
Cells
Peripheral blood mononuclear cells (PBMNC) from the
above case collected into preservative free heparin were
separated on ficoll-hypaque (Pharmacia, UK) and the inter¬
face cells were washed three times in Iscove's modified
Dulbecco's medium (IMDM) (Gibco, UK).
Assays for CFU-GM and BFU-E
Fresh PBMNC were assayed for their ability to form colonies
in semi-solid medium using a method similar to that de¬
scribed by Ash et al., 1981. For a CFU-GM assay, 2-8 x 104
PMF PBMNC were seeded in duplicate in a 1.0 ml volume
of IMDM containing 1.2% methylcellulose (Sigma), 20%
foetal calf serum (FCS, Gibco), 1 % deionised bovine serum
albumin (Sigma), 5 x 10"SM 2-mercaptoethanol (Sigma), 5%
phytohaemagglutinin stimulated leucocyte conditioned
medium (PHA-LCM) and 100 U ml"1 penicillin - 50pgml~'
streptomycin (Gibco). Colonies containing >40 cells were
enumerated at day 12. For assessment of BFU-E an identical
system containing erythropoietin (Eprex, Cilag UK) at
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3 U ml-1 was used, the cells were plated at densities of
0.5-1.0 x 105ml~' and the plates read after 14 days. Fresh
fractionated human foetal liver cells (Toksoz & Brown, 1984)
and normal bone marrow cells were used as positive controls.
The assays were performed on three different occasions,
firstly at diagnosis and on two other occasions when
hydroxyurea therapy had been stopped 96 h previously.
Initiation of haemopoiesis on irradiated stroma from long term
bone marrow cultures
Fresh PBMNC were also tested for their ability to initiate
haematopoiesis on irradiated stroma from long term bone
marrow cultures (LTC). A 10 ml long term bone marrow
culture containing 2 x 107 marrow buffy coat cells from a
normal marrow donor was established and maintained in
medium as previously described (Gartner & Kaplan, 1980).
After 30 days nonadherent cells were removed, the adherent
cells trypsinised, irradiated with 15 Gray (Co 60 gamma rays,
mean energy 1.25 MeV, dose rate 5.3 Gy min"') and 3 ml of
cells at 1 x 105ml"' reseeded (i.e. at 3 x 104cm"2) in each of
three 35 mm diameter wells of a 6 well tissue culture plate
(Nunc). After 5 days incubation, during which a healthy
stroma had re-established, 1.5 ml of supernatant was
removed from each of the three wells and to each of two
wells was added 1.5 ml of LTC medium containing 5.4 x 106
fresh PMF PBMNC. To the remaining well was added 1.5 ml
LTC medium alone to act as a negative control. To each of
two other empty 35 mm diameter wells was added 5.4 x 106
fresh PMF PBMNC in 3 ml of LTC medium to act as a
PMF control. The five cultures were fed weekly by removing
half of the supernatant and replacing this with fresh LTC
medium. After 5 weeks all nonadherent cells were removed
and the cells in the adherent layer harvested by trypsinisa-
tion. Nonadherent and adherent cells were pooled, washed
and assayed for progenitor cells as described above. The total
number of cells harvested from each culture was as follows:
PMF PBMNC alone 11 x 105 and 14 x 105; co-cultures of
PBMNC and irradiated stroma 15 x 105 and 17 x 105; and
irradiated stroma alone 1.4 x 105 cells. The cells in the
stroma alone culture were plated in duplicate at a density of
0.7 x 105mC in an erythroid colony assay. Otherwise cells
from the other cultures were plated in triplicate in separate
assays for CFU-GM and BFU-E at densities ranging from
1.5 x 105—2.3 x 105 ml-1.
Cytogenetic analysis
For analysis of peripheral blood cells, trypsin-Giemsa banded
slides were prepared from unstimulated cultures which after
24 h were treated with 0.02 pg ml"1 colcemid for either 1 h or
24 h. Metaphases were analysed using standard chromosome
criteria. To demonstrate any cytogenetic abnormality in
CFU-GM isolated from our patient, pooled GM colonies
grown from PBMNC were harvested into IMDM containing
20% FCS and 10% phytohaemagglutinin-leucocyte condi¬
tioned medium, and incubated overnight at 37°C in 5% C02.
Colcemid was added and after 1 h and 24 h cells were
harvested and processed as described above.
Results
Cytogenetic analysis
Analysis of 20 metaphases from unstimulated cultures of
PBMNC showed three cell lines: one metaphase showed a
normal male karyotype; 13 cells showed 46 chromosomes
with the loss of one chromosome 2 and one 11, the presence
of an abnormal chromosome 2 derived from a 2; 11 transloca¬
tion and an additional unidentified marker chromosome
(46,XY,— 2,— 11,+ der(2)t(2;ll)(q24/31;ql3),+ mar); and six
cells showed the above karyotype along with the loss of
one chromosome 17 and a deletion of part of the long arm of
one chromosome 7 (45,XY, — 2, — 11,+ der(2)t(2; 11 )(q24/31 ;q 13),
+ mar,— 17,del(7q)). Analysis of pooled GM colonies grown
from PBMNC showed the third karyotype described above in
8/10 metaphases. The other two metaphases described the
same karyotype with the addition of another unidentified
marker chromosome, implying some further clonal evolution
(Figure 1).
Colony forming ability of PBMNC
On three separate occasions culture of PBMNC revealed
greatly increased numbers of circulating CFU-GM with the
complete absence of erythroid colonies (Table I). The nature
of GM colonies was confirmed following staining of cytocen-
trifuged preparations of single colony contents. Positive con¬
trol erythroid colonies were grown from fractionated human
foetal liver cells and from bone marrow cells.
Initiation of haemopoiesis on irradiated stroma from LTC
No GM or erythroid colonies were grown from the culture
containing irradiated allogeneic normal bone marrow stroma
alone and only GM colonies were grown in the other cultures
containing PMF PBMNC. Co-cultures containing both
irradiated stroma and PMF PBMNC yielded much greater
numbers of GM colonies than cultures containing PMF
PBMNC alone whether numbers were expressed in terms of
total CFU per culture or per 105 inoculating cells (Table II).
Rowanowsky stained cytospins of cells taken from cultures at
the time of clonogenic assay did not show any cells of the
erythroid lineage.
Discussion
The main observations from this case study are the demon¬
stration of absent circulating erythroid progenitors in PMF,
an uncommon event, and its association with a previously
unreported karyotypic abnormality.
Circulating haemopoietic progenitors, particularly CFU-
GM, are usually greatly increased in PMF. Studies of cir¬
culating erythroid progenitors have shown normal or
increased levels in 18/18 cases studied by Carlo-Stella et al.,
1987, 17/18 cases studied by Partenen et al., 1982 and 2/2
cases studied by Douer et al., 1983. However, cases of PMF
have been reported in which erythroid progenitor cells are
absent. In the study of Hibbin and co-workers erythroid
progenitors were absent in four splenectomised patients (Hib¬
bin et al., 1984) and Croizat et al., 1983 observed an absence
of erythroid progenitors in four patients, two of which had
been splenectomised. The absence of circulating erythroid
progenitors in PMF patients is not invariably linked to
splenectomy since the patient reported in this study and the
one identified by Partenen and co-workers with absent BFU-
E (Partenen et a!., 1982) were not splenectomised. Further¬
more, the two larger studies of 18 patients showed normal or
increased levels of circulating BFU-E in many splenectomised
patients (Partenen et al., 1982; Carlo-Stella et al., 1987).
Many observations support the fact that circulating com¬
mitted progenitors in PMF largely arise from and circulate
from the spleen (Douay et al., 1987). Thus, in the patient
reported in this study the failure to detect circulating ery¬
throid progenitors is due to either a defect in the capacity of
haemopoietic stem cells to undergo commitment to the ery¬
throid lineage or the ability of committed erythroid
progenitors to undergo erythropoiesis or that erythroid pro¬
genitors are generated and sequestered in the spleen.
An intrinsic defect in erythropoiesis is the most likely
explanation for the following reasons. Douay and co-workers
have shown that, in PMF patients, CFU-GM can be main¬
tained in liquid suspension culture in the absence of a sub¬
stantial stromal layer over a 10-week period and concluded
that primitive stem cells circulated in PMF patients (Douay
et al., 1987). In our study, PBMNC were co-cultured with
normal marrow stroma to maintain circulating primitive stem
cells and assess whether they were able to give rise to ery-
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Figure 1 G-banded karyotype from the GM colony culture: 46,XY,— 2, — 11, + der(2)t(2;l 1 )(q24/31 ;q 13), + marl,
— 17,del(7q), + mar2.
Table I Number of colony forming cells grown from PMF PBMNC and normal cells
PMF PBMNC Foetal Liver Bone marrow
CFUml'1 of blood CFU per 105 cells
Time point CFU-GM BFU-E/CFU-E CFU-GM BFU-E CFU-GM BFU-E
1 2,644 0 206 153 33 22
2 7,912 0 244 166 70 28
3 7,605 0 300 90 27 ND
ND = not done.
Table II Mean number (+s.e.m.) of CFU isolated after culture of PMF
PBMNC on irradiated bone marrow stroma
CFU-GM
Culture condition Per 10s cells Per total culture BFU-E/CFU-E
Stroma alone 0 0 0
PMF cells alone 14 (1.1), 11 (1.7) 156 (12), 101 (16) 0
PMF cells + stroma 27 (2.1), 20 (0.7) 405 (31), 348 (11) 0
throid progenitors in a normal and appropriate microen-
vironment. Erythroid progenitor cells were not generated and
the existence of circulating stem cells was supported by the
generation of increased numbers of CFU-GM following
incubation of PBMNC with marrow stroma as compared
with control PMF PBMNC cultured in the absence of
stroma. The failure to detect circulating erythroid progenitors
for technical reasons can be excluded since the assays were
controlled by the demonstration of erythroid progenitors in
appropriate numbers from foetal liver and from bone mar¬
row cells.
Of those PMF patients previously studied with absent
circulating erythroid progenitors, cytogenetic data is available
for only one case which exhibited a complex karyotype -
47,XX,5q — . 1 lq — 20, + mar 1, + mar 2 (Partenen et al.,
1982). However, a common abnormality involving the long
arm of chromosome 11 between this and our case is of
interest and suggests a causal relationship between an abnor¬
mality in the long arm of chromosome 11 and defective
erythropoiesis. An abnormality at 1 lq 13 has been reported
once previously in a case of PMF, though whether ery¬
thropoiesis was defective in this case in unknown (Sessarego
et al., 1983). A review of the literature with regard to
oncogene associations at the relevant breakpoints in the case
ERYTHROPOIESIS IN PMF WITH ABNORMAL 1 lq 131
reported in this study reveals that the proto-oncogene SEA
(SI3 avian erythroblastosis oncogene homolog) maps to the
11 q 13 region (Williams et al., 1987; Nordenskjold et al.,
1989; Hayman et al., 1985). The involvement of this
oncogene should be explored at the molecular level.
In conclusion, the association between a distinct
cytogenetic abnormality on chromosome 11 and the absence
of committed erythryoid progenitor cells in PMF patients is
worthy of further study. Cytogenetic analysis of additional
patients with an absence of circulating erythroid progenitors
might reveal a common chromosome abnormality and point
to the location of genes which encode key intrinsic regulators
of erythoid lineage development. Furthermore, studies of
lesions in the generation of various committed progenitor
cells in PMF patients in relation to possible karyotypic
abnormalities offers a useful approach to the analysis of the
chromosomal location and organisation of genes which con¬
trol the generation and differentiation of haemopoietic pro¬
genitor cells.
We are grateful to Mr P. Anderson of the Department of
Immunology, University of Birmingham for assistance in the irradia¬
tion of stromal cells. We also thank the Leukaemia Research Fund
for support of research in our laboratory. W.N.P. is a clinical
research fellow supported by the United Birmingham Hospitals Trust
Fund.
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Defective erythropoiesis in myelodys-
plastic syndromes
We read with interest the report of William¬
son el al describing uncommon cases of red
cell aplasia (RCA) in patients with myelo-
dysplastic syndromes (MDS).' The mechan¬
ism of RCA in their first three cases was
attributed to an intrinsic defect ofmaturation
and proliferation of erythroid precursors
occurring as part of the myelodysplastic dis¬
order, whereas in the second three cases a
different, and possibly autoimmune aetiology,
was suggested. We believe that cytogenetic
and molecular study of such unusual cases is
important. Most cases of MDS and other
malignant haematological disorders are
associated with structural chromosomal ab¬
normalities. Cytogenetic study of unusual
cases with common features, such as these
cases of RCA, might indicate a common
chromosomal abnormality which would point
to the existence of genes which encode key
regulators of erythroid lineage development
at or near the junction of the chromosomal
aberration. The key regulators of lineage
commitment and differentiation in haemo¬
poiesis remain unknown, and an investigative
approach through the study of nature's
genetic errors might lead to their discovery.
Using such an approach we have recently
described a possible association between
defective erythropoiesis and an abnormality
of chromosome ll.2 A case of primary
myelofibrosis was identified which showed
morphological erythroid aplasia and absent
circulating erythroid progenitors. The
patient had greatly increased numbers of
circulating granulocyte-monocyte progenitor
cells (CFU-GM). Co-culture of peripheral
blood mononuclear cells with irradiated
allogeneic normal bone marrow stroma gen¬
erated increased numbers of CFU-GM com¬
pared with controls but failed to generate
erythroid progenitors, providing further
evidence for an intrinsic defect in eryth¬
ropoiesis. Our patient exhibited a previously
unreported complex karyotype. Only once
previously has the absence of erythroid
progenitors in primary myelofibrosis been
studied in relation to cytogctic abnormalities,
and this case also indicated a complex
karyotype which shared with our case a defect
on chromosome 11. The abnormality in our
case was llq-—with the break point at 11 q 1 3.
A literature review showed that die proto-
oncogene SF.A (SI3 avian erythroblastosis
oncogene homolog) maps to the 11 q 13 region
and we intend to study the possible role of this
gene at the molecular level.
WN PATTON
Department of Hacmatology, The Medical School
University oj Birmingham BIS 2TT
CM BUNCE
G BROWN
Department of Immunology, The Medical School
University of Birmingham BIS 2TT
S L.ARKIN
Department of Cytogenetics, Birmingham Maternity
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1 Williamson PJ, Oscier DG, Bell AJ, Hamblin
TJ. Red cell aplasia in myelodysplastic syn¬
drome. J Clin Pathol 1991;44:431-2.
2 Patton WN, Bunce CM, Larkin S, Brown G.
Defective erythropoicsis in ' primary
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Drs Williamson el at comment:
The case cited above is certainly of interest in
investigating the pathogenesis of red cell
aplasia in myelodysplasia (MDS). The over¬
lap of morphological features between MDS
and myelofibrosis is increasingly being recog¬
nised,' and it would be intriguing to know the
consequences at the gene level in this case of
1 lq- with break point at 11 q 13.
Our cases all had attempted cytogenetic
analysis of marrow aspirate. Four gave a
normal karyotype and two failed to yield
metaphases. Several of our cases date from
the early 1980s and the cytogenetic technique
has undoubtedly improved since then. Our
rate of clonal cytogenetic abnormality in
MDS in the Wessex region is about 35-^10%
which accords with the national average. A
few published series quote clonal abnormality
rates of 75% plus, but these may be the result
of repeated analysis of large numbers of cells
and may be influenced by case selection. In
the Wessex region we have never encountered
the 11 q 13 region as being involved in a case of
MDS. The 1988 Catalogue of Chromosomal
Aberrations in Cancer2 lists only five reported
cases where the 11 q 13 region has been
involved in myelodysplastic/proliferative dis¬
orders, often as part of a complex karyotype.
A review of the other published cases ofMDS
and red cell aplasia referenced in our paper
shows that all five in which cytogenetics are
reported yielded a normal karyotype. Thus
although of some interest, it remains to be
seen if the 11 q 13 region has a role in the
regulation of erythropoiesis.
1 Lambertcnghi-Deliliers G, Orazi A, Luksch R,
Annaloro C, Soligo D. Myelodysplastic syn¬
drome with increased marrow fibrosis: a
distinct clinico-pathologica! entity. Br J
Haematol 1991 ;78:161-6.
2 Mitleman F. Catalogue of chromosomal aberra¬
tions in cancer. 3rd cdn. New York: Alan R
I.iss, 1988.
Visceral leishmaniasis in human
immunodeficiency virus disease
I read the very interesting article by Curry,
Turner, and I .ucas.1 It is important to include
visceral leishmaniasis (VI.) as an opportunis¬
tic protozoan infection in patients infected
with HIV, as it is common in endemic areas.2
Although the authors comment on some of
the salient diagnostic and therapeutic features
ofVL in patients with HIV, the description is
perhaps incomplete as it is based on only a few
cases. Over the past few years, most cases of
VI. in HIV infection have been reported from
Spain, probably due to a high incidence of
both VL and HIV infection and a greater
awareness about this association once tire first
few cases had been described. In 1990 two
independent studies described the features of
VL in many cases of HIV.2' More recently,
our cooperative multicentre study of 40
patients, including most cases that had
appeared in Spain up to the beginning of
1990, has updated that experience.2
Although in some patients VL can be the
consequence of reactivated disease, the find¬
ing that 92-5% of the patients were intraven¬
ous drug misusers suggested that the disease
could be transmitted intravenously (which is
an occasional route of transmission in
immunocompetents). VL can occur at all
stages of HIV infection, but 77% of patients
were classified as stage IV with CD4 counts
below 4xl0'/l, suggesting that it is com¬
moner in the later stages of HIV infection.
Most patients present with a clinical picture
of "classic" Kala-azar with fever, hepato-
splenomegaly, and pancytopenia, but some
are asymptomatic and are diagnosed inciden¬
tally. In all patients l.eishmania amastigotes
were demonstrated in the bone marrow
smear, and in the liver of 94-5% of the
patients who had a biopsy. In four cases L
amastigotes were found in normal skin, and
were also present in skin lesions of a Kaposi's
sarcoma in one case. This is not a surprising
finding,as L amastigotes are found in normal
skin in immunocompetent patients with VL.
The two most remarkable findings were the
absence of leishmanial antibodies, present in
only 35-2% of cases, and the chronic relap¬
sing course of the disease. Although 75% of
patients had a good initial response to
antimony drugs, 42-5% followed a chronic or
relapsing course; 40% of patients died due to
HIV related causes, and death was only
inadvertently related to the relapsing course
of the disease.
These findings suggest that VL behaves like
other infections in HIV seropositive patients,
such as tuberculosis or Pneumocystis carinii,
showing a good response to initial treatment
but persisting as latent chronic disease. Con¬
ventional treatment with antimony is not
effective in half the patients and other
therapeutic approaches are needed. Produc¬
tion of a-interferon (a-INF) and other lym-
phokines are essential to activate macro¬
phages, but these are defective in both VL
and HIV infections. Adjuvant treatment with
y-INF has been effective in animals, in
experimental models of human macrophages,
and in refractory VL in immunocompetent
patients.' These results suggest that y-INF
could also be effective in VL in HIV
seropositive patients and a therapeutic trial is
currently being conducted in Spain.
VI. is an opportunistic infection in HIV
seropositive patients that is found increasin¬
gly often. It must be suspected and precluded
in patients presenting with fever, hepatos-
plenomegaly, and pancytopenia, and even in
less ill patients living in or travelling to
endemic areas.
C MONTAI.BAN
Ministerio de Sanidad y Consumo,
Institute Nacional de la Salud,
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Levels of inositol metabolites within normal myeloid
blast cells and changes during their differentiation
towards monocytes
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SUMMARY
A homogeneous population of undifferentiated myeloid blast cells was purified from human fetal liver by
rosette sedimentation of erythroblasts and macrophages, after coating these cells with monoclonal
antibodies, followed by a cell elutriation step. The undifferentiated blast cells were maintained in culture,
in a serum-free medium containing 1 mg T1 inositol, by the presence of a high concentration of
interleukin-3 (100 U mf1). This allowed equilibrium labelling of cells with [2-3H]myo-inositol and
analysis of the concentrations of inositol metabolites. The myeloid blast cells contained high concentrations
of an unidentified inositol metabolite, possibly .m-glycero-3-phospho-1 -inositol (GroPIns, 22 |J.m), inositol
monophosphate (InsT, 16 pM), an unidentified inositol bisphosphate (Ins.P2, 9.4 pM), inositol pentakis-
phosphate (Ins%, 37 pM) and inositol hexakisphosphate (Ins.P6, 31 pM). These high concentrations are
similar to those reported in the promyeloid cell line, HL60. Treatment of the blast cells with 10 nM
phorbol myristate acetate (PMA) resulted in rapid differentiation of48% of the cells towards monocytes.
Notable changes in the levels of inositol metabolites included an increase in the putative GroPIns peak
(to 73 pM) and decreases in the concentrations of InsP;l (from 4 pM to 1 pM) and InsT5 (to 21 pM). These
changes in response to PMA, with the exception of the rise in the putative GroPIns, are similar to those
reported in HL60 cells undergoing monocyte differentiation. These observations suggest that the
abundant inositol polyphosphates may have an as yet unknown role in myeloid differentiation.
1. INTRODUCTION
The breakdown of phosphatidylinositol 4,5-bis-
phosphate (Ptdlns(4,5) P2) following receptor acti¬
vation by an agonist is now well established as a
component of an important signalling system in cells
(Berridge & Irvine 1989; Downes & Macphee 1990).
Cleavage of Ptdlns(4,5) P2 leads to the production of
two distinct messengers, inositol 1,4,5-trisphosphate
Ins( 1,4,5) P3) and diacylglycerol (DAG). lns(l,4,5) P:i
generation leads to the release of Ca2+ from intra¬
cellular stores (Rasmussen & Rasmussen 1990;
Berridge 1990) and DAG activates protein kinase C,
leading to phosphorylation of a number of cellular
proteins (Nishizuka 1988; Parker et al. 1990). However,
these inositol metabolites involved in cellular signalling
represent only a small fraction of the complex pattern
of inositol metabolites present in cells. In particu¬
lar, cells contain high concentrations of the highly
phosphorylated inositol metabolites, inositol penta-
kisphosphate (InsP5) and inositol hexakisphosphate
(Heslop et al. 1985; Szwergold et al. 1987 ; Jackson et al.
1987).
Our recent studies of the inositol phosphates present
within the HL60 cell line have revealed an extremely
complex pattern of inositol metabolites, with concen¬
trations of InsP5 and InsP6 of about 25 rm and 60 pM,
respectively. Furthermore, the concentration of Ins/f
changes dramatically as HL60 cells differentiate
towards either neutrophils or monocytes. During
neutrophil differentiation there was a threefold increase
in the intracellular concentration of InsP5 and, in
contrast, there was a 90% decrease in the level oflns/J
as HL60 cells differentiated toward monocytes (French
et al. 1991). These studies of HL60 cells have suggested
that the abundant inositol polyphosphates may have
some, as yet unknown, role in myeloid differentiation.
It is, therefore, important to investigate whether high
levels of the highly phosphorylated species are a feature
ofeither immature myeloid cells or Ieukaemic cell lines,
and also whether the observed changes in levels occur
in normal myeloid cells as they undergo differentiation.
To approach these questions, a morphologically
homogeneous population of myeloid blast cells has
been purified from human fetal liver. Our previous
studies have shown that fetal liver is a rich source of
I*roc. R. Soc. Land. B (1992) 247, 27-33
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myeloid progenitor cells (Toksoz & Brown 1984). A
relatively homogeneous population of myeloid blast
cells has been obtained from fetal liver by using a nega¬
tive selection procedure, so as not to interfere with
subsequent physiological studies (Bunce et al. 1990).
These blast cells differentiate spontaneously in culture
towards neutrophils and monocytes. However, when
treated with phorbol myristate acetate (PMA) 62% of
the blast cells undergo rapid differentiation towards
monocytes, and the spontaneous differentiation of the
remaining blast cells towards neutrophils is inhibited
(Bunce et al. 1990). In this study the blast cell
population has been further fractionated by cell
elutriation to obtain a population of promyeloid cells
which is more uniform as regards their differentiation
status. These have been equilibrium-labelled with [2-
3HJmyo-inositol, in a serum-free medium containing
1 mg I-1 inositol and a high concentration of inter-
leukin-3 (IL-3) and then treated with PMA to induce
rapid differentiation towards monocytes. The concen¬
trations of inositol metabolites within the undifferen¬
tiated blast cells and the changes which occur during
their monocyte differentiation have been studied in
detail.
2. MATERIALS AND METHODS
(a) Purification of blast cells
Abortuses from prostaglandin-induced termination ofmid-
trimester pregnancies were obtained from two local hospitals.
All handling of fetal tissue was done in agreement with the
Polkinghorne Report, and was supervised within the Uni¬
versity ofBirmingham by a central co-ordinator. Under these
guidelines, maternal consent for the use of fetal material for
research purposes was obtained by a neutral third party and
the identity of patients and source of fetal material was
unknown to the investigators. This research was done under
special license from the Department of Health, and in
addition was approved by the local hospital ethical com¬
mittee.
A single cell suspension was prepared from whole human
fetal livers (16-18 weeks gestation) as follows. Tissue was
gently teased into small fragments, passed through a 19,g
needle and incubated for 40 nrin at 37 °C in RPMI 1640
medium (Gibco, Paisley, U.K.) containing collagenase H
(0.5 mg ml-1, Boehringer Mannheim, Lewes, U.K.), dispase
(l.OmgmT1, Boehringer Mannheim) and hyaluronidase
(0.5 mg ml-1, Sigma, Poole, U.K.). Enzymic digestion of the
tissue fragments was inhibited by the addition of an equal
volume of cold RPMI 1640 medium supplemented with
10% (by volume) fetal calf serum (FCS) (GIBCO) and the
cells were recovered by centrifugation at 500 £ for 10 min.
The preparation of light-density cells from the resulting
single cell suspension and the removal of erythroblasts and
macrophages from this population of cells have been
described in detail previously : Bunce et al. 1990). Briefly,
light-density cells were purified by fractionation of the above
cell preparation on Ficoll-Hypaque (Pharmacia, Milton
Keynes, U.K.; (Boyum 1968)), which was done twice. The
light density cells were coated with monoclonal antibodies
against glycophorin C (Ret 40F, Dr D. Y. Mason, (Gatter
et al. 1988)) and a monocyte cell surface antigen (61D3,
(Nunez et al. 1982)) and the cells were rosctted with sheep
erythrocytes coated with anti-mouse immunoglobulin (Ling
et al. 1977). The rosette-positive cells and excess sheep
erythrocytes were removed by fractionation on Ficoll-
Hypaque and the interface cells washed twice in RPMI 1640
supplemented with 2 % (by volume) FCS before being
fractionated by counterflow cell elutriation (cce). CCE was
done at 10 °C and at 1950 r.p.m. using a Beckman J-6M
centrifuge with a JE-6B elutriator rotor fitted with a standard
chamber (Beckman Instruments, Glenrothes, U.K.). Cells
were loaded at a flow rate of 4.7 ml min"1 in phosphate-
buffered saline containing 2% FCS, and eight 100 ml
fractions were collected at flow rates of (in ml min"1): 4.7,
9.0, 13.3, 17.8, 22.0, 26.3, 30.4 and 34.5. A final 'rotor off'
fraction was collected as the centrifuge came to rest at the end
of the procedure. For culture experiments, cells which eluted
at 13.3 and 17.8 ml min"1 were combined and washed once
(220 g) in RPMI 1640 medium containing 1 mg l"1 inositol
and supplemented with the serum replacement ITS+ (see
below).
(b) Culture of cells and induction of differentiation
After washing, the elutriated blast cells were cultured at
37 °C in a humidified atmosphere containing 5% C02, by
using a serum-free medium consisting of inositol-free RPMI
1640 (Northumbria Biologicals Ltd, Northumberland, U.K.)
supplemented with 1 mg l"1 inositol, ITS+ (6.3 mg l"1
insulin, 6.3 mg l"1 transferrin, 6.3 (ig l"1 selenous acid,
1.3 g l1 bovine serum albumin and 5.4 mg l"1 linolcic
acid (Flow Laboratories, Rickmansworth, U.K.)), 20 mm
glutamine (GIBCO), antibiotics (100 U ml"1 penicillin and
50 pg ml"1 streptomycin, GIBCO) and 100 U ml"1 recom¬
binant human interleukin-3 (IL-3) (Genzyme, Koch Light,
Hatfield, U.K.). 1 ml cultures were seeded with 5 x 105 cells
in 24 well plates (Nunc, Paisley, U.K.). For the study oflevels
of inositol metabolites and their changes during differ¬
entiation, blast cells were labelled to isotopic equilibrium
with 2 pCi ml"1 [3H]inositolf (TRK 883, Amersham In¬
ternational, Amershanr, U.K.) for five days before the
addition of 10 nM PMA (Sigma). [3H]inositol was maintained
in the medium at the same specific radioactivity during
differentiation. Differentiation was assessed by staining of
cytospin preparations with May-Grunwald-Giemsa and for
monocyte specific esterase using a-naphthyl acetate as the
substrate (Yam et al. 1971). Staining for CD10 (J5, Coulter,
Luton, U.K.), CD34 (ICH3. Professor R. Levinsky) and
CD15 (AGF4.48 (Fisher et al. 1982)) positivity was by the
indirect immunofluorescence technique, cither in suspension
(CD 10 and CD34) or on cytocentrifuged preparations
(CD15).
(c) Analysis of inositol lipids and phosphates
The acidic extraction of lipids and inositol phosphates and
high performance liquid chromatography (hplc) separation
of inositol phosphates have been described in detail previously
(French et al. 1991). The radioactivity in each hplc peak was
converted to an intracellular concentration, averaged
throughout the cell, by using values for the specific activity of
[3H]inositol in the growth medium and for the cell volume,
calculated from the mean cell diameter (assuming the cells to
be perfect spheres). The concentration of inositol in the
culture medium was measured using a chemiluminescence
assay (Gudermann & Cooper 1986).
3. RESULTS
(a) Purification ofmyeloid blast cells
As described previously, the cell population obtained
from fetal liver mononuclear cells after rosette depletion
f 1 Ci = 3.7 x 1010 Bq.
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cell fraction
Figure 1. Elutriation profile of fetal liver blast cells. Blast cells
were enriched by negative selection as described in §2 before
fractionation by counterflow cell elutriation. Fractions were
collected at the incremental flow rates defined in §2.
Cytospun preparations of the cells were analysed by
Romanovsky staining to reveal the percentages of lympho¬
cytes (open squares), blast cells (closed squares), and
promonocytes (open triangles). Cells were stained in sus¬
pension by indirect immunofluorescence to identify cells
expressing the CD 10 (open circles) and CD34 (closed circles)
antigens.
of erythroblasts and monocytes consisted of 73%
undifferentiated blast cells, cells at the promyelocyte to
neutrophil stages of differentiation (9%), lymphocytes
(4%), and unidentified cells (11%). The blast cells
exhibited variation in cell size and both nuclear and
cytoplasmic characteristics (Bunce et al. 1990). These
cells were therefore further fractionated by the use of a
cell elutriator (figure 1). The first two fractions
contained cells with a lymphoid appearance, which
represented 46-66 % of the cells in these fractions.
Immunofluorescence studies revealed that these cells
express the CD 10 antigen and are therefore most likely
to be B-cell progenitors. Undifferentiated blast cells
were eluted predominantly in fractions 3-7, obtained
at flow rates of 13.4-30.4 ml min% However, as shown
in figure 1, beyond fraction 4 there was increasing
contamination of the undifferentiated blast cells with
cells that had the clear morphological appearance of
promonocytes. These cells, identified in Romanovsky-
stained preparations, had the distinguishing character¬
istics of increased size with increased quantities of
cytoplasm that was less basophilic, vacuolated and had
irregular edges. The nuclei of these cells were
eccentrically placed, reniform in shape and contained
nucleoli. To achieve optimal separation of undiffer¬
entiated blast cells from promonocytes and lymphoid
progenitor cells, cells within fractions 3 and 4 (obtained
at flow rates of 13.3 ml min-1 and 17.8 ml min-1) were
pooled for use in experiments. In five experiments, the
mean yield of elutriated blast cells was 2.1 x 106
( + 0.7xl06 (s.e.)). Analysis of Romanovsky-stained
preparations of the purified cells used in experiments
showed that they were mostly blasts (73.9%), lymph¬
oid cells (14.3%) and promonocytes and cells at the
promyelocyte to neutrophil stages of maturation
(11.8%). Comparison of the morphology of the blast
cell populations before and after cell elutriation
revealed that the elutriated blast cells were more
uniform in size and nuclear characteristics. The nuclear
outline of the elutriated blast cells was more regular,
and the chromatin pattern contained multiple nucleoli.
The cytoplasm of these cells was scant to moderate in
quantity and basophilic. Cytochemical staining
showed that the blast cells did not express chloroacetate
esterase or monocyte-specific esterase. They were not
stained by procedures for either Sudan black or
periodic acid Schiff positivity. Thus the blast cells
lacked characteristics of the precursors of either
neutrophils or monocytes. A considerable percentage
of the blast cells (32-40%) expressed the CD34
antigen, which is present on haemopoietic progenitor
cells and some myeloid cells (Peschel & Roller 1989).
(b) Maintenance and differentiation of blast cells in culture
When the purified blast cells were cultured in serum-
free medium containing 1 mgh1 inositol and ITS +
there was rapid loss of cell viability such that by day 2
the cells had declined in number from 5 x 10° ml-1
(figure 2a). The addition of IL-3 to the culture
medium, at a concentration of 100 U ml , resulted
in a small initial decline in cell number at day 2
(to 2.4 xlO5) followed by a gradual increase to
5.4 x 105 ml-1 at day 5 and 6.4 x 105 at day 7. The
nature of the cells that had increased in number was
assessed by staining of cytospin preparations (figure 2 b,
table 1). After five days of culture in medium
containing IL-3, the cell population still consisted
mostly of undifferentiated myeloid cells (85 %). By this
time, cells with the morphological appearance of
lymphocytes had died and they now represented less
than 1 % of the cell population. The remaining cells
were at the promyelocyte to neutrophil stages of
differentiation (2%), promonocytes (7.5%) and cells
that could not be readily identified (4.6%). Although
the morphology of the blast cells changed slightly over
five days (predominantly an increased cytoplasm to
nuclear ratio) they exhibited no clear evidence of
differentiation towards either monocytes or neutro¬
phils. Furthermore, the low rate at which cells
spontaneously differentiated in the cultures was con¬
firmed by the small percentages ofcells which expressed
CD 15, an antigen which appears at the promyelocyte
stage of neutrophil differentiation (2.0-5.5%) or
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Figure 2. Maintenance of fetal liver blast cells in IL3. (a)
Elutriated blast cells were cultured in serum-free medium
containing no IL3 (open squares) or 100 U mf1 IL3 (closed
squares). Cultures were harvested at 0, 1, 2, 5 and 7 days,
and the numbers of viable cells were assessed by phase
contrast microscopy. (b) Cytospun preparations of cells
cultured in the presence of IL3 were Romanovsky stained to
determine the percentages of blast cells (closed squares),
lymphocytes (open triangles), promyelocytes -> neutrophils
(closed triangles) and promonocytes-monocytes (closed
circles). Cytospun preparations were also stained to identify
cells which express CD 15, an antigen which appears at the
promyelocyte stage of neutrophil differentiation (open
squares) or ct-naphthyl acetate esterase positive cells (open
circles).
Table 1. Differentiation of normal blast cells towards
monocytes in response to PMA
(Cells were cultured for five days in 100 U mf IL3a before
adding 10 nM PMA for a further 24 hb. Data are mean + s.e.
of four experiments.)
percentage of cells
characteristic — PMAa + PMAb
differential:
normoblasts < 1 < 1
blasts 85 ± 1.7 47 ±8.0
promonocytes 7.5 ± 1.6 48 ±8.0
monocytes < 1 < 1
promyelocytes -> myelocytes 2.0±0.7 < 1
granulocytes < 1 < 1
lymphocytes < 1 < 1
others 4.6+1.0 4.8 ± 1.5
a-naphthyl acetate esterase 15.6 + 3.6 19.6 ± 3.0
60 90
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Figure 3. hplc separation of inositol phosphates from (a) fetal
liver blast cells and (b) HL60 cells. Typical hplc traces of
inositol metabolites extracted from 1 x 106 elutriated blast
cells and 1 x 10' HL60 cells (first shown in French et al. 1991)
are shown. In each case peaks corresponding to inositol (Ins),
putative GroPIns (GPI) and inositol phosphates (InsP-*-
InsP6) are highlighted.
monocytes in Romanowsky-stained preparations. As
shown in table 1, after 24 h of exposure to PMA, 48%
of the cells were classed as promonocytes and mono¬
cytes, compared with 7.5% of cells immediately before
PMA treatment. The percentage of cells expressing ct-
naphthyl esterase had risen only slightly, from 16% to
20%. This small rise in oc-naphthyl acetate esterase
positively after 24 h exposure to PMA is consistent with
our previous studies of normal blast cells, in which a
significant increase in the percentage of positive cells
was not seen until the second day of treatment with
PMA (Bunce et al. 1990). The above changes are
consistent with cells having undergone differentiation
towards monocytes.
monocyte associated a-naphthyl acetate esterase
(15.6-17.3%) (figure 2).
The addition of PMA to cultures of blast cells which
had been grown for five days in medium containing
IL-3, and labelled with [3H]inositol, resulted in rapid
differentiation of the blast cells towards monocytes.
The appearance of the cells in cultures treated with
PMA for 24 h had changed; they had become both
adherent and pleomorphic. The percentage of cells
which had undergone differentiation towards mono¬
cytes was assessed by the number of promonocytes and
(c) Levels of inositol metabolites in blast cells and changes
during their differentiation
Analysis of aqueous extracts obtained from undiffer¬
entiated blast cells revealed a complex pattern of
inositol metabolites. Figure 3 compares the pattern of
water-soluble inositol metabolites within undifferenti¬
ated blast cells, as revealed by hplc, with that obtained
for exponentially grown HL60 cells in a previous study
(French et al. 1991). The myeloid blast cells contained
a much higher free inositol concentration than FIL60
cells. Growing F1L60 cells contained approximately
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40 |im free inositol, averaged throughout the cell
volume (French et al. 1991), whereas the blasts
contained approximately 2.6 mM (table 2). In contrast
to the large differences in inositol content, the relative
levels of the inositol phosphates seen in the undiffer¬
entiated blasts cells and growing HL60 cells were
similar. However, the blast cells contained a higher
concentration of Ins/f than Ins/% whereas in growing
HL60 cells this ratio was reversed. This difference in
the relative concentrations of InsT5 and Ins/3,, is unlikely
to be related to the leukaemic character of HL60 cells,
as another leukaemic myeloid cell line, KG la, contains
levels of the InsP5 higher than InsP6 (C. M. Bunce &
P.J. French; unpublished observation).
As shown previously in HL60 cells, the undifferenti¬
ated blast cells contained remarkably high concen¬
trations of a number of inositol metabolites. These
included a compound which eluted between inositol
and inositol monophosphates on hplc (probably
GroPIns; 22 pM), Insl/3 or InsS/3 and Ins2/3 (16 gM),
InsPj (37 (o.m) and InsPg (31 pM). Lower concentrations
were observed of an inositol bisphosphate which co-
eluted with Ins(l,4) P2, an inositol trisphosphate which
co-eluted with Ins(l,4,5)% and an inositol tetra-
kisphosphate which eluted close to Ins( 1,3,4,5) Pi
(Table 2). Co-elution of the peaks on hplc with
authentic standards only provides an indication of
their possible identities, as other inositol polyphosphate
isomers may also elute within some of these peaks.
The concentrations of certain inositol metabolites
within the myeloid blast cells changed in response to a
24 h exposure to PMA. Significant decreases were
observed in the levels of both Ins/3, and Ins/% The level
of Ins/3, decreased by about 75% from 4.2 gM to
1.1 pM, and the level of Ins/f decreased by about 50%,
from 37 pM to 21 pM. In contrast, there was a marked
increase in the level of the putative GroPIns from
22 pM to 73 pM. No significant changes were observed
in the levels of free inositol, Ins/3, Ins/% Ins/3, or Ins/3,.
Table 2. Intracellular concentrations of inositol and inositol
phosphates in normal blast cells
(Cells were cultured for five days in serum-free medium
containing 100 U ml-1 IL3 and [3H]inositol. On day five,
PMA was added to a final concentration of 10 nM. Control0"
and treated0" cells were harvested 24 h later. Data are
means ±s.e. of values obtained from four experiments, except
for Ins/3, which represents one determination only.)
concentration (gM)


























A population of myeloid blast cells with a hom¬
ogenous primitive morphology has been purified from
human fetal liver and maintained in serum-free
medium containing high levels ofIL3. The potential of
IL3 to support the blast cells in culture is analogous to
the maintenance of the undifferentiated status of
murine IL3 dependent cell lines. (Heyworth et al.
1990). Labelling of blast cells under these culture
conditions, in medium with a known specific activity of
("HJinositol, and measurement of the mean cell volume
has allowed us to determine the concentrations of
inositol metabolites within these cells. The levels of
several inositol phosphates within undifferentiated
myeloid blast cells were similar to those observed
within the promyeloid cell line HL60 (French et al.
1991). The concentrations of Ins/3, Ins/% Ins/3, and
Ins/2 observed in blast cells and HL60 cells, re¬
spectively, were as follows: Ins/3, 16 pM against 24 pM;
Ins/% 9 pM against 14 pM; Ins/% 4.2 pM against 4.4 gM
and Ins/% 37 gM against 27 gM. Other compounds
display differences in concentration between the two
cell populations. HL60 cells contained more Ins/^ than
the fetal liver blast cells (63 gM against 31 gM) and less
GroTIns (11 gM against 22 gM). A particularly striking
difference between the two cell populations is the
concentration of free intracellular inositol. Within the
blast cells the concentration of inositol was 2.6 mM,
which is much higher than the 39 gM observed within
HL60 cells. This may in part be accounted for by the
fact that the blast cells were obtained from fetal tissue,
which has a high extracellular concentration of inositol
in the surrounding fluids (125 gM, (Lewin el al. 1978;
Quirk & Bleasdale 1983)). In contrast, the HL60 cells
had been maintained long term in medium containing
low amounts of inositol (5 gM). The similar levels of
higher inositol phosphates found in cells with very
different-sized pools of free intracellular inositol sug¬
gests that cells can actively control their levels of highly
phosphorylated derivates even when the level of
intracellular inositol is restricted.
The changes described previously in inositol phos¬
phates during HL60 differentiation towards monocytes
included rapid and sequential declines in Ins/3, and
Ins/% and a slower fall in Ins/^ which was not
significant until 48 h (French et al. 1991). In HL60 cells
treated for 24 h with PMA there was a 75% decrease
in the level of InsP4, an 80% decrease in the level of
Ins/3, and no change in the level of Ins/% Similar
changes in the levels of these three compounds were
observed at 24 h when the fetal blast cells differentiated
towards monocytes in response to PMA: the level of
Ins/3, had declined by 75% and that of Ins/3- by 50%,
whereas Ins/3,, remained unchanged. It is possible that
the change in the concentration of Ins/3, seen in both
cell types is related to activation, by protein kinase C,
of the 5-phosphatase which degrades Ins(l,4,5) % and
Ins(l,3,4,5) Z3,, which is likely to be a major component
of the Ins/3, peak. However, in the HL60 studies no
depletion of Ins(l,4,5)/3, was observed in response to
PMA, which contradicts this possible explanation for
the depletion of Ins/% The decreases in the levels of
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Ins.P4 and Ins.P5 which occurred in both normal myeloid
blast cells and HL60 cells undergoing monocyte
differentiation may be a key feature of cell maturation
along this pathway. It will, therefore, be of particular
interest to determine whether similar decreases in the
amounts of Ins,P4 and InsP5 occur in the normal blast
cells as they undergo differentiation in response to M-
CSF. However, as yet we cannot undertake an analysis
of the changes in inositol metabolism in this situation.
This is because the blast cells committed to neutrophil
and monocyte differentiation cannot, at present, be
separated, and addition of M-CSF to the mixed blast
cell population does not result in sufficient promotion
of monocyte differentiation such that this exceeds the
concomitant, spontaneous granulocyte differentiation.
Thus, appropriate analysis of inositol metabolites
cannot as yet be undertaken.
As the blast cells underwent differentiation towards
monocytes there was an increase in the concentration
of the putative GroTIns peak (from 22 (im to 73 |1m).
This was not observed as HL60 cells differentiated
towards monocytes, but there was a fourfold rise in the
level of this peak during HL60 neutrophil differentia¬
tion (French et al. 1991). Preliminary studies in HL60
cells have shown that mild periodate treatment of this
compound followed by reduction by dimethyl-
hydrazine yields predominantly Ins(1/3) P, suggesting
that most of this material is bona fide GroPIns (data not
shown). If this peak is indeed GroPIns, then its
accumulation could be a reflection of Ptdlns deacy-
lation by phospholipase A2 (PLA2) and a lysophospho-
lipase (as suggested in Alonso & Santos 1990). An
important difference between the cell populations
might therefore lie in the control of PLA2.
In summary, normal myeloid blast cells and HL60
promyelocytic cells contain a similar complement and
levels of inositol phosphates. These two cell popu¬
lations also show similar changes in inositol metabolism
as they onset differentiation towards monocytes in
response to treatment with PMA. These data support
the suggestion, from our studies of HL60 cells (French
et al. 1991), that the inositol polyphosphates have some
role in the process of myeloid cell differentiation. In
future studies, it will be important to undertake
analysis of changes in the levels of inositol metabolites
within precursor cells as they undergo differentiation
in response to appropriate physiological factors.
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